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A history of head and neck surgery: a story of light 
In the early 1800s dr. Liston stated, "the patient with malignancy of the head 
and neck region may be numbered with the dead", and that its surgical 
treatment "is totally inadmissible; it is a piece of unmeaning and entirely useless 
cruelty".1 Despite this remark, some surgeons attempted and reported on the 
removal of cancer in this region.1 For instance, the first recorded attempt of the 
removal of tongue cancer by cautery was by dr. Marchette in 1664. In 1805, 
other attempts for tongue cancer removal were performed by dr. Inglis and dr. 
Home through ligation. It is impressive to think of the fearlessness and courage 
these surgeons presented, considering that ether and chloroform were 
discovered decades later (1842 and 1847, respectively). Despite these 
anesthetic game-changers, operations in the oral cavity and pharynx presented 
with significant danger. For example, drowning from aspirated hemorrhage was 
a feared and not uncommon complication of surgery as bleeding control 
remained difficult. It was not until the discovery of cocaine and procaine, in 
1880 and 1923 respectively, that the risk of significant bleeding complications 
was greatly reduced.  
Remarkably however, the surgeon’s greatest challenge revolved around 
light. A critical necessity in performing surgery is orientation within the surgical 
field, something that is only conceivable with the presence of light. Traditionally, 
operations were performed in the early morning to save daylight hours and use 
natural sunlight for illumination. If surgery was prolonged after dark, due to 
complications, the surgeon would have had to work with candlelight as the only 
source of illumination.1 For this particular reason, historical operating rooms 
were preferably built on an elevated location and designed with large windows 
in the ceiling and walls facing south-east. A remarkable example is that of St. 
Thomas’ Hospital in London, one of world’s oldest (+/- 1800s) operating rooms, 
which was built in St. Thomas’ Church’s attic (Figure 1.1). After the invention of 
the incandescent light bulbs around 1878 by Joseph Swan, surgical light has 
affected major change in surgery, especially in the cavity rich region of the 
head and neck. 
In present day, we have the opportunity to bring different types and 
wavelengths of light into the operating room. Now, we are truly capable of 




















Figure 1.1 The attic of St. Thomas’ Church. 
 
Head and neck oncology  
Today, head and neck cancer (HNC) is responsible for almost 200,000 deaths 
each year worldwide and is the sixth most common cancer by incidence.2 
Interestingly, over the past 30 years, the epidemiology of head and neck 
cancer is changing drastically; despite a steady decline of older patients with 
head and neck squamous cell carcinomas (HNSCC) caused by alcohol and 
tobacco abuse, recent studies suggest a substantial increase of human 
papillomavirus (HPV) related oropharyngeal cancer in young non-smoking, non-
drinking males.3 Some studies suggest an astonishing 22% increase of HPV-
related HNSCC within a period of four years.4 Whilst patient epidemiology is 
changing, the primary pillar of treatment for HNSCC remains surgical resection 
using wide local excision; a surgical technique that involves tumor resection 
with a margin of clinically healthy tissue surrounding the macroscopic gross 
tumor border to achieve microscopic tumor clearance.5,6 
Failure to excise all cancer tissue leads to inadequate margins (tumor 
within <5mm of the surgical margin), which are directly correlated to 
locoregional recurrence and poor overall survival.7 On the other hand, 
aggressive radical resection brings forth the risk of removing excessive healthy 
tissue, resulting in unnecessary morbidity and deformity. 
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In general, an adequate margin in HNSCC is perceived clear when the 
margin of healthy tissue surrounding the excised tumor is 5 mm or more (Figure 
1.2). An inadequate or positive margin is called close when the margin is 1-5 
mm and cut-through when bellow 1 mm.7,8 Despite many efforts, positive 
surgical margins are still found in 20-30% of patients at final histopathology 





Figure 1.2 Definition of a positive margin is the presence of tumor within 5 mm of the specimen 
edge for head and neck cancers. 
 
 
The need for enhanced intraoperative margin management is, besides 
poor survival rates, further illustrated by the seriousness of the consequences 
that accompany inadequate margins, such as additional chemoradiation 
therapy or even second surgeries.10 Currently, frozen section analysis (FSA) is 
the only intraoperative margin assessment tool broadly used by surgeons. The 
surgeon hereby samples small sections of suspicious tissue during the 
operation for immediate histopathological assessment. During a typical case 
multiple sections are required, and with an average processing time of 15-20 
min per sample, FSA is considered immensely time intensive. Other more 
substantial limitations are caused by the relatively small area that can be 
sampled from the entire tumor specimen (approximately 10x5mm). As surgeons 
and pathologists struggle to identify which suspicious regions necessitates 
evaluation using FSA, sampling errors are inherent to this technique and in turn 
contribute to the high positive margin rates.10 These rates may be further 
worsened by the limited ability of the surgeon to predict (and thus select) 
tumor-involved margins, as is suggested by a 36% surgeon sensitivity for 
positive margins stated by Gao et al..11 The issues above can best be 
described by the needle-in-the-haystack metaphor: searching for microscopic 
tumor cells in a similar looking mass of healthy tissue is like searching for a 
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needle in a haystack. Whereas failure to find the needle potentially results in 
leaving cancer within the patient with all subsequent consequences.  
Next to margin status, the presence of lymph node (LN) metastases is 
considered the second most important negative prognostic factor for overall 
survival.12,13 Despite clinical and radiographic evidence of tumor absence in 
cervical LNs of HNCSS patients, occult metastasis occurs in 20-30% of LNs.13 
For this reason, patients with early stage disease often undergo a therapeutic 
elective neck dissection,14,15 stressing a substantial workload on pathologists, 
who manually have to evaluate every single harvested LN (up to 37 LNs in a 
typical case; internal quality data, Stanford School of Medicine, unpublished). 
With a recent increase of LNs that need to be evaluated in each case to 
enhance quality standards by the American College of Surgeons and European 
Society of Pathologists, the likelihood of sampling and human errors intensifies.  
To address the challenges mentioned above, this thesis explores several 
fluorescence imaging strategies that we developed to enhance intraoperative 
decision-making, improve pathological workflow efficiency and occult 
metastasis detection in LN evaluation. Optical fluorescence imaging is a 
concept that could improve accuracy of intraoperative cancer detection and 
distinction, as it can be utilized for non-invasive visualization of biochemical 
events at molecular level within cells, tissues or even living patients in real-time. 
As such, rather than a diagnostic tool, intraoperative optical imaging should be 
perceived as a complementary technique, since it provides an additional layer 
of surgical information, on top of traditionally acquired tactile and visual 
information. Hence, it is assumed that this technique can improve procedural 
and patient outcomes, as clinical decisions are made, based upon additional 
and more detailed information. 
The principles of fluorescence imaging 
Upon excitation of a NIR-fluorophore with an appropriate wavelength, electrons 
in the molecule move from ‘ground state’ to an ‘excited state’. Shortly thereafter, 
energy is lost to the environment and the electrons enter the lowest excited 
state and remain there for a short period of time (nanoseconds). Relaxation 
from this lowest excitement state results in emission of a photon with a longer 
wavelength. This released photon with a NIR-wavelength, invisible to the human 
eye, can be visualized by dedicated imaging cameras in the operating room. 
Optical imaging is based on the detection of these photons, and the length of 
the path that photons travel through tissue is called penetration depth. This 
distance (in human tissue) is the leading predictor of the efficacy of an imaging 
agent. The depth of penetration mainly depends on 1) the wavelength of the 
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emitted photon from the fluorophore and 2) the optical properties of the tissue 
that the photon moves through. These optical tissue properties are defined as 
absorption of photons, scatter of photons and autofluorescence of surrounding 
tissues. Reducing these factors is needed for effective imaging and enhanced 
imaging quality. In contrast to conventional imaging in the visible window 
between 400 and 700 nm, the first NIR-window, around 700 to 900 nm, has 
numerous merits, including higher spatial resolution and higher penetration 
depth. Furthermore, absorption is reduced because the absorption coefficient 
of blood (<600 nm) and lipids (>900 nm) within this spectrum gap are low and 
therefore less photons are lost by unspecified tissue-uptake. Also scattering, 
the phenomenon in which a traveling photon deviates from its original path after 
contact with a scattering agent, mainly lipids, is reduced substantially by using 
a 790 nm wavelength. And lastly, autofluorescence, which refers to the intrinsic 
fluorescence abilities of certain tissues after being excited by light with a proper 
wavelength, is reduced in this window. This last property makes it challenging 
to distinguish the origin of where a certain photon derived from (i.e. healthy 
surrounding tissue or tumor tissue). All the above factors influence the quality of 
imaging and these effects tend to become more significant as the traveled 
distance through tissue becomes larger. Therefore, it is important to bear in 
mind that it is simply impossible to correct for all these factors in an 
inhomogeneous patient with an inhomogeneous tumor, and consequently, a 
level of ambiguity must be accepted when evaluating the quality of the imaging 
data.   
Tumor-targeted fluorescence imaging agents compromise a signaling 
fragment (i.e. fluorophore) that is conjugated to a targeted ligand (e.g. cytokine, 
antibody etc.) for specificity, which can be administered orally, topically or 
systemically. In this work, the used tracer-ligand was panitumumab, a fully 
human monoclonal anti-epidermal growth factor receptor (EGFR) antibody, 
conjugated to the near-infrared (NIR) fluorophore IRDye800CW 
(excitation/emission max: 774/789 nm). EGFR is overexpressed on the cell 
membrane of more than 90% of HNSCC cells.16 Due to accumulation of the 
exogenous agent within the tumor, contrast between targeted tissue and 
adjacent untargeted (healthy) tissue can be established. The accumulation and 
distribution of the agent in the tumor occurs through various processes, such as 
capillary extravasation (hours to days), diffusion with binding (minutes to days), 
internalization (minutes to days) and enhanced permeability and retention 
(EPR) effect.17 EPR effect is a controversial concept which allows molecules of 
a certain sizes to flow into the tumor due to the low interstitial pressure, caused 
by the tumor’s microenvironment. Note that, in addition to the processes 
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mentioned above, it is presumed that multiple other factors are responsible for 
agent accumulation.17 These are subject to ongoing debate and therefore are 
assessed outside the scope of this thesis.  
The combination of contrast agent with a suitable, dedicated, imaging 
system is needed to provide highly specific visualization of disease extent 
against a low signal background. The main challenge here lies in the detection 
of small cancerous lesions while maintaining a high tumor-to-background ratio. 
Both imaging agent and imaging system need to be perfectly aligned with each 
other to generate the highest imaging quality and results. Currently, the wide 
variety of near infrared (NIR) camera systems and platforms can broadly be 
divided into two groups. 1) Open-field NIR-imaging systems, which enable 
qualitative in situ imaging with intermediate resolution. These systems are 
subject to environmental and operator variables such as ambient light, camera-
to-tissue distance, surgical approach (open versus minimally invasive) surgeon 
preferences, and image post-processing. 2) Closed-field NIR-imaging systems, 
which are black box-based platforms, that have a controlled environment for 
light and imaging distance. Closed-field systems provide consistent 
quantitative data, which allow interpatient comparison with high imaging 
resolution. 
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Thesis outline 
For decades, molecular fluorescence imaging has been subject of preclinical 
testing and research. Fluorescence imaging just recently made its way into 
clinical testing and it is now that we can start to capture its clinical value. This 
thesis aims to lay a clinical foundation for future use of real-time intraoperative 
fluorescence-guidance in surgical head and neck oncology. By answering the 
following questions: “Which clinical goals can be achieved using intraoperative 
optical imaging?” (PART I and II), “What are current bottle necks and limitations 
of this technique?” (PART III) and “What will the future of optical imaging offer 
us?” (PART III), this thesis provides an overview of various in situ and ex vivo 
intraoperative imaging approaches. Altogether, this can smoothen the transition 
of optical imaging from the research bench to standard clinical practice.  
After the reader is introduced to the current challenges faced during 
surgical head and neck cancer cases, Part I describes the concept of in situ 
open-field imaging strategies in a prospective setting to counter these 
problems. Chapter 2 provides an overview of different factors that could 
influence successful intraoperative in situ imaging of primary head and neck 
tumors (n=20). Furthermore, the influence of ambient light present in today’s 
operating room is described in a phantom experiment, illustrating one of the 
major challenges inherent to usage of open-field imaging systems. In Chapter 
3, fluorescence imaging is evaluated in multiple surgical settings (i.e. pre-
incision, during excision, post-excision/wound cavity). Results were measured 
in clinically significant changes to preoperative surgical planning, such as 
detection of a positive surgical margin, recognition of a secondary primary 
tumor, and visualization of unexpected disease extent during surgical removal 
of a cervical tumor mass with an unknown primary tumor. All these clinical 
changes are thought to have a direct impact on surgical outcomes and thus 
patient care.  
Part II of this thesis elaborates on a more recent aspect of optical surgical 
imaging: ex vivo imaging. This part makes up the greater portion of this thesis 
as it comprises various completely novel imaging approaches for different 
challenges, such as intraoperative surgical margin assessment and high-grade 
dysplasia recognition. First, Chapter 4 illustrates the concept of constructing a 
three-dimensional optical surface map from a resected tumor specimen. We 
hypothesized that fluorescence is capable to pinpoint areas at risk of harboring 
tumor closer than 5 mm with high sensitivity. In other words, if an area on the 
surface of a specimen was fluorescent, likelihood of tumor being present within 
5 mm is high, if fluorescence is absent in a particular area, chances of tumor 
Chapter 1 
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being present within this margin are presumed low. The concept presented in 
this study laid the foundation for optical surface mapping, defining penetration 
depth in human tissue and further research concerning the use of fluorescence 
signal relativity. To counter challenges concerning interpatient variability, 
Chapter 5 and Chapter 6 describe the concept of relative fluorescence 
intensity-peaks in which patients are used as their own internal control. Relative 
fluorescence intensity-peaks can be used to detect and pinpoint the closest 
margin (distance from tumor border to surgical specimen edge) on a tumor 
specimen regardless of margin adequacy (i.e. smaller or larger than 5 mm). 
Chapter 5 elaborates on ex vivo margin assessment of the peripheral (i.e. 
mucosal) margin solely. However, for most surgical oncology cases using wide 
local excision, the deep margin — defined as the nonepithelial margin of the 
tumor specimen, exposed only after surgical resection — is specifically 
challenging to assess intraoperatively, due to absence of natural landmarks 
and lack of visible tissue feedback. Chapter 6 presents a novel imaging 
strategy that allocates the closed margin on the deep surface of resected 
specimen. This concept of detecting the closest margin on a particularly large 
surface, could form an important bridge between traditional tissue evaluation by 
the surgeon and the difficulties in selecting high-risk tissue sections for frozen 
section analysis. Next, Chapter 7 discusses the results of ex vivo fluorescence 
imaging for identification of high-grade dysplasia in head and neck cancer 
patients.  
After extensive intraoperative research, Part III explores the possibilities of 
fluorescence imaging for surgical pathology. Chapter 8 discusses contact 
probe-based fluorescence dosimetry — a form of spectrometry — to differentiate 
between healthy and cancerous tissue in real-time. Chapter 9 focusses on the 
impact of a novel fluorescence imaging strategy that could facilitate the 
identification of metastatic lymph nodes (LNs) that need to undergo 
pathological evaluation. Importantly, for cancer staging and treatment, 
identification of metastatic LNs is essential, and as a result, surgeons harvest 
large amounts of LNs for pathological evaluation placing an enormous workload 
on surgical pathologists. Highlighting and preselecting high-risk LNs would 
allow for a more exact evaluation of fewer LNs leaving less room for error.  
Part IV encompasses the general discussion, limitations inherent to 
intraoperative fluorescence imaging in the head and neck region, future 
perspectives and the conclusion of this thesis. In Chapter 10, the advantages 
and disadvantages of both in situ and ex vivo imaging are discussed. This is 
followed by general limitations in Chapter 11 concerning optical tissue 
properties, the effects of tumor heterogeneity and tumor infiltration. 
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Furthermore, Chapter 11 elaborates on the difficulties in defining clinical 
endpoints for fluorescence-guided surgery trials. This is an important issue that 
needs careful consideration when this research field will engage the next step 
towards clinical routine. Next, in Chapter 12 the future perspectives of 
intraoperative fluorescence imaging are discussed in terms of multimodality 
systems, such as the combination of molecular imaging and light sheet 
microscopy for intraoperative margin assessment and direct pathological 
evaluation. 
This thesis sets the first step towards future clinical application of this 
relatively young surgical imaging technique. In Chapter 13, the conclusion, in 
short, states that although significant challenges are decreased by various 
novel strategies, some challenges remain. Nevertheless, fluorescence-guided 
surgery is presumed to be a major benefit for surgical oncology, not exclusively 
for malignancies deriving from the head and neck region but in all areas where 
wide local excision is required. Finally, Part V summarizes the results of this 
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In head and neck cancer, surgical resection using primarily visual and tactile 
feedback is considered the gold standard for solid tumors. Due to high 
numbers of tumor-involved surgical margins, which are directly correlated to 
poor clinical outcomes, intraoperative optical imaging trials have rapidly 
proliferated over the past 5 years. However, few studies report on intraoperative 
in situ imaging data that could support surgical resection. To demonstrate the 
clinical application of in situ surgical imaging, we report on the imaging data 
that are directly (i.e. in real-time) available to the surgeon.  
 
Study design 
Fluorescence intensities and tumor-to-background ratios (TBRs) were 
determined from the intraoperative imaging data — the view as seen by the 
surgeon during tumor resection — of 20 patients, and correlated to patient and 
tumor characteristics including age, sex, tumor site, tumor size, histologic 
differentiation, and epidermal growth factor receptor (EGFR) expression. 




Under these circumstances, intraoperative TBRs of the primary tumors 
averaged 2.2 ± 0.4 (range 1.5 to 2.9). Age, sex, tumor site, and tumor size did 
not have a significant effect on open-field intraoperative molecular imaging of 
the primary tumors (p>0.05). In addition, variation in EGFR expression levels or 
the presence of ambient light did not seem to alter TBRs. 
 
Conclusions 
We present the results of successful in situ intraoperative imaging of primary 
tumors alongside the optimal conditions with respect to both molecular image 
acquisition and surgical workflow. This study illuminates the potentials of open-
field molecular imaging to assist the surgeon in achieving successful cancer 
removal. 
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Introduction 
For decades, surgeons have almost exclusively relied on visual and tactile cues 
for surgical tumor resection of head and neck squamous cell carcinoma 
(HNSCC). Unfortunately, positive surgical margins are found in 20% to 30% of 
patients at final histopathology 5 to 7 days after the surgery, a percentage that 
has not changed over the past 30 years.1-3 This is in part due to the intricate 
anatomy of the head and neck, with critical unresectable structures and areas 
of challenging visualization. Subsequently, surgeons often face difficulties in 
achieving a complete resection without significant loss of function and poor 
cosmesis.4-6 
Fluorescence-based intraoperative molecular imaging is a burgeoning 
field, reflected by the steep rise of clinical trials evaluating novel agents as well 
as the development of imaging hardware in the near-infrared range to detect 
these agents.7,8. Both targeted and nontargeted imaging agents have been 
shown to be effective for identification of ex vivo tumor specimen and tumor 
margins with millimeter resolution.9-11 However, these ex vivo modalities do not 
provide real-time in situ feedback of the primary tumors within the surgical 
field.12 Real-time, tumor-specific molecular imaging could assist the surgeon in 
intraoperative clinical decision-making. Nonetheless, presenting objective in 
situ imaging data remains challenging as patient, environmental, and operator 
variables affect imaging parameters (e.g. ambient light, camera-to-tissue 
distance, surgical approach [open vs. minimally invasive], image post-
processing12,13), and therefore limit interpatient consistency of intraoperative in 
situ data. The aim of this study was to evaluate the effect of various patient and 
tumor characteristics on successful in situ primary tumor visualization and to 
report on the optimal conditions for image acquisition. 
Materials and methods 
Establishment of intraoperative imaging parameters 
A phantom experiment was performed to establish the optimal light conditions 
for the clinical use of real-time intraoperative fluorescence imaging in a 
standard operating room. An open-field fluorescence imaging device (SPY-PHI, 
Novadaq) was tested in the operating room under multiple light conditions, 
using half sphere-shaped tumor tissue-mimicking phantoms loaded with 
various concentrations of IRDye800CW-carboxylate (excitation/emission max: 
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774/789 nm; concentrations 0.5 ng/mL, 1.0 ng/mL, 2.0 ng/mL and blank; LICOR 
Biosciences Inc). Phantom production and composition have been previously 
described by us and others.10,14 The effect of the surgical overhead lights 
(Berchtold, 4,000 k LED, 50/50 Hz, 140W,) and ambient mercury vapor gas 
lights (16x TL-D, 36W, Philips) on imaging acquisition was tested in the 
following light settings: both on; overhead light off, ambient on; overhead light 
on, ambient off; and both off. The fluorescence signal was assessed from the 
grey-scale imaging data acquired by the fluorescence camera as mean signal 
intensity (MSI) in arbitrary units (a.u.) using ImageJ (version 1.50i, National 
Institute of Health). Oversaturation was perceived as phantoms being visually 
indistinguishable from the next concentration in combination with reaching the 
maximal grey value of an 8-bit image (i.e. 255 a.u.) in ImageJ. 
Intraoperative primary HNSCC imaging 
Twenty patients with biopsy-proven HNSCC, scheduled to undergo surgical 
resection with curative intent, were included in our ongoing phase I study 
evaluating the anti-epidermal growth factor receptor (EGFR) antibody 
panitumumab conjugated to a near infrared dye (panitu-mumab-IRDye800CW). 
The study protocol was approved by the Stanford University Institutional Review 
Board (IRB 35064) and the FDA (NCT02415881), and written informed consent 
was obtained from all patients. The study was performed in accordance with 
the Declaration of Helsinki, FDA’s ICH-GCP guidelines, and United States 
Common Rule. 
Included patients received an intravenous infusion of 25 mg (n=4) or 50 
mg (n=18) panitumumab-IRDye800CW (excitation/emission max: 774/789 nm) 
before surgery, as reported previously.15 Primary tumors were imaged in the 
operation room before the first incision was made using the hand-held imaging 
device (SPY-PHI, Novadaq) optimized for the detection of IRDye800CW. During 
intraoperative image acquisition, 3 types of imaging modes were evaluated: 
bright field, fluorescence imaging in grey-scale mode, and fluorescence 
imaging in a pseudo-colored, heat-map overlay. Throughout image acquisition, 
camera settings were kept consistent and the overhead lights were turned off to 
avoid oversaturation of the camera. All imaging data (i.e. 8-bit video and still-
frame images) gathered during surgery were stored for study purposes. 
Imaging analysis of the acquired fluorescence imaging data 
After surgery, the fluorescence signal coming from the primary tumor on the 
stored imaging data was analyzed using ImageJ by calculating tumor-to-
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background ratios (TBRs) on representive fluorescence grey-scale 8-bit 
images. The TBRs were calculated by dividing the signal of the area of interest 
— the primary tumor — to that of background; buccal mucosa in the oral lesions, 
and gross tumor-negative skin for cutaneous lesions.15,16 The mean 
fluorescence signal of the primary tumor was extracted by averaging 10 
measurements of circular regions of interest (ROIs) over the gross tumor. The 
surgeon delineated the tumor area by visual inspection and palpation. The 
same strategy was performed for the background, where ROIs were selected 
30 to 40 mm from the edge of the gross primary tumor. Each tumor and 
background ROI had exactly the same size of 5 mm in diameter (1,020 pixels 
per ROI, 1,920x1,080-pixel images). Histopathologic evaluation was used to 
confirm diagnosis and for the concordance of fluorescence signal and tumor 
tissue of in situ imaging, as previously described.17 The TBRs were then 
correlated to different patient and tumor characteristics: sex, age (<60, >60 
years), tumor site (lateral tongue, retromolar trigone, other), pathologic tumor T-
stage (T1-T2 vs T3-T4) to indicate tumor size, histologic differentiation (well, 
moderate, and poor), and presence or absence of squamous cell carcinoma 
(SCC). Assessment of both tumor T-staging and histologic differentiation was 
performed by a board-certified pathologist. 
Epidermal growth factor receptor immunohistochemistry and 
expression 
To assess the EGFR expression in all primary tumors and compare this with 
intraoperative imaging, the specimens were formalin-fixed overnight, serial 
sectioned into 5-mm macrosections, and paraffin embedded. Later, a 
representative 5-mm section was cut from the macrosections. The slides were 
baked at 60 C for 1 hour and stained using an autostainer (DAKO Link48 and 
PT link, Agilent Technologies Inc). Slides were digitized at 20x magnification 
using a high-resolution slide scanner (NanoZoomer 2.0-RS, Hamamatsu 
Photonics). The EGFR membrane intensity was scored from 0 to 3+ using a 
previously established immunohistochemistry staining intensity method.18,19 The 
membrane expression score was as follows: 0 if tumor cells had no staining or 
less than 10% of faint staining; 1+ if more than 10% of tumor cells had faint 
staining; 2+ if tumor cells had moderate focal staining; and 3+ when tumor cells 
had strong diffuse EGFR staining. This system of immunohistochemistry 
interpretation has been validated by the American Society of Clinical Oncology 




Statistical analysis for TBR comparison was performed using the unpaired 
Mann-Whitney U-test for dichotomous data and the 1-way ANOVA for categorial 
data with more than 3 units. Results are reported as means standard 
deviations; p values of 0.05 or less were considered significant. 
Results 
Clinical study 
Twenty patients were included in this study. Patient and tumor characteristics 
are detailed in Table 2.1. The average patient age was 64 years (range 48 to 76 
years); 18 patients presented with biopsy-proven oral cavity cancer and 2 
patients with cutaneous cancer. All tumors were completely surgically excised. 
Final histopathologic assessment concluded invasive SCC in 18 patients. In 
2 patients, the excised tissue specimens were found to be negative for SCC 
despite preoperative biopsies showing SCC. 
 
Table 2.1 Patient and tumor characteristics. 
Age (yr) Sex (M/F) Tumor site  Pathologic (TN-stage) Tumor size (mm) 
71 M Lateral tongue T2N0 22 
48 M Lateral tongue T3N2c 45 
58 F Retromolar trigone T3N0 45 
65 F Buccal mucosa T2N2b 35 
70 F Buccal mucosa T3N0 42 
63 F Alveolar ridge T2N0 26 
71 F Lateral tongue T2N2b 21 
71 F Floor of mouth T1N1 20 
47 F Retromolar trigone T4bN3b 63 
68 F Lateral tongue T3N2b 43 
75 M Lateral tongue Tx* NA 
69 M Maxillary sinus T4aN0 53 
76 M Cutaneous - scalp Tx* NA 
59 F Lateral tongue T4aN2c 52 
57 F Retromolar trigone T4N2c 83 
57 M Lateral tongue T4aN3b 90 
56 M Retromolar trigone T4aN0 44 
57 M Cutaneous e neck T4N0 60 
70 M Lateral tongue T4aN3b 68 
70 M Lateral tongue T3N0 45 
*Negative for squamous cell carcinoma on final histopathologic assessment. F, female; M, male; 
NA, not applicable. 
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Intraoperative imaging workflow 
All SCC-positive and SCC-negative cases could successfully be imaged 
intraoperatively using the hand-held fluorescence imaging device. The imaging 
data were available, in real-time, to the operating surgeon through an LED-





Figure 2.1 Workflow for in situ fluorescence imaging. (a) Schematic concept of real-time 
fluorescence imaging of a tongue lesion, courtesy of the authors. (b) Hand-held 
imaging device which combines fluorescence signal information with vivid white light 
imaging in real-time. (c) Example of a surgical operation using intraoperative 
fluorescence imaging to visualize primary tumor extent and tumor margins. 
 
 
Figure 2.2 displays still-frames from the surgical view of a lateral tongue 
tumor in the different acquisition modes. In the operating room, the sterile-
draped, hand-held device was used to capture images from the surgical field 
while switching through the different modes (bright field, fluorescence grey-
scale, and fluorescence heat-map overlay). Each mode offered the surgeon 
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distinctive information on the primary tumor and its position within the surgical 
field. The fluorescence heat-map overlay offered signal intensity-based 
imaging; high fluorescence signal areas (e.g. primary tumor) were presented to 
the viewer as red or orange. Therefore, the fluorescence heat-map provided the 
surgeon with more semiquantitative information about the fluorescence intensity 
distribution in comparison with other modes. Switching between the different 
modes allowed the surgeon to correlate primary tumor extent with its anatomic 
location. It should be noted that the grey-scale imaging mode was found to be 
the most sensitive imaging mode because the overlay of the fluorescence heat-
map over the brightfield image obscured fluorescence intensity. Over-head 
lights (4,000k LED, 50/50Hz) resulted in significant oversaturation of the images 
(Supplemental Figure S2.1). In contrast, ambient light from ceiling-mounted 
mercury vapor gas lamps resulted in only a slightly increased fluorescence 
intensity compared with absence of ambient light. We found that the optimal 
setting — that with the least disturbance to clinical workflow and adequate 
imaging data — was when the surgical overhead lights were switched off and 










Figure 2.2 Different imaging modes for fluorescence imaging. Intraoperative imaging of a primary 
tongue squamous cell carcinoma (white arrow), visualized in various modes: (a) bright 
field, (b) fluorescence grey-scale, and (c) fluorescence heat-map overlay. 
 
Fluorescence imaging analysis 
Intraoperative fluorescence imaging results correlated to ex vivo imaging and 
histology for 4 representative patients are shown in Figure 2.3. In all tumor-
positive patients, the primary tumor was consistently brighter when compared 
with the surrounding normal tissue, with TBRs ranging from 1.5 to 2.9 (average 
2.2 0.4). When examining TBR vs. patient characteristics, a significant 
difference in overall TBRs was found when comparing tumor-negative to tumor-
positive patients (p<0.05, n=20). No significant differences were observed in 
TBRs with regard to age, sex, histologic differentiation, T-stage, and tumor site 
(Figure 2.4). Furthermore, no significant difference was found in TBRs between 
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patients who received a 25-mg flat-dose of panitumumab-IRDye800CW vs. a 





Figure 2.3  Intraoperative imaging of patients preoperatively determined to have either primary 
lateral tongue lesion or scalp lesion. Bright field image (a, e, i, and m), in situ imaging 
(b, f, j, and n), ex vivo imaging (c, g, k, and o) using an Odyssey imaging-platform (LI-
COR), and final hematoxylin and eosin (H&E) stained histology (d, h, l, and p). Lesions 
were assessed for presence of squamous cell carcinoma (SCC); positive (a-h) and 
negative (i-p) examples are shown. Black dotted line outlined tumor area; yellow 
dashed line, fluorescence histopathology location; red circle, location where tumor was 
thought to be located. 
 
 
Interestingly, in the patients in whom there was no SCC on final pathology, 
the fluorescence signal at the previous biopsy site was similar to that of 
adjacent tissue (background), as shown by TBRs ranging from 0.9 to 1.0 
(average 0.95 ± 0.5). This indicates that the fluorescence signal of the 
suspicious areas was the same as that of surrounding tissue and consistent 
with final pathology, which did not identify SCC in the specimen. One patient 
had a biopsy-positive scalp lesion (SCC) after previous wide local excision, but 
no residual tumor on final histopathologic assessment. The other case in which 
imaging showed no fluorescence signal elevation was a lateral tongue 
resection of a scar from a previous excisional biopsy of an SCC, with final 
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pathology showing no residual tumor. To evaluate the impact of EGFR 
expression on in situ imaging, we scored the immunohistochemistry membrane 
intensity (0, 1+, 2+, and 3+) and compared this with the TBRs. All primary 
tumors had EGFR expression: 1+ was found in 4 tumors, 2+ in 5 tumors, and 
3+ in 9 tumors. The intensity score of EGFR is presented in Figure 2.5, which 







Figure 2.4  Influence of patient and tumor characteristics on obtained tumor-to-background ratios 
(TBRs). Tumor fluorescence vs background fluorescence was quantified and TBRs 
were plotted vs patient (a) age, (b) sex, (c) tumor site, (d) T-stage to indicate tumor 
size, (e) tumor presence or absence, and (f) histologic differentiation grade. Other, 
alveolar ridge, buccal mucosa, cutaneaous, floor of mouth, maxillary sinus; RmT, 
retromolar trigone. 
 





Figure 2.5  Primary tumor fluorescence tumor-to-background ratio (TBR) vs epidermal growth 
factor receptor (EGFR) expression. (a-c) In situ tumor visualization in fluorescence 
heat-map mode. White dashed lines indicate gross primary tumor borders, scale bars 
indicate intensity range. (d-f) EGFR expression levels (1+, 2+ and 3+), where 0 was 
left, as this level was not encountered in this study. (g) Graph of TBR vs EGFR 
expression. 
Discussion 
We present the results of in situ intraoperative molecular imaging in 20 patients 
with head and neck cancer to understand the clinical potential of this 
technology during surgery. We also identified the optimal conditions for image 
acquisition with respect to surgical workflow. Tumors could clearly be imaged 
in situ, and all tumors were consistently and significantly brighter when 
compared with adjacent healthy tissue (average TBR 2.2 ± 0.4, p<0.05). 
Importantly, we found that in pathologically negative re-resections, the 
fluorescence signal was equivalent to adjacent background signal (average 
TBR 0.95 ± 0.5), which supports the value and predictive capability of this 
technique during surgery. 
We believe that the diagnostic data deriving from intraoperative fluorescent 
imaging will be used by the surgeon in the context of other relevant information, 
such as tactile and visual feedback. The fluorescent signal therefore does not 
definitively “rule-in” or “rule-out” disease; it provides an additional layer of 
information to inform surgical decision-making. From this perspective, the 
surgeon would incorporate fluorescence imaging with tactile, visual, and 
preoperative imaging to distinguish healthy from tumor tissue and realize an 
adequate surgical margin intraoperatively (Figures 2.2 and 2.3). In particular, 
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for advanced tumors, tumors with ill-defined visual margins, re-resections, and 
anatomically complex sites (e.g. retromolar trigone and alveolar ridge), 
fluorescence data may be beneficial in tumor resection. 
We found that differences in tumor site and size did not change imaging 
contrast (as measured by TBR), which suggests that real-time imaging data 
provided to the surgeon are consistent sources of information. In addition, if the 
fluorescence signal extends beyond the tumor borders as perceived by visual 
and tactile information, the surgeon can adjust the surgical margin accordingly. 
This in situ assessment of tumor margins could therefore potentially lead to a 
reduced positive margin rate at final pathology. Furthermore, the TBR was 
consistent across a range of histologic differentiation and EGFR expression. 
This is in contrast to ex vivo studies using high dynamic range closed-field 
systems, in which we and others identified a correlation between target (EGFR) 
expression and fluorescence intensities.12,21 Moreover, this indifference to EGFR 
expression demonstrated that intraoperative fluorescence imaging is similar 
between high and low EGFR-expressing tumors. 
The main limitation of this study is that imaging results may vary depending 
on which intraoperative imaging platform is used. Software to accommodate for 
intensity differences may differ between open-field platforms, creating 
inconsistency in TBRs when comparing various devices. The purpose of this 
study, however, was to assess the clinical information that is available to the 
surgeon using this commercially available imaging device. Furthermore, 
despite the significant difference that was detected between SCC positive and 
negative cases, limited conclusions can be drawn from these results due to the 
small sample size. Also, it should be noted that although this study shows the 
potential utility of real-time fluorescence imaging for surgical oncology, the true 
value of this technique will be seen when patient outcomes data, such as 
prolonged survival, become available. 
It is widely recognized that open-field optical imaging is subject to a 
significant number of external variables such as interference from external light, 
surface reflectance, and camera placement.16,22 Yet, it remains difficult to 
standardize intraoperative data acquisition; the wound cavity depth differs per 
case, the camera distance to tissue varies per operator and area of interest, the 
angle of viewing is variable, and ambient light conditions are often different in 
each operating room.23 As a result, it is simply not possible to perform rigorous 
imaging analysis, which controls for these variables. However, because this 
data set represents the real surgical setting, it ought to be analyzed the way it is 
interpreted by the surgeon. To this end, we proposed to overcome the absence 
of true quantitative imaging data by reporting the “surgical view.” Furthermore, 
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switching off overhead lights gave a minor interruption of surgical workflow, 
which can be a burden, especially compared with closed-field ex vivo 
specimen imaging (image-guided pathology) that does not interfere with 
surgical workflow.24 It is, however, thought that these limitations will become 
less burdensome as software and hardware continue to evolve collectively. 
Furthermore, as countless novel near infrared probes are being developed for 
various cancer types such as lung and breast (e.g. OTL38, bevacizumab-
IRDye800, respectively), we believe that this open-field imaging technique will 
potentially play a substantial role in surgical oncology in the near future. 
Conclusions 
This study demonstrates the potential value of real-time in situ imaging during 
surgical resection of head and neck tumors. Typically, image analysis in clinical 
trials is performed in the context of ex vivo imaging, only after resection of the 
primary tumor has taken place. This study, however, successfully evaluated the 
surgical view during resection, which is believed to be of great importance 
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Figure S2.1 Identifying optimal light settings for intraoperative in situ fluorescence imaging. Various 
light settings tested: (a) overhead light off (-), ambient light on (þ), (b) all lights off, (c) 
overhead light on, ambient light off, and (d) all lights on. (e-h) Near-infrared 
fluorescence imaging of various IRDye800CW loaded phantoms under the light 
conditions. Visual representation of the phantoms in the fluorescence grey-scale mode. 
(i-j) Quantification of the visual representation shown in e-h with mean signal intensities 
of the different dye concentrations showing that in the presence of overhead light 
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Although surgical resection has been the primary treatment modality of solid 
tumors for decades, surgeons still rely on visual cues and palpation to delineate 
healthy from cancerous tissue. This may contribute to the high rate (up to 30%) 
of positive margins in head and neck cancer resections. Margin status in these 
patients is the most important prognostic factor for overall survival. In addition, 
second primary lesions may be present at the time of surgery. Although often 
unnoticed by the medical team, these lesions can have significant survival 
ramifications. We hypothesize that real-time fluorescence imaging can enhance 
intraoperative decision making by aiding the surgeon in detecting close or 
positive margins and visualizing unanticipated regions of primary disease. The 
purpose of this study was to assess the clinical utility of real-time fluorescence 
imaging for intraoperative decision making.  
 
Methods 
Head and neck cancer patients (n=14) scheduled for curative resection were 
enrolled in a clinical trial evaluating panitumumab-IRDye800CW for surgical 
guidance (NCT02415881). Open-field fluorescence imaging was performed 
throughout the surgical procedure. The fluorescence signal was quantified as 
signal-to-back-ground ratios to characterize the fluorescence contrast of 
regions of interest relative to background.  
 
Results 
Fluorescence imaging was able to improve surgical decision making in 3 cases 
(21.4%): identification of a close margin (n=1) and unanticipated regions of 
primary disease (n=2).  
 
Conclusion 
This study demonstrates the clinical applications of fluorescence imaging on 
intraoperative decision making. This information is required for designing phase 
III clinical trials using this technique. Furthermore, this study is the first to 
demonstrate this application for intraoperative decision-making during 
resection of primary tumors. 
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Introduction 
Surgical resection is one of the cornerstones of therapy for patients with head 
and neck squamous cell carcinomas (HNSCC). Moreover, the most important 
factor for predicting long-term cancer survival is the completeness of the 
surgical resection.1-4 Despite this awareness, between 15% and 30% of oral 
cavity cancer patients have positive surgical resection margins after surgery, 
which is associated with poor outcomes and necessitates additional therapy.1,5,6 
Furthermore, there can be concomitant primary malignancies that are often 
undetected at the time of the surgical resection. Notably, additional primary 
malignancies represent the second leading cause of death in patients with 
HNSCC.7  
For centuries, surgeons have relied exclusively on visual and tactile cues 
during surgical resection. However, tumors, and in particular tumor margins, 
remain challenging to ascertain. The subjective nature of the resection can be 
especially challenging in the oral cavity, due to a small working area and 
proximity of critical structures that are at risk for injury. The current strategies of 
detecting tumor margins during resection have demonstrated that the surgeon 
has only a 36% accuracy to detect true-positive margins.8 Recognizing this, 
several attempts have been made to develop techniques for assessment of 
tumor tissue during the surgery that does not solely rely on visual and tactile 
cues. The current standard for detecting residual disease is gross inspection of 
the surgical specimen or wound bed, followed by frozen sectioning analysis of 
suspicious areas.9 Besides the time-consuming nature of the procedure (15-20 
min per frozen section), frozen section analysis can only examine a small 
fraction of the specimen.9 Consequently, alternative real-time intraoperative 
imaging techniques have been proposed to assist the surgeon in decision 
making, including ultrasound, radiofrequency spectroscopy, Raman 
spectroscopy, optical coherence tomography, and photoacoustic imaging.10-12 
Recently, there has been a rapid growth in development of optical contrast 
agents for the real-time assessment of tumors during surgery using 
fluorescently labeled, tumor-specific probes.13-16 In the current study, we ask if 
intraoperative visualization of tumor margins and occult cancer can be 
performed using fluorescently labeled antibodies to improve the rate of 
successful resection. Despite the large number of clinical trials that have 
identified the safety and feasibility of tumor-targeting optical imaging agents, 
only a limited number of publications have successfully demonstrated their 
clinical value.17-19 The objective of this study was to assess the clinical value of 
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real-time fluorescence imaging during surgery to guide intraoperative decision 
making. 
Materials and methods 
Study design 
Fourteen patients with biopsy-proven HNSCC scheduled to undergo surgical 
resection with curative intent were included in our ongoing phase I study 
assessing panitumumab-IRDye800CW. These patients received an intravenous 
infusion of panitumumab-IRDye800CW 1—5 days before surgery as previously 
described.8 Panitumumab-IRDye800CW is a near-infrared fluorescence 
imaging agent with an excitation/emission maximum at 774/789 nm and a half-
life of approximately 24 h13 and a maximal observed penetration depth of 6.3 
mm.20 At the time of surgery, intraoperative fluorescence imaging was 
performed at 4 stages during the surgery using a dedicated hand-held near-
infrared fluorescence imaging device (Novadaq) specialized for the detection 
of IRDye800. Throughout the surgery, image acquisition was performed 
intermittently at different stages during the procedure. First, the surgical field 
was imaged before incision to demarcate the primary tumor and screen for 
potential other primary lesions. Next, during the resection the surgical field was 
imaged to visualize the deep surgical margin (the cut surface on the primary 
specimen). After primary tumor resection, the wound cavity was imaged to 
potentially visualize any residual disease. Last, the entire surface of the surgical 
specimen was imaged ex vivo to assess the surgical margins on the tumor 
specimen. Throughout image acquisition, camera settings were kept consistent 
and the overhead lights were turned off. The study protocol was approved by 
the Stanford University Institutional Review Board (IRB 35064) and the Food 
and Drug Administration (NCT02415881), and written informed consent was 
obtained from all patients. The study was performed in accordance with the 
Helsinki Declaration of 1975 and its amendments, Food and Drug 
Administration’s International Conference on Harmonisation—Good Clinical 
Practice guidelines, and the laws and regulations of the United States. 
Fluorescence analysis 
To estimate signal-to-background ratios (SBRs) in the image presented to the 
surgeon, images were loaded into ImageJ (version 1.50i; National Institutes of 
Health) where regions of interest were drawn around tissue areas of interest. In 
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line with previously published literature,8,21-23 the estimated SBR was calculated 
by dividing the mean signal intensity (MSI) of the region of interest drawn 
around the area of interest (i.e., tumor or wound bed) by the MSI of the back-
ground signal (i.e., nearby normal tissue). A background value was estimated 
from 10 regions of interest for different tissue types (i.e., tongue, gingival and 
buccal mucosa) in the oral cavity for each patient, with each region of interest 
located at least 3-4 cm from the edge of the gross tumor. An average 
background was identified by comparing the MSI and variance in MSI for all 
tissue types (tongue, gingival and buccal mucosal tissue) before and after 
resection of the primary tumor specimen. The variance in signal was defined as 
the coefficient of variance (CV), which is the SE divided by MSI and describes 
the heterogeneity of the tissue (e.g., tumor often has high variation in signal and 
thus a high CV). Subsequently, the tissue type with the most constant signal 
and CV was selected as background. 
Histologic assessment 
Intraoperative fluorescence-guided tissue sampling through frozen sectioning 
was performed per standard of care. Final histopathologic assessment of the 
tissue specimens was conducted by a board-certified pathologist after routine 
hematoxylin and eosin (H&E) staining. To assess the distance from the tumor 
border to the cut edge of the specimen on the deep aspect of the specimen, 
known as the deep margin, the pathologist outlined regions of tumor on the 
H&E slides. Thereafter, the H&E slides were imaged using an Odyssey imaging 
platform (LI-COR Biosciences) to identify fluorescence signal within the tissue, 
which was later correlated with in vivo imaging. 
Results 
Variation in fluorescence per tissue type 
Of the 14 patients with HNSCC who were included in this study, a total of 
700 data points was obtained from the acquired intraoperative fluorescence 
images. For background fluorescence level establishment, we found that 
besides being visually different, each background tissue type, including normal 
tongue and gingival and buccal mucosal tissue, had its own MSI range and 
distribution pattern of signal (CV). The tissue’s unique MSI and CV allowed 
surgeons in the study to discriminate the different tissue types (Supplemental 
Figure S3.1; supplemental materials are available at http://jnm.snmjournals.org). 
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Buccal mucosal tissue was selected as the optimal background because it 
showed the least change in MSI and subsequent CV. The visual fluorescence 
signal was also most homogeneous when compared with normal tongue and 
gingival tissue. With buccal mucosal tissue serving as the background, the 
SBRs of the primary tumors were found to be much higher than those of the 




Figure 3.1  Fluorescence guided deep margin assessment. Left column represents the case of a 
negative deep margin with indication of the planned surgical cut (red dotted line) and 
mucosal surface (green dotted line). After the incision the deep margin (blue dotted 
line) is opened up with forceps (Asterix with arrow). At the bottom left the measured 
distance of tumor border to deep margin on the hematoxylin and eosin slide with 
correlating fluorescence image. The right column represents a case where a close 
deep margin (yellow circle) was detected using fluorescence imaging. Bottom right; 
the actual measured distance from tumor to deep margin (<5mm). FLU = Fluorescence 
imaging of the hematoxylin and eosin slides. 
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Clinical value of fluorescence imaging during surgery 
Of all studied cases, we found that fluorescence imaging improved surgical 
decision making in 3 cases (21.4%). Improved surgical decision making is 
defined as instances when the fluorescence imaging information changes the 
surgical procedure to ensure better surgical outcome. Table 3.1 summarizes 
the clinical value of fluorescence imaging during the surgical procedure for 
each patient. In all cases, real-time fluorescence imaging of the tumor before 
surgery successfully outlined the tumor as defined by histology. Furthermore, in 
some cases, visualization of unrecognized tumor led to modification of the 
planned borders of the surgical resection. Specific use of fluorescence imaging 
is further discussed in the following paragraphs. 
Real-time deep margin assessment 
Although remaining a topic of debate in head and neck surgery, a margin is 
often considered positive if there is tumor present within 2 mm of the edge of 
the surgical specimen, close if there is tumor present within 2-5 mm, and 
negative if tumor is further than 5 mm from the surgical specimens’ edge.4 
Gross assessment of the deep margin (defined as the distance from the tumor 
border to the cut edge of the specimen on the deep aspect of the specimen) 
remains challenging due to variations in tumor depth and subtle tissue changes 
associated with tumor extension. We were able to accurately assess the deep 
margin using fluorescence imaging in 10 patients with tumor invading soft 
structures (71.4%). Assessment of the deep margin in patients with cancer 
adherent to bone (retromolar trigone squamous cell carcinoma [SCC] [n=2], 
maxillary sinus SCC [n=1], or palate SCC [n=1]) remained difficult, partly 
because the open-field devices are not currently designed for deep wound 
cavity imaging. In 9 of 10 patients, the imaged deep margin of the tumor was 
negative for fluorescence, and the tumor margins were later confirmed to be 
greater than 5 mm on final histopathology (average distance, 7.6 mm; range, 5-
15 mm; Supplemental Figure S3.2). The remaining patient presented with a 
buccal lesion that revealed a region of high fluorescence signal when viewed 
from the deep margin during resection (Figure 3.1). After histologic evaluation 
of the H&E slide, this fluorescence-positive deep margin was found to contain 
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Visualization of unanticipated regions of primary disease 
Second primary lesions are common in HNSCC and often go unnoticed by the 
surgical team. In 1 case, fluorescence imaging of buccal SCC, before the 
surgical incision, led to identification of such a secondary lesion outside the 
planned surgical incision (Figure 3.2). On the basis of this intraoperative 
finding, the surgeon extended the surgical incision to include the suspicious 
lesion that correlated with the location of the fluorescence signal. Quantitative 
assessment of the lesion indicated an SBR greater than 2, both for in situ and 
ex vivo imaging. Final pathologic evaluation of the second lesion revealed an 
invasive SCC that was separated from the primary tumor by a bridge of 4.2-mm 
normal mucosa. 
Regional metastasis with extracapsular extension often requires complex 
surgical intervention. In one case, preoperative MRI revealed a suspicious 
lymph node (LN) and an indistinct mass in level II of the right neck, as well as a 
suspicious LN in level V of the right neck. Although not uncommon (24), PET 
imaging only disclosed a solitary 18F-FDG—avid spot in neck level II (Figure 3.3) 
that was positive on fine-needle aspiration. Intraoperative fluorescence imaging 
demonstrated several fluorescent LNs in level II as well as the level V LN that 
was seen on preoperative MRI. Repeated fluorescence imaging was 
particularly valuable for the visualization of the extent of the level II mass, which 
was found to have infiltrated the deep neck musculature. On complete gross 
resection of this mass, it was found that fluorescence imaging allowed for the 
identification of multiple small pieces of residual tissue that were not detected 
by the surgeon’s gross inspection (SBRs >2; Figure 3.3). Pathologic 
assessment of these tissue samples by frozen section analysis confirmed SCC. 
Assessment of wound cavity 
After complete gross surgical resection of the primary tumors, fluorescence 
imaging of the wound was performed. In all wound cavities, the estimated SBR 
remained below 1 (ranging from 0.2 to 0.7), indicating that the signal in the 
wound cavity was never higher than that of the background signal (i.e., buccal 
mucosal tissue). Final histopathologic assessment of the resected specimens 




































Figure 3.2  Detection of secondary primary. The first two rows display the bright field and 
corresponding fluorescence images of the primary tumor (black dotted line) and 
secondary tumor (red circle) in situ and ex vivo. The red dotted line delineates the 
location from where the hematoxylin and eosin slide (H&E slide) was obtained. The 
bottom row displays the H&E slide and corresponding fluorescence image of the slide 
with measured distance from primary (black solid line) to secondary tumor (red solid 
line). 
 



































Figure 3.3  Detection of unanticipated extend of disease. Top row shows the MRI (a) and FDG-PET 
(b) images of the level II lesion (red circle). Second, third and fourth row display the 
bright field and corresponding fluorescence images during resection. Second row 
indicates two distinct masses (yellow solid line), after removal of the level IIa LN, the 
extend of the level IIb tumor becomes visible using fluorescence imaging. At the 
bottom row the detection of residual disease is illustrated. FDG-PET = positron 




Surgeons traditionally rely on visual inspection of subtle surface changes and 
palpation to determine tumor margins. Findings from our current study suggest 
that open-field fluorescence imaging can improve detection of tumor and tumor 
margins. Our data suggest that fluorescent imaging can be used to evaluate 
the primary tumor, surrounding mucosa, and regional metastatic disease during 
ablative resection. We believe that our findings illustrate scenarios in which 
surgical experience, visualization, and palpation can be successfully 
augmented with fluorescence imaging to improve clinical care and patient 
outcomes.  
Quantifying imaging data remained challenging because open-field 
devices are not used in a light-controlled environment where ambient light, 
distance, and signal can be standardized. Furthermore, the surgeon uses the 
real-time information throughout the case, continuously incorporating the 
fluorescence data with tactile information, white light images, and experience. 
As a result, isolating the value of the imaging information can be difficult to 
assess objectively.  
We have sought to identify 2 different strategies to assess the value of real-
time imaging; one in which disease can be visualized encroaching on the deep 
margin of the tumor and the other in which disease is outside expected 
boundaries. These findings are uniquely valuable in that imaging information 
leads to immediate reevaluation of the surgical site, preventing a close or 
microscopically positive margin. Our findings are consistent with previously 
published results. The randomized-controlled study by Stummer et al.18 
reported that fluorescence visualization of malignant glioma during surgery 
resulted in a significant increase in complete resection (65% vs. 36%, 
p<0.0001) and subsequently fewer reinterventions. Clinical trials such as these 
will be critical to show the value of these real-time open-field techniques.  
Previously, we demonstrated the safety, sensitivity, and specificity of 
antibody-fluorescence dye for surgical imaging.8,13 Also, we demonstrated that 
closed-field ex vivo imaging of the surgical specimen has the advantage over 
open-field in situ imaging due to less reflectance and no interference of 
ambient light.8 Closed-field systems can be used for optical mapping of the 
surgical specimen in a highly sensitive and quantitative fashion to identify 
suspicious areas that may guide pathologic assessment. Nevertheless, closed-
field systems are incapable of in situ disease assessment. Therefore, open-field 
systems are needed for in situ evaluation of disease extent and assessment of 
close and positive deep margins in real time.  
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Although open-field imaging technologies have advanced significantly, 
important limitations must be considered. Although this study demonstrates the 
potential utility of real-time fluorescence imaging for surgical tumor resection, 
the true value of this technique will be seen when patient outcome data become 
available. Other limitations encountered during this study offer important insight 
in the value of open-field devices for surgical navigation. In their current form, 
imaging results are not quantitative using open-field devices because the 
instruments are influenced by ambient light in the operating room environment, 
camera angle, and distance between the camera and the patient. To obtain 
quantifiable imaging information, a controlled environment using a closed-field 
fluorescence imaging device is needed, which requires an ex vivo setting.20 
Currently, some open-field systems are able to suppress a significant amount of 
ambient light by synchronizing the acquisition to the 120 Hz of room light with 
pulsed LED excitation.25 Furthermore, to be widely applicable, software 
adaptations have to allow the camera to accommodate in a wide range of 
signal intensities and distances. Although this will enable small fragments of 
tumor to be distinguished from the background, various contrast-enhancement 
schemes may also increase the estimated SBR for nonspecific structures in the 
absence of a definitive high-intensity signal (such as tumor). We also believe 
that in order for open-field systems to be successful, the surgeon’s experience 
and other operative information must be integrated with use of the camera 
system. Tumor signals appear highly heterogeneous, compared with the 
uniform, smooth appearance of the mucosal signal. We showed that different 
tissue types have unique fluorescent patterns (visually, MSI and CV), which can 
be incorporated into the surgeon’s armamentarium to distinguish normal from 
cancerous tissue. Routine use of fluorescence imaging may permit 
development of pattern-recognition skills to identify suspicious areas or to 
distinguish tumor from off-target signal in a fashion similar to the pattern-
recognition skills that radiologists use when interpreting anatomic imaging. 
Consistent with this analogy, radiologists often identify specific tissues based 
on their radiographic appearance (Supplemental Figure S3.1, similar to salt-
and-pepper signals in MRI literature26). We predict that as fluorescence 
imaging further develops into the clinic, software and hardware improvements, 
pattern recognition, and background identification could be used to set a 
baseline for imaging at the beginning of the case. In this manner, a patient-
specific, fixed threshold could be established and used to quantify suspicious 
areas throughout the whole case. Furthermore, future studies might involve the 
use of machine-learning approaches to delineate tumor from healthy tissue 




In this study, we demonstrated potential utilities of real-time fluorescence 
imaging for intraoperative guidance in oncologic head and neck surgery. 
Furthermore, we proposed modifications for future open-field camera systems 
to augment successful surgical resection and improvement of patient outcome. 
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Figure S3.1 Fluorescence tissue patterns. (A and B) Bright field (A) and corresponding 
fluorescence image (B) of a representable patient with a buccal mucosa squamous 
cell carcinoma. (C and D) Close up of heterogenetic tumor tissue (C) and mucosal 
tissue (D). (E and F) Represents the signal intensity (E) and signal distribution (F) for 
each tissue type. a.u. = arbitrary units; MSI = mean signal intensity; pre = pre-
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Surgical resection remains the primary treatment for the majority of solid 
tumors. Despite efforts to obtain wide margins, close or positive surgical 
margins (< 5 mm) are found in 15—30% of head and neck cancer patients. 
Obtaining negative margins requires immediate, intraoperative feedback of 
margin status. To this end, we propose optical specimen mapping of resected 
tumor specimens immediately after removal. 
 
Materials and methods 
A first-in-human pilot study was performed in patients (n=8) after infusion of 
fluorescently labeled antibody, panitumumab-IRDye800 to allow surgical 
mapping of the tumor specimen. Patients underwent standard of care surgical 
resection for head and neck squamous cell carcinoma (HNSCC). Optical 
specimen mapping was performed on the primary tumor specimen and 
correlated with pathological findings after tissue processing. 
 
Results 
Optical mapping of the specimen had a 95% sensitivity and 89% specificity to 
detect cancer within 5 mm (n=160) of the cut surface. To detect tumor within 
2 mm of the specimen surface, the sensitivity of optical specimen mapping was 
100%. The maximal observed penetration depth of panitumumab-IRDye800 
through human tissue in our study was 6.3 mm. 
 
Conclusion 
Optical specimen mapping is a highly sensitive and specific method for 
evaluation of margins within <5 mm of the tumor mass in HNSCC specimens. 
This technology has potentially broad applications for ensuring adequate tumor 
resection and negative margins in head and neck cancers. 
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Introduction 
Surgical resection remains the gold standard for the majority of solid tumors.1 
Despite improved medical technologies for pre-operative surgical planning2,3 
and intraoperative guidance, including radio-guided and fluorescence imaging-
based approaches,4,5 head and neck surgeons still primarily rely on their vision 
and palpation to determine surgical margins. Not surprisingly, tumor-positive 
margins are still found in 15—30% of all head and neck cancer resections.6-8 In 
head and neck cancer, a positive margin is defined as tumor within 2 mm of the 
cut edge, and a close margin is defined as tumor tissue 2-5 mm from the cut 
edge. Importantly, positive margin status is directly correlated with locoregional 
residual cancer and overall survival.9-11 Although controversial and situation 
dependent, both close and positive margins are often clinically treated similarly, 
with recommendations for further resection to achieve negative margins. 
However, as margins are not definitively established until final pathology reports 
are issued many days after surgery, re-resection can be challenging clinically 
and can add morbidity to the patient’s care. Immediate assessment of the 
specimen’s margins in the operating room would provide immediately 
actionable information to the surgeon. 
The current standard for detecting residual disease is gross inspection of 
the surgical specimen and/or wound bed, followed by frozen sectioning of 
suspicious areas for further histopathological assessment.12 Besides the time-
consuming nature of the procedure (15-20 min per frozen section), frozen 
section analysis can only examine a small fraction of the specimen.12 Another 
limitation of frozen section analysis is the risk of sampling error, which may be 
further impaired by the limited ability of the surgeon to predict and thus select 
areas with tumor involved margins.15,16 In order to overcome these limitations, 
we propose a technique that allows real-time intraoperative evaluation of the 
entire surface of the resected specimen to preselect “at risk” margins using an 
optical scanning technique. 
Using systemically administered near-infrared (NIR) dye labeled tumor 
targeting antibodies, we and others demonstrated that the fluorescent signal 
detected in tumor tissue is much higher than surrounding normal tissue.16-19 The 
NIR fluorescence can penetrate through approximately 5-6 mm of tissue, 
allowing for precise identification of tumor and normal tissue. The goal of the 
current study was to understand if the properties of NIR light can be used 
clinically to identify close margins and quantify the distance between the 
specimen’s surface and the depth of the tumor mass. We hypothesize that with 
macroscopic optical specimen mapping (OSM) of the whole surgical specimen, 
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we can accurately predict close and/or positive tumor margins. This OSM 
technique will allow the surgeon to evaluate the entire surface of the specimen 
for suspicious areas that need further assessment using frozen sectioning in 
order to achieve a complete oncological resection. 
Materials and methods 
Optical specimen mapping device 
The OSM device (IGP-ELVIS, LI-COR, Lincoln, NE, USA) provides an enclosed 
ambient light-free space for consistent and reliable closed-field fluorescence 
imaging. Inside the closed-field space, a motion and rotational stage offers a 
variety of view angles of the specimen within an imaging sequence along two 
rotational axes. To achieve OSM, motion stages in the chamber were 
synchronized with the excitation and detection components in the optical 
module. Figure 4.1 provides an overview of the device used for OSM of the 
deep surface of the tumor. The imaging volume is formed by the illumination 
light field together with the depth-of-focus and the field of view of the imaging 
lens (Figure 4.1b). The controlled light sources comprise laser diodes at 785 
nm and visible white light LEDs. Illumination is below the maximum permissible 
exposure (ANSI Z136.1-2007) so the specimen is not damaged by the light. 
The imaging resolution of the device was about 100 LP/in. (125 μm) within the 
imaging volume of 500mL. Imaging at a higher resolution of 150 LP/in. (85 μm) 
is available for small samples under 50 mL. The fluorescence images were 
collected through an 800 nm channel with center wavelength at 820 nm. A 
control program (based on LabVIEW, National Instrument, TX, USA) ran the 
imaging process connected to a customized Image Studio software (LI-COR 
Biosciences) for imaging collection, storage, and analysis. 
Establishing imaging parameters 
To determine the maximal fluorescence penetration depth of IRdye800CW-
carboxylate and to test the three-dimensional surface mapping functionality, a 
tissue-mimicking phantom with homogenous IRdye800CW-carboxylate 
distribution was created in 1% agarose (Life Technologies, Carlsbad, CA, 
USA), 1% whole bovine blood (Sigma-Aldrich, Saint Louis, MO, USA) and 1% 
intralipid emulsion (Sigma-Aldrich).17  





Figure 4.1. Fluorescence Optical Specimen Mapping Device. The device is an instrument for 
sensitive and consistent specimen mapping (specimen sizes up to 10 cm × 10 cm). 
The fluorescence images can be assessed through two wireless viewers. One of the 
viewers is mounted on the device, the other can be detached from the device and 
allows the user to view the images in another room or building. (a). Schematic drawing 
of the illumination light (red beams) and the imaging volume, which is formed by the 
illumination light fields, imaging depth-of-focus and field of view of the imaging lens (b). 
Optical phantom with dye plugs (c). First, a bright field image, second an overlay of 
fluorescence and white light image and third a fully fluorescence image. (For 
interpretation of the references to color in this figure legend, the reader is referred to 
the web version of this article.) 
 
 
First, the agarose in water solution was heated to 80°C and allowed to cool 
down to 45°C before adding bovine blood, intralipid and IRDye800CW-
carboxylate (916 nM) under continuous stirring to ensure homogeneous 
distribution. The concentration of IRDye800CW used in the phantom was 
selected to be clinically relevant by matching the fluorescence with tumor 
samples from patients. Hereafter, the mixture was poured into cube shaped 
molds (12.7 × 12.7 × 12.7 mm; volume: 2.0 mL) and cooled down to solidify. 
The phantom was then imaged with the OSM device, after which increasing 
stacks of bovine muscle (thin sliced ribeye) were placed over the phantom 
(Figure 4.3). Upon increasing stacks, the phantom was reimaged on the device 
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whereby the thickness of stacks was measured by taking the average of three 
measurements of all stacked layers. Quantitative analysis of the images was 
performed using Image Studio (LI-COR Biosciences) by drawing regions of 
interest (ROIs) in the middle of the phantom and extracting the mean 
fluorescence intensity (MFI). The MFI was then plotted against the depth (i.e. 
thickness) of all overlaying non-fluorescent muscle stacks. Signal-to-noise ratios 





Figure 4.3 Penetration depth of fluorescence for IRDye-800CW loaded phantom. Visual 
presentation, of two series of representative bright field and corresponding 
fluorescence images (first image without stacking, second image is one layer, third 
image two layers, etc.) that show the decrease in fluorescence signal as the distance 
to the phantom increases. Row (a) and (b) were imaged by the top view camera, row 
(c) and (d) were imaged with the side view camera. Informative bright field and 
corresponding fluorescence image of side view on phantom (e). Quantitative analysis 
of the fluorescence signal with increasing distance to the phantom (f). Color bars are 
given were applicable. 




Prior to enrollment, written informed consent was obtained from all patients. The 
Phase I study evaluating panitumumab-IRDye800CW was approved by the 
Stanford Institutional Review Board (IRB-35064) (NCT02415881). More details 
on the phase I study can be found in Gao et al..19 Briefly, patients (n=8) were 
infused 1-4 days prior to surgery with a flat dose of 25 mg (n=4) or 50 mg (n=4) 
panitu-mumab-IRDye800CW (excitation/emission max: 774/789 nm; half-life: 24 
h19). After resection, the tumor specimens were imaged with the OSM device 
before being sent to pathology for standard of care histological assessment. 
There, the specimen was formalin-fixed and cut in 5 mm tissue sections. The 
specimen was then reconstructed from the 5 mm sections and reimaged. 
Thereafter, the 5 mm tissue sections were processed and paraffin-embedded. 
From each 5 mm section, a representative 5 m section was cut for routine 
hematoxylin and eosin (H & E) staining for diagnosis. On the acquired H&E 
slides, areas with invasive or in situ SCC were outlined by a board-certified 
pathologist. The slides were then digitized and analyzed for our study. 
Correlation of fluorescence signal with margin distance 
To assess the fluorescent signal, a binary yes/no approach was used by 
placing a raster (5 × 1 mm) over the lateral side of the imaged specimen. 
Similar to the approach previously described,16,19-22 the threshold was adjusted 
for each specimen to reveal heterogeneity in fluorescence intensity within the 
gross tumor and no signal in normal tissue (i.e. muscle, fat). Areas on the 
surface exceeding the threshold within the raster were considered positive for 
fluorescence, and areas below the threshold were considered negative for 
fluorescence. On the digitized outlined H & E slides, we used ImageJ (version 
1.50i, National Institute of Health, Washington D.C., Maryland, USA) to measure 
the distance from the tumor border to the specimen’s edge, further defined as 
margin distance (Figure 4.2). This margin distance for fluorescence positive 
areas was then compared to the margin distance for fluorescence negative 
areas using an unpaired, two-tailed t-test. To determine the sensitivity and 
specificity of OSM for tumor detection on the deep surface, a receiver operation 
characteristic (ROC) curve was generated. Values were reported as means with 
standard deviation and 95% confidence intervals (95%CI) where applicable. 
False-positive results were specified as an area positive for fluorescence but 
negative for tumor within 5 mm from the specimen’s edge; false-negative 
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results were defined as an area negative for fluorescence but positive for tumor 




Figure 4.2.  Flow diagram of optical surface mapping analysis. Lateral side view of representable 
specimen (buccal) (a) which was formalin fixed, sectioned in 5 mm serial sections 
(white lines) (b). Tumor areas were outlined (black dashed line) on the H&E slides and 
margin distances (red lines) were measured at 1 mm intervals (c). Consequently, the 
number of measurements was defined by the maximal tumor depth as measured from 
the mucosal surface to the deep surface on the H&E slide. Margin distances in 
fluorescence areas were compared to margin distances in areas without fluorescence. 
T = tumor tissue; M = medial; L = lateral; H&E slide = Hematoxylin and eosin slide. (For 
interpretation of the references to color in this figure legend, the reader is referred to 
the web version of this article.) 
Results 
Optical specimen mapping validation  
In order to validate optical scanning as a means to predict the distance 
between the tumor border and cut specimen edge (the margin distance), we 
conducted a phantom study using physiologically relevant concentrations of 
the dye in the phantom and fresh bovine tissues. An IRDye800CW loaded 
tumor phantom (tissue-mimicking lipid and blood mixture) was imaged in the 
optical scanner using a concentration of dye consistent with what we found in 
the tumor specimens obtained during the clinical trial. OSM was performed 
using incremental thickness of normal tissue to determine the maximal distance 
at which the fluorescent signal was still detectable. Figure 4.3 shows the visual 
appearance of the phantom experiment. The signal-to-noise ratio (MFI-phantom 
divided by MFI-background) of the non-stacked phantom was found to be 253 
(Figure 4.3). The penetration depth of IRDye800CW signal though unloaded 
muscle layers was 11 mm (lowest signal-to-noise ratio 1.2 ± 0.1). 
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Clinical study 
Optical surface mapping of the specimen 
OSM was performed on the back table in the operating room in parallel with the 
surgery. After the surgeon had removed the primary tumor specimen from the 
patient, it was imaged directly in the OSM device whereby the deep margin 
side was positioned upwards (i.e. facing the camera). There were no issues 
with specimen positioning. The acquisition time for a two-dimensional top view 
image was around 25 s (1 image) and 7 min (17 images) for a full three-
dimensional optical specimen map. By scaling the fluorescence threshold, 
suspicious regions could easily be recognized on the specimen to be further 
interrogated by the surgeon based on clinical judgement. As the device 
captured both white-light images and fluorescent images simultaneously, we 
were able to project the white-light channel over the fluorescence channel to 
further “isolate” suspicious areas. Consequently, data interpretation was 
intuitive for the surgeon since specific landmarks could be identified on the 
specimen and suspicious areas rapidly located on the specimen. Location 
within the operating room was considered by the surgeon to be optimal for 
immediate assessment and specimen orientation. 
Fluorescence signal vs. margin distance 
To determine if OSM could predict close (<5 mm) or positive (<2 mm) margins, 
we performed optical scanning of the primary tumor specimens of eight 
consecutive patients with HNSCC (Table 4.1). Of these eight patients, six were 
eligible for analysis using our methodology (see Table 4.1 for details). Figure 
4.4 shows a representative example of an optical surface map that was 
generated from a patient with lateral tongue cancer. 
Following serial sectioning of the surgical specimens, a total of 39 sections 
contained tumor tissue, and a total of 160 data points were extracted. As shown 
in Figure 4.5a—e, the presence or absence of fluorescence on the specimens’ 
surface correlated with the presence or absence of tumor close to the 
specimen’s margin. Specifically, when a fluorescence signal was present on 
the deep surface of the specimen, tumor was significantly closer to the edge 
than when no fluorescence signal was detected (2.6 ± 0.1 mm versus 6.9 ± 0.2 




Table 4.1 Patient and tumor characteristics. 
Age Gender Tumor location pTNM 
54 M Buccal mucosa* T2N0M0 
48 M Lateral tongue T3N2cM0 
71 M Lateral tongue T2N0M0 
58 F Retromolar trigone** T3N0M0 
65 F Buccal mucosa T2N2bM0 
71 F Buccal mucosa T3N0M0 
63 F Palate T2N0M0 
71 F Lateral tongue T2N2bM0 
The first patient (SCC of the buccal mucosal tissue) was excluded as the fluorescence signal was a 
factor 10 lower (MFI = 0.025) than the other patients (MFI = 0.25). It is likely that the reduced signal 
is caused by the prolonged time of infusion to surgery of the panitumumab-IRDye800CW compared 
to the other patients (92 h versus 21 h average). Another patient with SCC of the retromolar trigone 
was excluded. Although the tumor could be imaged successfully in the OSM device, the exophytic 
nature of the tumor prevented three-dimensional pathological reconstruction of the specimen. This 
reconstruction is needed for accurate analysis of the margin distances and therefore the patient 
was excluded. 
 
Sensitivity and specificity of optical surface mapping 
Sensitivity and specificity of OSM for tumor detection were determined using a 
ROC curve (Figure 4.5g). Optical specimen mapping achieved high sensitivity 
regardless of cut-off margin distances. In particular, at the <5 mm cut-off 
distance (clinically defined as close or positive margin), positive fluorescence 
status was highly sensitive and specific (95% and 89%, respectively). In addition, 
fluorescence was able to detect 100% of cancer tissue within <2 mm of the 
surgical resection margin (i.e. true positive margins).  
At the 2-5 mm range (close margin range) the sensitivity was 95-100%. 
Notably, specificity was lower at the <2 mm range and the 2-5 mm range (1-
41% and 41-89%, respectively). The area under the curve (AUC) was 0.97 
using the 5 mm cut-off (p<0.0001, n=160). From all 160 data points, false-
positive results (i.e. fluorescence positive edge, but tumor distance >5 mm) 
were found in 7% of all fluorescence positive margins, whereas 2% of all 
fluorescence negative margins resulted in false-negative findings (i.e. 
fluorescence negative edge, but tumor distance <5 mm). 
 





Figure 4.4  Optical specimen map of representable patient. Optical specimen mapping of a 
surgical specimen from a patient who underwent a hemiglossectomy. Bright field and 
fluorescence images of mucosal margin and deep margin (a) with anatomical 
orientation of resected surgical specimen in the oral cavity (b). Color bar indicates the 
threshold settings. Furthermore, the rotational views of the specimen (d—l) with 
illustration (c) indicating the rotational direction and corresponding views (d, i, f and l). 
Interactive animation allows the user to scroll through the tumor-surface map (along 
multi-axis) and pause at a specific view for detailed inspection. Note that this figure 
contains merely a representative selection of 11 from the 22 images that make up the 
three-dimensional rendering. sup = superior; inf = inferior; ant = anterior; post = 









Figure 4.5 Fluorescence signal versus margin distance. Bright field and corresponding 
fluorescence top view images of surgical specimen are shown (a and b). The red 
dashed line (b) indicates the position from where the 5 mm serial section (c) was 
obtained. The H&E slide (d) with delineated tumor (dashed black line) and 
corresponding illustration of the H&E slide (e). Quantitative analysis demonstrates a 
significant difference in tumor distance between fluorescence positive and negative 
areas. T = tumor; Flu neg = negative for fluorescence; Flu pos = positive for 
fluorescence; Margin distance = tumor-edge-to-specimen-edge distance. 
Penetration depth of panitumumab-IRDye800 
While the penetration depth of fluorescent signal in an ideal phantom set-up 
reached a maximum of 11.0 mm (Figure 4.2), in human tissue the maximal 
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observed penetration depth of panitumumab-IRDye800 was 6.3 mm; at higher 
margin distances, 100% of the overlying surface remained negative for 
fluorescence signal, whereas at distances <6.3 mm fluorescence signals could 
be detected. 
Discussion 
Although frozen section examination has shown to be highly accurate (90%) if 
performed by an experienced pathologist,15 only a small fraction of the 
specimen can be sampled with identification of suspicious areas based on 
visual inspection and palpation. This may, amongst other factors, contribute to 
the large portion of positive margins (15-30%) still found in all HNSCC 
resections at permanent pathological analysis.6-8,13 Here we demonstrate that 
the use of optical mapping may allow identification of high-risk areas on the 
surgical specimen that need further evaluation using clinical judgment or frozen 
sectioning. Our data suggests that fluorescence is highly sensitive to detect 
cancer within the clinically relevant cut-offs (<2 mm and <5 mm; 100% and 
95%, respectively) and could be valuable as confirmation of a negative margin. 
When a margin is positive for fluorescence, the surgeon would have the 
opportunity to reresect additional tissue at the suspicious area. This additional 
tissue can be imaged as well to assess fluorescence status and assure a 
negative margin. The 3D information from the specimen that details the location 
of close or positive margins becomes available to the surgeon immediately after 
resection and may provide important information that the surgeon can 
incorporate into decision making. 
Here we use the unique properties of NIR light to our advantage; 
penetration of NIR light through normal soft-tissue (i.e. muscle and fat) is 
approximately 5-6 mm, and therefore can be used to select areas at risk for 
positive margins during imaging of the specimen. Consistent with the known 
properties of NIR light, we demonstrated the maximum penetration depth of 
panitumumab-IRDye800 being 6.3 mm whereby we reached >95% sensitivity 
and specificity for identifying tumor involved margins. Although variations in 
soft-tissue composition and signal intensity will certainly influence the depth of 
penetration, from a clinical perspective, a margin of greater than 5 mm is 
considered negative. This technique could ultimately identify areas that are 
suspicious for tumor within 5-6 mm of the specimen edge. If validated by 
clinical judgement or frozen section analysis as well, then the surgeon has the 
immediate opportunity to return to the wound bed to further resect that specific 
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margin. This strategy would be more efficient, reduce sampling error and 
provide confidence and additional guidance for the operating surgeon. 
We believe that due to limited exposure and challenging anatomy in 
patients with HNSCC, they particularly may benefit from closed-field OSM 
rather than intermittent in situ imaging, which is not always adapted easily into 
the surgical workflow. We have previously demonstrated that specimen imaging 
using a closed-field system to obtain quantitative fluorescence imaging 
information has distinct advantages.14,23,27 However, a single planar image of 
the specimen had significant limitations and as a consequence we worked 
collaboratively to develop the OSM device for complete imaging of all 
specimen surfaces. The OSM device performs nearly complete surface 
mapping in approximately 7 min, which allows immediate evaluation in the 
operating room. Importantly, the OSM imaging methods provide a quantitative 
and scalable image in high resolution, unlike open-field devices that are 
currently the standard of care for most surgical imaging. 
While this study represents a successful first-in-human proof-of-concept of 
OSM, important limitations should be addressed. First and foremost, although 
many optimal imaging agents are currently being evaluated in late stage 
clinical trials,19,24,25,27 it will require the approval of a successful optical imaging 
agent for general use. Another limitation is inherent to the use of the OSM 
device, and directly relatable to fluorescence imaging: limited penetration 
depth and presence of autofluorescence. Although, the autofluorescence is 
strongly reduced and the penetration depth improved compared to visual 
fluorescence dyes, it is still limited compared to that of radiotracers.3 
Optical imaging strategies that identify tumor at the cut surface are 
appropriate for tumors deriving from the breast or the brain, but for lung, head 
and neck, colon and pancreas cancers the margin is considered close/positive 
within 5 mm of the tumor. Therefore, given the penetration depth of IRDye800, 
our proposed method might not be appropriate for breast and brain cancers, 
since fluorescence signal at the specimen edge might be detected up to 5-6 
mm from the tumor edge. For these tumor types, one might consider a slightly 
different approach, such as visual fluorescent dyes (i.e. fluorescein iso-
thiocyanate; penetration depth 1-2 mm). However, for tumor types in which a 5 
mm margin is required, the relative high penetration depth of panitumumab-
IRDye800 is a distinct advantage. If the margin appears clear on gross 
inspection and no fluorescence signal is observed, the margin should be 
considered not suspicious for tumor within 5 mm. The robustness for this 
proposed approach is validated in our cohort by the low false-negative rate (i.e. 
no fluorescence signal, and tumor within <5 mm) of 2% and excellent sensitivity 
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and specificity. Moreover, as we reduce the acceptable margin distance, we 
find a corresponding decrease in the false negative rate with a corresponding 
reduction in the number of false-positive margins (decreased specificity). This 
is likely due to scatter of light within the soft tissue. From a clinically relevant 
perspective, one would rather have a false-positive result than a false-negative 
result as leaving malignant tissue behind can have significant consequences 
for the patient.11,26 Such a technique could significantly decrease our current 
poor margin control rate and thereby effectuate improved locoregional disease 
control and patient survival. In addition, due to the expression of EGFR by 
regional metastatic disease, we believe OSM also has potential for the 
identification of tumor-involved lymph nodes and this application is currently 
under evaluation. 
Conclusion 
Our proposed strategy using fluorescent OSM could have substantial 
advantage in rapidly and accurately assessing tumor margins in real-time. OSM 
can provide a highly sensitive method to detect cancer within 5 mm of the 
surgical margin and thereby assist the surgeon in judging completeness of 
resection or preselect areas of interest for further frozen sectioning analysis. 
The proposed technique of OSM, while optimal in HNSCC, would be very useful 
in many other cancers for which wide margin status is desired (e.g. lung and 
colorectal cancer). The data presented here supports further development of 
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Complete surgical resection is the standard of care for treatment of oral cancer 
although the positive margin rate remains 15-30%. Tissue sampling from the 
resected specimen and from the wound bed for frozen section analysis (FSA) 
remains the mainstay for intraoperative margin assessment but is subject to 
sampling error and can require the processing of multiple samples. We sought to 
understand if an ex vivo imaging strategy using a tumor-targeted fluorescently 
labeled antibody could accurately identify the closest peripheral margin on the 
mucosal surface of resected tumor specimen, so that this ‘sentinel margin’ could 
be used to guide pathological sampling. 
 
Materials and methods 
Twenty-nine patients with oral squamous cell carcinoma scheduled for surgical 
resection were consented for the study and received systemic administration of 
a tumor-targeted fluorescently labeled antibody (Panitumumab IRDye800CW). 
After surgical resection, the tumor specimen was imaged using a closed-field 
fluorescent imaging device. Relevant pathological data was available for five 
patients on retrospective review. For each of these five patients, two regions of 
highest fluorescence intensity at the peripheral margin and one region of lowest 
fluorescence intensity were identified, and results were correlated with histology 
to determine if the region of highest fluorescence intensity along the mucosal 
margin (i.e. the sentinel margin) was truly the closest margin. 
 
Results 
Imaging acquisition of the mucosal surface of the specimen immediately after 
surgery took approximately thirty seconds. In all of the specimens, the region of 
highest fluorescence at the specimen edge had a significantly smaller margin 
distance than other sampled regions. The average margin distance at the 
closest, “sentinel”, margin was 3.2 mm compared to a margin distance of 8.0 
mm at other regions (p<0.0001).  
 
Conclusions 
This proof-of-concept study suggests that, when combined with routine FSA, ex 
vivo fluorescent specimen imaging can be used to identify the closest surgical 
margin on the specimen. This approach may reduce sampling error of 
intraoperative evaluation, which should ultimately improve the ability of the 
surgeon to identify the sentinel margin. This rapid sentinel margin identification 
improves the surgeon’s orientation to areas most likely to be positive in the 
surgical wound bed and may expedite pathology workflow. 
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Introduction 
Surgical resection with curative intent remains a mainstay in the treatment of 
solid tumors. Patient outcomes are largely dependent on obtaining clear 
surgical margins, as locoregional recurrence rates are significantly higher when 
residual disease exists at or near the margin.1 Unfortunately, the rates of 
positive margins in most branches of surgical oncology have remained 
stagnant over the past 15 years.2 This has been a particular burden in the 
management of head and neck cancers, with positive margin rates ranging 
from 15-30%.3 
To obtain a tumor-negative margin in head and neck cancer, the surgeon 
must attain a 5-mm margin of normal tissue around the tumor, based on 
extensive survival data demonstrating that smaller margins result in worse 
survival.4 To accurately measure this margin of normal tissue, the margin should 
be assessed on the specimen rather than the wound bed, although this remains 
controversial.5,6 Obtaining a consistent 5-mm cuff of normal tissue is 
challenging since surgeons largely rely on visual and tactile cues when 
operating. While many novel technologies have emerged to assist in delineation 
of margins, none have been incorporated into the standard surgical and 
pathological workflow.7 Therefore, currently the standard of care for 
intraoperative margin assessment is the use of frozen section analysis (FSA). 
Here, the specimen margins are sampled by the surgeon and/or pathologist for 
immediate processing and evaluation in parallel to surgery. Results are 
communicated back to the surgeon so that further resection can be performed 
if required. 
There are two critical limitations with this current practice of identifying 
positive margins. The first limitation is the fact that sampling of the tumor 
margin, whether by the surgeon or by the pathologist, is subject to error. Most 
specimens are 5-10 cm in diameter, and only a fraction of the margin can be 
sampled; therefore, the likelihood of a false negative assessment is high. The 
second limitation is that following resection, the tumor specimen must leave the 
operating room, and the orientation of the specimen relative to the wound bed 
is often lost. Consequently, when the pathologist reports the FSA results to the 
operating room, it is challenging for the surgeon to correlate where in the 
patient the positive margin was identified. 
A number of novel imaging technologies have been utilized in surgical 
oncology and have been met with variable success. Narrow band imaging 
(NBI) has been available for many years and has been used for both early 
detection and screening of head and neck cancer, as well as for intraoperative 
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margin assessment.8,9 The technology relies on the detection of hemoglobin, 
which in turn allows for enhanced visualization of neoangiogenesis, a known 
phenomenon in solid tumors.10 However, the technique is challenging to 
master, and is heavily reliant on the subjective interpretation of the images. 
Furthermore, the technique is influenced heavily by tissue properties and 
modified vascularity, which are often seen with tumors of the head and neck.11 
Another emerging technology for intraoperative margin analysis during 
oncological surgery is the use of fluorescence molecular imaging.12-14 
Fluorescently labeled antibodies allow for highly specific targeting of cancer 
cells and can be utilized for a myriad of imaging techniques. Leveraging this 
technology in the current study, we propose a novel methodology for rapid, 
objective and reproducible identification of the closest margin on the peripheral 
mucosal surface of the resected tumor specimen, termed the ‘sentinel margin’. 
We have previously demonstrated that the sentinel margin strategy can be 
applied to evaluate the deep surface of the surgical specimen, and here we 
focus on the mucosal margin.15 
Successful validation of the proposed fluorescent imaging-based 
specimen mapping technique would allow for more accurate sampling for FSA 
from the tumor specimen. This would lead to improved accuracy of 
intraoperative tumor margin analysis and ultimately improve patient prognosis. 
Furthermore, by targeting the sentinel margin for FSA, fewer samples would be 
required to adequately assess the entire peripheral margin, with secondary 
benefits such as a significantly reduced burden on the pathologist and fewer 
delays in operating time. 
The objective of this retrospective proof-of-concept study was to determine 
if the ‘sentinel margin’ as identified by our proposed fluorescent imaging-based 
specimen mapping technique could accurately identify the closest surgical 
margin at the peripheral, mucosal border in order to improve accuracy of FSA 
sampling and to improve surgical orientation to the wound bed when further 
resection is required. 
Materials and methods 
Study design 
A Phase I study evaluating panitumumab-IRDye800CW was approved by the 
Stanford Institutional Review Board (IRB-35064; NCT02415881). The study 
process, safety of panitumumab-IRDye800CW, and pharmacokinetics of the 
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drug have been previously reported.16 Consented patients were infused 1-5 
days prior to surgery with a 50 mg dose of panitumumab-IRDye800CW. 
Following primary tumor resection, the mucosal surface of the tumor specimen 
was imaged in a closed-field fluorescence-imaging device (PEARL Trilogy, 
LICOR Biosciences Inc., Lincoln, NE). The specimen was then sent to 
pathology for standard-of-care histological assessment. Specimens were 
formalin-fixed overnight and serially cross sectioned at 5 mm intervals. These 
cross-sections were then further divided as necessary to fit in cassettes for 
paraffin embedding, after which a representative 5 m section was cut from 
each paraffin block for routine hematoxylin and eosin (H & E) staining. 
Histopathological assessment was performed by a board-certified pathologist 
who outlined regions of squamous cell carcinoma on the slide. The slides were 
then digitized (NanoZoomer 2.0-RS; Hamamatsu Photonics K.K., Hamamatsu, 
Japan) and analyzed for study purposes. Included in the current retrospective 
study were patients with oral cavity squamous cell carcinoma whose primary 
tumor had less than a 1 cm depth of invasion and no cortical bone involvement. 
These strict inclusion criteria were applied to ensure patient specimens were 
amenable to the rigorous retrospective histological analysis as described 
below. Therefore, 5 patients were included in this proof-of-concept study. 
Fluorescent imaging-based specimen mapping 
The brightfield and fluorescence images obtained from the closed-field imaging 
device were loaded into ImageJ (version 1.50i, National Institute of Health, 
Washington D.C., ML). Using the brightfield image of the primary tumor 
specimens, a mask was manually created along the periphery of the specimen, 
approximately 1 mm within the edge to avoid any potential for edge artifact 
during fluorescence imaging. This mask was then applied onto the 
fluorescence image obtained from the closed-field imager, allowing for 
measurement of the fluorescence signal along the length of the mask. The raw 
fluorescence data was analyzed in an 8-bit grayscale format with black as 0 
and white as 255. A graphical representation of the workflow can be found in 
Figure 5.1. 
As the specimens were processed according to current standard-of-care 
for gross histological assessment, only a portion of the periphery was 
retrospectively analyzable with available perpendicular sections of tumor to 
peripheral margin. From this analyzable portion of the specimen, two regions of 
highest fluorescence intensity were selected, as well as one region of lowest 
fluorescence. Careful annotation of brightfield images taken throughout each 
stage of gross specimen processing allowed for a direct correlation of 
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specimen fluorescence in the regions of interest with corresponding 
microscopic histology. 
To decrease interference of interpatient variables such as dose, infusion-
to-surgery window, epidermal growth factor receptor (EGFR)-expression and 
other biological factors, patients were used as their own internal control by 
comparing high fluorescence regions to low fluorescence regions on the same 
specimen as was previously described and validated in our deep sentinel 
margin mapping study.15 
 
 
Figure 5.1 Overview of workflow. Representative brightfield (A) and closed-field fluorescence 
image (B) of a resected specimen. (C) Fluorescent image with mask applied 
circumferentially around tumor margin. Specimen divided into 4 quadrants labeled Q1 
— 4 clockwise from 0 degrees. (D,F) H&E slides taken from regions of highest 
fluorescence intensity and control region of low fluorescence intensity with tumor and 
normal mucosa delineated. (E) Graph illustrating corresponding fluorescence 
intensities to peak and control at location on circumferential mask. 
 
Correlation of fluorescence signal with margin distance 
Along the periphery of the specimen, for each of the two regions of the highest 
fluorescence intensity and for one region of low intensity (which served as 
control), the margin distance was measured. The margin distance was defined 
as the distance in millimeters between the tumor edge and the specimen edge 
(i.e. the surgical cut) on the H&E-stained microscopic sections. First, the margin 
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distance at the region of highest fluorescence within the analyzable domain 
was compared to the margin distance at the lowest fluorescence intensity 
region. Second, to determine if the margin distance correlated with the 
fluorescence signal, the margin distance at the highest fluorescence intensity 
region was compared to the second highest fluorescence intensity region. 
In order to register the microscopic findings to the fluorescence signal on 
the intact specimen, the specimen was virtually reconstructed from the 5 mm 
thick macroscopic cross-sections. This process has been described 
previously.17,18 As the cross-sections are approximately 5 mm thick with each 
submitted for microscopic evaluation, the margin of error for mapping histologic 
findings to points along the mucosal edge of the intact specimen is less than 5 
mm; this margin of error does not influence the margin distances which are 
measured in perpendicular planes. On each histological section, the margin 
distance was measured using ImageJ (US NIH, Bethesda, MD USA) three 
independent times and then averaged. 
Statistical analysis 
Data was imported into GraphPad, Version 8.0c (La Jolla, California, USA), and 
the intra-specimen comparison of margin distance was done using the 




Between December 2015 and June 2018, a total of 29 patients underwent 
infusion of panitumumab-IRDye800 for intraoperative fluorescent imaging 
including ex vivo fluorescence imaging of their tumor specimen directly after 
resection. Of these patients, only five had sufficient pathological data to be 
included in the study. Patient and tumor characteristics are presented in Table 
5.1. Imaging acquisition of the peripheral surface of the specimen took 
approximately 30 seconds, after which the specimen was sent to pathology and 
processed for standard of care assessment. As part of the retrospective 
analysis, the sentinel margin was identified by determining the region of highest 
fluorescence intensity along the specimen edge. Each serial cross-section of 
the specimen was also assessed by fluorescence imaging, and the sentinel 
margin distance was compared to all the other margin distances with low 
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fluorescence signal obtained in the tissue sections (approximately 8-18 
analyzable margins per specimen). We chose to evaluate two margins as 
potential sentinel margins (where the fluorescence was highest and second 
highest at the specimen edge). 
High fluorescence intensity regions (sentinel margin) vs. low 
fluorescence intensity regions (controls) 
From each primary tumor specimen, two sentinel margins were identified by 
determining the regions of highest fluorescence at the cut mucosal surface of 
the specimen. The margin distance at the sentinel margin was compared to the 
margin distance at other sites with low fluorescence. In all specimens (100%), 
as shown in Figure 5.2, the margin distances at the sentinel margins were 
significantly lower than the margin distances at other regions; the average 
margin distance at the sentinel margins was 3.2 mm compared to 8.0 mm in 
other regions evaluated (p<0.0001). 
 
Table 5.1 Patient and tumor characteristics.  
# Age Sex Tumor site Tumor stage Tumor grade Smoking Alcohol LVI 
1 62 M Buccal T2N0Mx II N N N 
2 46 M Lateral tongue T1N0Mx I-II Y Y N 
3 69 F Buccal T1N0Mx I-II N N N 
4 65 F Buccal T2N2bMx II Y Y N 
5 70 F Buccal T3N0Mx I N Y N 
Tumor stage was the pathologic staging, and tumor grade was the histologic grading (I: well-
differentiated, II: moderately-differentiated, III: poorly-differentiated). Smoking and alcohol use were 
considered ‘yes’ if the patient had a prior history or was an active user. LVI: lymphovascular 
invasion; N: No; Y: Yes. 
 





Figure 5.2  Margin distance by fluorescent signal. (A) Graph showing increase in margin distance 
at control regions when compared to sampled regions of highest fluorescence 
intensity. Representative brightfield image of resected tumor specimen (B) taken from 
buccal region in patient, seen in (D). (C) Corresponding closed-field fluorescent image 
of resected tumor specimen with black dotted line indicating overlaid circumferential 
mask, white dashed line indicating slice from which H&E slide (E) was taken, 
highlighting the difference in margin distance at the periphery between control region 
and region of highest fluorescence intensity. (F) High resolution image taken from 
Odyssey demonstrating fluorescence distribution within microscopic section. 
 
Comparison of margin distances at the fluorescence extremes 
Next, we sought to determine if margin distance would increase linearly in the 
regions of highest to lowest fluorescence intensity along the periphery of the 
mucosal surface. A significant difference was found for margin distance when 
comparing each group (first sentinel margin, second sentinel margin, and low-
fluorescence control). The sentinel margin (highest fluorescence region at the 
cut edge of the specimen) measured on average 2.4 mm, compared to 4.0 mm 
for the second sentinel margin and 8.0 mm for control regions (p<0.0001). As 
shown in Figure 5.3, in all the imaged specimens, the margin distance was 
closest at the point of highest fluorescence signal, the sentinel margin, 
compared to the second, with the largest margin at the low fluorescence 
intensity region. The average increase in margin distance when comparing the 
first and the second sentinel margins was 1.5±0.90 mm. Importantly, the 
fluorescence intensity also accurately predicted the closest margin distances 
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Figure 5.3  (A) Box and whisker plots demonstrating margin distance by fluorescent signal. (B) 
Graph demonstrating margin distance trends from region of highest fluorescence 
intensity to second highest fluorescence intensity, to control region per patient. 
 
Discussion 
The present study demonstrates that after systemic administration of a targeted 
fluorescent agent, resected oral tumor specimens can be quickly imaged to 
determine the closest or ‘sentinel’ margin on the peripheral mucosal surface. 
This proof-of-concept study has two important clinical implications for future 
specimen analysis in near real-time during surgery. First, it will reduce sampling 
error when selecting tissue for FSA from the primary specimen. Second, by 
generating an immediate intraoperative image available to the surgeon and 
pathologist, it improves the surgeon’s ability to remain oriented to which areas 
are sampled for FSA and aids with the accurate, targeted reresection from the 
wound bed if required. 
The proposed approach has previously been described by our team for 
targeting the closest tumor margin on the deep surface.15 The term ‘sentinel 
margin’ was first introduced to designate the closest margin, which may or may 
not be positive but will be the margin most at risk. If the sentinel margin is 
identified as negative (>5 mm) on FSA, one could reliably predict that the rest 
of the margins from other areas of the tumor specimen would also be negative 
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in the current study. Accurately selecting margins that are most at risk for being 
close and/or positive on FSA has potential to not only decrease the burden on 
the pathologist, but also to shorten the surgical procedure time. In the case 
where the sampled margin returns positive for carcinoma within 5 mm of the cut 
edge, the surgeon can resect additional tissue and repeat the FSA procedure 
until the margin is clear. In these instances, because tumor specimen imaging 
takes place on the back table in the operating room, in parallel with the 
operation, the surgeon can assess the fluorescence image from reresected 
tissue in near-real time. 
The other potential contribution of this technology to the surgical workflow 
is the opportunity to perform the initial assessment immediately after removal of 
the specimen so that the surgeon can remain oriented to the wound bed. Once 
the sentinel margin is identified, the surgeon can confirm the corresponding 
area in the wound bed and then send the specimen for pathological 
determination by FSA. Fluorescence images can then also be made available 
to the pathologist, allowing for more direct and accurate communication of the 
margins at risk and those sampled by FSA. 
This proposed technique is built upon the knowledge that 90% of 
squamous cell carcinomas in the head and neck have upregulated EGFR.19 
Antibody-based contrast agents, such as panitumumab-IRDye800CW, leverage 
this fact and strongly and specifically bind tumor cells with higher affinity than 
adjacent, healthy tissue. This allows for a robust imaging technique that can 
detect regions of tissue harboring cancer. Specificity for this antibody-dye 
bioconjugate for its receptor has been thoroughly studied, and previous studies 
have demonstrated excellent specificity for EGFR.20,21 Although demonstrated 
for EGFR, this proposed technique can be used for margin assessment to any 
highly specific targeted-imaging agents, provided the expression of the target 
in tumor tissue is vastly different from that of normal tissue. Furthermore, since 
this technique relies on using relative fluorescence intensity differences where 
each patient serves as their own control, the methodology is not influenced by 
differences in infusion time or dosing. It is known that fluorescence imaging 
techniques have suffered from limitations with tissue autofluorescence. 
Fluorescent dyes in the near-infrared range of the light spectrum do not suffer 
from these limitations to any reasonable extent, allowing for improved contrast 
and deeper penetration. Depths up to around 6 mm have been reported with 
IRDye800CW, which is fortuitous as positive surgical margins in the head and 
neck are 5 mm or less.5 Breast and skin cancer are two other cancer types that 
leverage these facts and may also be amenable to the proposed intraoperative 
imaging-based specimen mapping technique. 
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A limitation of this study is its retrospective nature and therefore the low 
number of patients that could be included. Because accurate assessment of 
the margin distance requires taking a perpendicular section of tumor to the 
closest (sentinel) margin, microscopic assessment of the relevant fluorescent 
area was possible only in select cases retrospectively. Nevertheless, we feel 
that since each specimen had numerous peripheral margins analyzed, the 
current data is sufficient to ensure the robustness of this methodology. 
However, in order to further evaluate the clinical efficacy of this technique, a 
larger prospective trial is warranted where sentinel peripheral margins 
highlighted fluorescently on the back table are correlated to clinical suspicion 
prior to undergoing selective FSA as appropriate. Such a trial investigating the 
accuracy of sentinel deep and peripheral margins using this technology is 
currently underway at our institution. This technique, once validated on a larger 
series of specimen, could join other techniques, such as NBI, aimed at 
improving margin control. 
Conclusion 
This retrospective, proof-of-concept study demonstrates that fluorescence 
molecular imaging can be used to detect regions on the periphery of the 
resected tumor specimen that correlate with the closest mucosal margin, the 
‘sentinel margin’. The clinical application of this specimen mapping technique 
to surgical management would allow identification of the sentinel margin for 
more accurate and efficient intraoperative sampling. Fluorescence-guided FSA 
could thus reduce diagnostic error secondary to specimen sampling and 
expedite the pathology workflow. When additional resection is required 
following FSA, near real-time fluorescent imaging can facilitate improved 
communication of positive or close margins between the surgeon and 
pathologist by maintaining orientation of the specimen to the wound bed and 
aiding with completeness of resection. With these benefits in mind, this ex vivo 
near real-time imaging strategy has great potential to ultimately improve margin 
control rates in oncological head and neck surgery. 
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Despite major advancements in surgical oncology, the positive margin rate for 
primary head and neck cancer resection remains around 15%—30%. In 
particular, the deep surface margin is the most challenging to adequately 
assess. Inadequate margins are directly correlated to poor survival, and as 
such, mitigation of these rates is critical to improve patient outcomes. We have 
developed an ex vivo imaging strategy that utilizes fluorescence intensity peaks 
(relative to background signal) of an injected anti-EGFR antibody conjugated to 
a fluorescent probe to locate potential close or positive margins on the deep 
surface of the resected tumor specimen.  
 
Experimental design 
Twelve patients with head and neck cancer scheduled for surgery received 
systemic administration of a tumor-specific contrast-agent (panitumumab-
IRDye800CW). After surgical resection, the tumor specimen was imaged using 
a fluorescence imager. The three highest fluorescence intensity-peaks on the 
deep surface of the specimen were isolated and correlated to histology to 
determine the margin distance at these regions.  
 
Results 
Relative fluorescence peak intensities identified the closest margin on the deep 
surface of the specimen within 2.5 minutes. The highest intensity peak 
consistently (100%) detected the closest margin to the tumor. The difference in 
tumor margin distance between the first and second highest fluorescence 
intensity peak averaged 2.1 ± 1.4 mm. The tumor-margin difference between 
the second and third highest peak averaged 1.6 ± 0.6 mm. 
 
Conclusions 
Fluorescence intensity peaks can identify the region on the specimen where 
tumor is closest to specimen's edge on the deep surface. This technique could 
have broad applications in obtaining adequate margins in oncological surgery. 
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Introduction 
Surgical resection is the primary curative treatment for the majority of solid 
tumors. In the management of head and neck squamous cell carcinoma, 
resection of the primary tumor is considered adequate or clear when the 
surgical margins are >5 mm and inadequate if <5 mm, on final histology.1-3 
Failure to obtain clear surgical margins is associated with locoregional 
recurrence and poor overall survival rates4 and may necessitate additional 
therapy such as chemotherapy, radiotherapy, and/or revision surgeries.5 
Unfortunately, the highest overall inadequate margins rates (15%-30%) in all of 
surgical oncology are found in head and neck cancer.6 Despite the introduction 
of many novel technologies, inadequate margin rates have not changed over 
the past 30 years as surgeons cannot successfully differentiate healthy from 
diseased tissue.6,7 The most commonly used method for intraoperative margin 
control is frozen section analysis (FSA); however, this technique suffers from 
sampling errors as surgeons often struggle to identify which suspicious regions 
should be sent for histopathologic assessment.8 This makes FSA not only a 
time-intensive technique (15—20 minutes/ section), but also a subjective 
evaluation method.9 
After resection, the tumor specimen is anatomically divided into the 
peripheral surface (i.e., epithelial or mucosal surface) and the deep surface. 
The term deep surface describes the nonepithelial margin of the tumor 
specimen, which is exposed after surgical resection. In general, intraoperative 
margin assessment of the deep surface is more challenging compared with the 
visible and palpable peripheral margins.10 The lack of visual feedback makes 
the deep surface more at risk for having inadequate margins.11 This is 
illustrated by Woolgar and colleagues who evaluated 301 patients with oral 
cancer and showed that 87% of inadequate margins were located on the deep 
surface compared with 16% on the peripheral surface.1 
To address the challenges hindering effective intraoperative margin 
assessment (and in particular the deep margin), we propose a novel 
methodology for rapid and accurate identification of the closest surgical margin 
on the specimen. We investigated real-time margin detection assessment using 
relative fluorescence intensity peaks after injection of a targeted fluorescent 
agent to identify positive and close margins (tumor <5 mm). This methodology 




Materials and methods 
Study design 
A phase I study evaluating panitumumab-IRDye800CW was approved by the 
Stanford Institutional Review Board (IRB-35064; NCT02415881) and the FDA 
(NCT02415881); written informed consent was obtained from all patients. The 
study was performed in accordance with the Declaration of Helsinki, FDA's 
ICH-GCP guidelines, and United States Common Rule. More details on the 
safety and pharmacokinetics of the phase I study can be found in Gao and 
colleagues.13 Briefly, consenting patients (n=16) were infused 1-5 days prior to 
surgery with panitumumab-IRDye800CW (excitation/emission max: 774/789 nm; 
dose: 25 mg/50 mg flat-dose; half-life: 24 hours (13)). The dosing was not 
weight based: subjects received either a 25 mg (n=5) or a 50 mg (n=11) flat-
dose of panitumumab-IRDye800CW. After resection, the deep surface of the 
tumor specimen was imaged using a closed-field fluorescence imaging device 
(PEARL, LI-COR Biosciences) before being sent to pathology for standard-of-
care histologic assessment. A closed-field device is a small animal imaging 
platform that was repurposed for near-infrared fluorescence imaging on the 
back table in the operation room. This device is particularly valuable for ex vivo 
tissue specimen imaging as it has a wide dynamic range and is "closed" which 
allows for controlled imaging environment, including elimination of ambient 
light.12,14 At pathology, the specimens were formalin-fixed and sectioned into 
5-mm tissue sections. Subsequently, the tissue sections were paraffin-
embedded, and a representative 5-mm section was cut for routine hematoxylin 
and eosin (H & E) staining and diagnosis. On the acquired histologic H&E 
sections, areas with invasive or in situ squamous cell carcinoma were outlined 
by a board-certified pathologist. The slides were then digitized and analyzed 
for study purposes. In addition, EGFR expression of all patients was assessed 
through IHC of two representative tissue sections and results were scored as 
described previously.14 
Fluorescence intensity peak isolation and background reference 
The fluorescence signal of the entire deep surface of the specimen was plotted 
using an interactive 3D signal-mapping plug-in (ImageJ plugin, interactive 3D 
surface plot) for ImageJ (version 1.50i, NIH, Washington D.C., MD). Utilizing 
this 3D signal-mapping tool, we were able to isolate high-intensity regions, 
further described as intensity peaks, from background signal (Figure 6.1). By 
scaling of the threshold of fluorescent signal, a fluorescence signal surface 
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map was generated from which multiple intensity peaks could be isolated. The 
highest intensity peaks (relative to background) were numbered, whereby the 
highest intensity peak (which appears first upon scaling) was assigned as the 
first peak, followed by the second and third peaks (Figure 6.1D-G). Further 
isolation than the third intensity peak region was deemed unnecessary given 
the objective to find the closest tumor margin on the deep surface. Patients 
were used as their own internal control by assigning background regions 
located 10-15 mm from each intensity peak on the same specimen. For the 
statistical analysis of the fluorescence signal differences between intensity 
peaks and background regions on the same specimen, we quantified the signal 
at these regions by drawing circular (5 mm diameter) regions of interests to 




Figure 6.1  Overview of workflow. Representative brightfield (A) and fluorescence image (B) of a 
specimen's deep margin. Number 1—3 allocate the fluorescence peaks in order of first 
appearance throughout the whole figure. C, Side view on the entire fluorescence 
surface map of deep margin (white arrow image B indicates angle). D—F, Identification 
of highest fluorescence intensity peaks on the deep surface (with color bar). The white 
dotted lines and asterisks (red/blue) indicate the orientation in which the H&E slides 
were cut. G—I, H&E slides with delineated tumor (black line) on which the margin 
distance was measured (white box). T, tumor. 
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Correlation of fluorescence signal with margin distance 
For each intensity peak and background region we measured the margin 
distance, which is defined as the distance in millimeters between the tumor 
edge and the specimen edge on the histologic sections. First, to validate our 
method, we evaluated whether the margin distance at the intensity peaks would 
be significantly less when compared with the margin distance at the 
background regions. Second, to evaluate whether the first intensity peak would 
accurately predict the closest margin, we determined whether the margin 
distance at the first peak would be less when compared with the second peak, 
and whether the margin distance at the second peak was less than the margin 
distance at the third peak. 
To correlate the histologic sections to the appropriate intensity peaks or 
background regions on the deep surface, the specimens were reconstructed 
from the 5 mm tissue sections. This process, described by others,15 allowed us 
to register the margin distance measurements performed on histologic 
sections, to the fluorescence intensity peaks (and background regions) located 
on the deep surface of the specimen, within a 1-2 mm margin of error. The 
margin distance was measured five times on each histologic section and 
averaged, using ImageJ. 
Statistical analysis 
Per specimen, MFI [a.u.] and margin distance [mm] between the intensity 
peaks and background regions were compared using the Wilcoxon signed rank 
test. To compare MFI between the intensity peaks and background regions, the 
median signal intensity of the first, second, and third intensity peaks was 
compared with the median signal of the corresponding background regions 
(i.e., one/ intensity peak) for each specimen. To compare margin distances for 
the first, second, and third intensity peak, the Wilcoxon signed rank test was 
used. P-values of 0.05 or less were considered statistically significant. 
GraphPad software (Version 8.0c) was used for statistical analysis. The median 
is used because it is a more robust summary measure to outliers compared 
with the mean. 




A total of 16 patients underwent fluorescent evaluation of their primary 
specimen after systemic infusion of panitumumab-IRDye800CW. Primary tumor 
specimens were imaged with a closed-field back table device to assess the 
fluorescence intensity-peaks of the deep surface. The process of imaging 
acquisition (30s/image) and peak-intensity isolation (120s) of a single specimen 
took approximately 2.5 minutes on average. Patient characteristics are 
summarized in Supplementary Table S6.1. Four patients with specimen 
involving bone were excluded from analysis because histologic reconstruction 
of the specimen could not be performed after the decalcification process. In 
one excluded case, shown in Supplementary Figure S6.1, the intensity peak 
region could successfully be correlated to the corresponding H&E slide due to 
demarcation using a suture. For the remaining 12 patients, a total of 36 intensity 
peaks and 36 background regions were analyzed. Furthermore, using IHC we 
have identified high levels of EGFR expression in all resected tumors, as 
previously reported in this population.14 
Intensity peaks: higher signal, closer margin distance 
First, the method was validated to determine whether intensity peaks would 
indeed have higher fluorescence signal and lower margin distance when 
compared with background regions of the same specimen. Using all 
specimens, the median signal for the intensity peak regions had a significantly 
higher MFI compared with the median signal for the background regions 
(p<0.05, n=24; Figure 6.2A). Figure 6.2B shows the difference in margin 
distance of the intensity peaks compared with background regions for each 
patient. The overall margin distance at the intensity peaks was significantly less 
than the background regions in all cases (p<0.05, n=24). 
In all specimens, the distance from margin to tumor (i.e., margin distance) 
was lower at the location of the first fluorescence intensity peak when 






Figure 6.2 Comparison of intensity peaks versus background. First graph indicates the relative 
increase in MFI of all background regions to intensity peak regions per patient. The 
second graph illustrates the difference in margin distance for background and intensity 






















Figure 6.3 Intensity peak versus margin distance. Representative brightfield (A) and fluorescence 
image (B) of the deep margin (with color bar). C, Identification of highest fluorescence 
intensity peaks on the deep surface. Number 1—3 allocate the fluorescence peaks in 
order of first appearance. D, Graph showing the margin distance at the 1st, 2nd and 
3rd intensity peak region per patient. 
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Similarly, the second highest peak intensity had a closer margin distance 
in 83% of samples when compared with the third highest fluorescence peak. 
The first fluorescence intensity peak had a significantly closer margin distance 
(by 2.1 mm, p<0.05, n=24) than the second intensity peak. In all 12 cases 
evaluated, the first intensity peak identified the area that harbored tumor closest 
to the deep surface when compared with all subsequent intensity peaks 
(p<0.05, n=36). The average increase in distance between the tumor and the 
specimen surface was 1.6 mm when comparing the second and third intensity 
peaks. It is worth noting that there were two instances where the distance from 
the tumor to the specimen surface did not increase between the second and 
third intensity peak. However, in both of these cases, the difference between 
the second and third intensity peak was not substantially different: the peaks 
were found to correlate with a margin distance that was within the margin of 
error (5.8 0.1 mm vs. 5.6 0.4 mm; and 11.4 0.6 mm vs. 10.2 0.6 mm). 
Discussion 
In this study, we showed that after systemic administration of a targeted 
fluorescent agent, surgical specimens can be noninvasively imaged to 
objectively determine where tumor is located closest to the deep surface of the 
specimen. Because this process can be performed intraoperatively, the 
surgeon could use this information to immediately resect additional tissue or 
send a tissue sample of a suspicious region for further assessment with FSA. 
Despite many advances in the field of surgical oncology, exact and 
reliable prediction of positive of close tumor margins remains a significant 
challenge, with subjective and often inaccurate use of FSA as standard-of-care. 
Thus, there is an important need to develop new technologies to facilitate 
improved intraoperative margin assessment. Here, we describe utilizing 
detection of a conjugated fluorescent antibody to rapidly and accurately assess 
intraoperative tumor margins. We have termed the margin segment with the 
highest fluorescence intensity as the sentinel margin–the location where the 
closest margin is mostly likely to be located. Analogous to sentinel lymph node 
assessment (where intraoperative mapping with an injected agent allows for 
identification of the lymph node at highest risk for metastasis), the sentinel 
margin may be analyzed using our described technique to identify the margin 
most at risk to be close or positive in a tumor specimen. This approach has 




Currently, multiple samples, sometimes upward of 15, are subjectively 
obtained and sent for FSA, averaging 30 minutes per sample for analysis.9,16 
The process of sentinel margin analysis takes approximately 2.5 minutes and 
provides an objective sampling strategy that could save a great amount of time 
by reducing the number of samples sent for FSA, while improving accuracy. In 
addition, as the process of imaging acquisition and sentinel margin analysis 
takes place on the back-table in parallel with the operation, it does not delay or 
add time to the surgery. 
The success of this ex vivo specimen mapping method relies on several 
key optical principles. First, as a direct result of light absorption and scattering, 
the near-infrared signal is not detectable when it is obscured by 6 mm of tissue 
or more. This results in a consistently low fluorescent signal after the margin 
distance exceeds 5 mm, an important clinical distance in several cancer types 
(including head and neck cancer) as 5 mm denotes a clear margin. Historically, 
it has not been common to have close margins (1-5 mm) because it can be 
difficult to assess how much normal tissue exists between a cancer and the 
surgical margin. This issue can be successfully addressed utilizing this 
technology. Second, the optical signal intensifies as the tumor comes closer to 
the specimen surface. The region that has the strongest fluorescent signal 
(namely, the highest fluorescence intensity peak), will be easily identified at any 
thresholding level because the specimen fluorescence is relative to adjacent 
tissue of the same specimen. Ultimately, the surgeon may be able to correlate 
this information with clinical judgment to facilitate frozen section assessment 
and/or reresection.17 If infiltrative tumor tissue is found closer than 5 mm to the 
deep surface using FSA, the surgeon has the opportunity to resect additional 
tissue from the wound cavity using the fluorescence intensity peaks as 
guidance. A clear overview of the proposed intraoperative workflow is shown in 
Figure 6.4. 
In previous studies, we have shown that fluorescence surface mapping is 
highly sensitive for detection of cancer within 5 mm of the surgical margin using 
an absolute intensity value.12,14 However, this approach is limited as the 
absolute fluorescence intensity will differ between patients as a result of 
variance in dose and infusion-to-surgery time.14 This study, however, uses 
relative values, with intensity compared with background regions on the same 
specimen and each patient serving as his or her own internal control. 
Ultimately, we show that in each individual specimen we can identify the 
sentinel margin, and that this consistently identifies the location with the closest 
margin. Although we recognize that a ratio between normal and tumor tissue 
varies with dose, timing, and EGFR expression,14 the proposed tumor-to-tumor 
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ratio measures relative intensity of fluorescence between different regions of the 
same specimen, which we hypothesize varies with the amount of overlying soft 
tissue (i.e., the margin distance). The data presented here provide empirical 







































We have previously demonstrated that expression of EGFR, which is 
overexpressed in more than 90% of HNSCC, positively correlates with 
fluorescence intensity.14,18 Besides the fact that fluorescence can be localized 
to tumor cells and varies with the level of EGFR expression, we also 
acknowledge that enhanced permeability and retention effect may contribute to 
the accumulation of panitumumab-IRDye800CW within the tumor. 
Although squamous cell carcinoma is known to have a heterogeneous 
EGFR pattern,18,19 overall expression appears to be high enough for successful 
detection of the sentinel margin in this study. It is possible however, that 
significant heterogeneity of EGFR expression within the tumor may influence the 
tumor-to-tumor ratio more than the overlying soft-tissue margin. Despite this 
possibility, the findings in this study suggest that sentinel margin assessment 
should be compatible with any fluorescent probe as well as different imaging 
systems as long as the probe has a similar distribution pattern as 
panitumumab-IRDye800CW, and the device is capable of signal quantification 
and threshold scaling for isolation purposes. 
Although the study included a range of tumor subsites in the head and 
neck region and used many data points for each specimen, the sample size 
limits the conclusions that can be drawn. An additional challenge is the 
decalcification process, although this methodology works excellent for the 
analysis of soft-tissue tumors, limitations presented with bone involvement will 
necessitate alternative research strategies. 
The current standard-of-care for analysis of surgical margins remains 
controversial–should samples for FSA be obtained from the patient or from the 
specimen20? Our proposed strategy may help standardize specimen-driven 
sampling and obtaining perpendicular margins to measure tumor distance.20 
Notably, our proposed sentinel margin analysis technique can be 
performed in all patients undergoing tumor resection with a fluorescent contrast 
agent and could therefore potentially improve poor margin control in other fields 
where wide local excision is required, such as melanoma, colon cancer, and 
vulvar cancer. 
Conclusion 
Fluorescently labeled antibodies in combination with intraoperative 
fluorescence imaging can successfully identify the closest margin in head and 
neck cancer specimen. This technique could potentially assist intraoperative 
decision-making for oncologically sound resections. 
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Supplemental information 
Table S6.1 Patient characteristics. 







(mg flat dose) 
Infusion - 
Surgery (days) 
71 M Lateral tongue T2N2b 10 20 50 5 
52 M Floor of mouth T2N2b 30 9 50 3 
73 M Lateral tongue T3N2b 55 20 25 3 
69 F Buccal mucosa T1N0 18 3 50 3 
51 F Lateral tongue T3N1 43 8 50 2 
58 F Retromoral trigone* T1N0 45 6 50 1 
65 F Buccal mucosa T2N2b 18 10 50 2 
70 F Buccal mucosa T3N0 35 3 50 1 
63 F Alveolar ridge* T2N0 26 3 25 1 
71 F Lateral tongue T2N2b 21 5 25 2 
68 F Lateral tongue T3N2b 45 15 25 4 
71 F Lateral tongue T1N1 20 5 25 3 
47 F Retromolar trigone* T4bN3b 63 60 50 3 
62 M Buccal mucosa T2N0 24 6 50 3 
56 M Floor of mouth T4aN2b 40 37 50 3 
69 M Maxillary sinus* T4aN0 53 42 50 3 
(*) Excluded due to bone containing specimen/ DOI: depth of invasion; hrs: hours'mg: mi;;igram; 






Figure S6.1 Annotation of suspicious area by suture. (a + b) Bright field (a) and corresponding 
fluorescence image (b) of the specimen’s deep margin after maxillectomy. White solid 
line indicates peak intensity area in a. and b. White dotted line delineates the infiltrated 
left concha inferior (nasal cavity). (d) Isolated fluorescence intensity-peak area where 
suture was placed (with color bar). (c) Hematoxylin & eosin slide of suture marked 
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High-grade dysplasia is associated with a risk of malignant transformation, and 
it is necessary to distinguish from normal epithelium or low-grade dysplasia, 
especially in the intraoperative setting. We hypothesize that an anti-epidermal 
growth factor receptor (EGFR) contrast agent can be used to differentiate high-
grade dysplasia from low-grade dysplasia and normal epithelium. 
 
Materials and methods 
Patients with biopsy proven head and neck squamous cell carcinoma (HNSCC) 
were enrolled in a clinical trial using systemically injected fluorescently labeled 
anti-EGFR antibody (panitumumab-IRDye800CW) (NCT02415881). Paraffn 
embedded tumor specimens from 11 patients were evaluated by fluorescence 
histopathology. Hematoxylin and eosin (H&E) slides were reviewed by a board-
certified pathologist, and regions of invasive squamous cell carcinoma, high-
grade dysplasia and low-grade dysplasia were delineated. EGFR expression 
was assessed for each patient by way of immunohistochemistry. 
 
Results 
11 patients were included in the study with a total of 219 areas on tissue 
sections analyzed; 68 normal epithelium, 53 low-grade dysplasia, 48 high-
grade dysplasia, and 50 malignant regions. The signal-to-back-ground ratio 
(SBR) increased proportionally with increasing grade of dysplasia; normal 
epithelium (1.5 ± 0.1), low-grade dysplasia (1.8 ± 0.1), high-grade dysplasia: 
(2.3 ± 0.2). High-grade dysplasia had a significantly higher SBR when 
compared to normal or low-grade dysplasia (p<0.05). Fluorescence 
histopathology positively correlated with EGFR expression by immuno-




Molecular imaging with an anti-EGFR agent can successfully discriminate high-
grade dysplastic lesions from low-grade dysplasia and normal epithelium. 
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Introduction 
Field cancerization and mucosal dysplasia pose a significant diagnostic 
challenge with serious implications for patient outcomes.1,2 As a result, there is 
significant interest in the development of real-time, widefield imaging strategies 
for the detection of premalignant and early stage malignant lesions. Recent 
studies suggest that malignant transformation is found in 12.1% (range 0—
36.4%) of patients with any degree of dysplasia, with a median follow-up of 1.5—
10 years.3 
However, patients with high-grade dysplasia (HGD) have a 2-fold higher 
chance of malignant transformation when compared to low-grade dysplasia 
(LGD), at around 24.1% (range 13.3—39.5%).3 Furthermore, the presence of 
low-grade, including mild to moderate, dysplasia at the surgical margins is 
associated with increased local recurrence rates and poorer patient outcomes, 
and as such, detection of premalignant disease is of importance in the 
operating room as well.1,2 Unfortunately, these lesions are very difficult to detect 
and diagnose without histopathologic assessment. Although topical application 
and imaging technologies, including high resolution magnifying endoscopy 
(HRME) and optical coherence tomography (OCT), have been developed for in 
vivo histological evaluation of tissues, these methods are not able to evaluate 
the surgical view.4-7 This ultimately results in similar challenges as with tissue 
biopsy, namely sampling error, time, and cost.8 An ideal system would be 
highly specific, allow for rapid assessment of the entire field, and involve 
minimal burden on the patient. Activation and upregulation of EGFR is a known 
phenomenon in HNSCC, with up to 90% of all HNSCC overexpressing EGFR.9,10 
Conveniently, this transmembrane receptor is also upregulated in 
countless other solid tumors, and as such, this target has become a mainstay in 
oncologic therapies.11,12 Recently, this has been leveraged for detection and 
diagnosis of cancers by functionalizing humanized anti-EGFR antibodies with 
fluorescent tracers with promising results.13-15 This has been particularly 
effective for fluorescence-guided surgery. Moreover, it is also known that 
dysplastic epithelium overexpresses EGFR, with expression increasing linearly 
with increasing degree of dysplasia.16 Given this important point, we 
hypothesized that an anti-EGFR antibody could be an effective means to 
delineate dysplasia. 
The primary aim of this study was to demonstrate differences in EGFR 
expression between dysplastic epithelium and normal epithelium, and secondly 
to leverage this in order to detect areas of dysplasia in surgical specimens 
obtained from patients with HNSCC; if successful, this technique could be used 
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to identify areas of high-grade dysplasia and facilitate complete resections 
intraoperatively, as well as set the groundwork for a potential screening tool of 
premalignant lesions in the clinic. 
Methods 
Study design 
The phase I study protocol was approved by the Stanford University 
Institutional Review Board (IRB-35064) and the FDA (NCT02415881), and 
written informed consent was obtained from all patients. The study was 
performed in accordance with the Helsinki Declaration of 1975 and its 
amendments, FDA’s ICH-GCP guidelines, and the laws and regulations of the 
United States. 
All patients with biopsy-proven, primary or recurrent HNSCC scheduled to 
undergo standard of care surgery with curative intent were eligible. Patients 
received an infusion of panitumumab-IRDye800CW, intravenously 1-5 days 
prior to surgery, and fluorescence imaging was obtained before, during, and 
after surgery as previously described.13,17 
Patients were then retrospectively included in this study on the basis of 
dysplasia being noted by the pathologist on the initial hematoxylin and eosin 
(H&E) sections generated as part of standard of care. Tissue sections were 
pulled and re-assessed by the pathologist to further delineate regions of 
dysplasia and invasive carcinoma. 
Tissue processing 
Intraoperatively, tumors were resected per standard of care, with fluorescence-
guidance augmenting surgical decision-making.13,17 After resection, specimens 
were formalin-fixed overnight and serially sectioned into 5 mm-thick 
macroscopic cross-sections, referred to as macrosections, which were 
occasionally additionally bi- or trisected to fit into cassettes for processing as 
formalin-fixed and paraffin-embedded (FFPE) tissue blocks. Microscopic 
sections (5 μm in thickness) were then cut from each tissue block, and 
standard histopathological assessment of routine H&E-stained slides was 
conducted by a board-certified pathologist with expertise in head and neck 
pathology. To assess the varying grades of dysplasia, the pathologist outlined 
regions of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and 
invasive squamous cell carcinoma (SCC) on the H&E slides, as well as regions 
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of non-dysplastic epithelium for reference. A two-tiered grading system was 
utilized to simplify the analysis and increase statistical power of this small study 
while maintaining clinically meaningful groups. The pathologist was blinded 
from the fluorescence images for the entirety of the study. 
Fluorescence imaging acquisition and analysis 
Fluorescence images were taken before, during, and after surgical resection as 
previously described.13,17 Directly after tumor resection, whole specimens were 
imaged ex vivo in a closed-field specimen imager (IGP-Elvis, LI-COR 
Biosciences, Lincoln, NE USA).18 Subsequently FFPE blocks were imaged 
using the Odyssey CLx imaging platform (LI-COR Biosciences, Lincoln, NE 
USA). From each FFPE block, slides were cut for H&E staining as well as two 
blank slides (5 μm) for fluorescence imaging and immunohistochemical 
staining, respectively. The 5 μm blank slides were then imaged using the 
Odyssey CLx imaging platform (LI-COR Biosciences, Lincoln, NE, USA) to 
identify fluorescence signal within the regions of interest (ROI) corresponding to 
the H &E delineations from the pathologist. Subsequently, the H&E slides were 
mapped back to the original tissue blocks (n=5 patients) and eventually to the 
complete primary tumor (n=3 patients). 
To estimate signal-to-background ratios (SBRs), ROIs were drawn around 
areas of malignant, dysplastic, or normal epithelium, as outlined by the 
pathologist. Subsequently, the SBR was calculated by dividing the mean 
fluorescence intensity (MFI) of the ROI (i.e. malignant, dysplastic, or normal 
epithelium) by the MFI of the background signal (i.e. adjacent uninvolved 
tissue, generally skeletal muscle). For the tissue blocks, the same analysis was 
performed to calculate SBR; however, the SBR of each region was then 
normalized to normal epithelium, as delineated by the pathologist, to account 
for differences in total fluorescence between the blocks. 
For whole specimen analysis, each specimen was virtually reconstructed 
from the macroscopic tissue sections, allowing for histologic mapping of the 
microscopic tissue sections. After cross-sectioning, a brightfield image was 
taken of the sectioned specimen and annotated to ensure accurate registration 
of each macrosection to its original location. Each macrosection was placed 
into corresponding tissue block(s), as annotated in the brightfield image. The 
slides cut from each tissue block were then registered to the original location 
within the primary specimen, allowing accurate reconstruction. To further 
ensure accurate reconstructions, only patients with multiple contiguous slides 
containing dysplasia were included in the whole specimen analysis. ImageJ 
(U.S. NIH, Bethesda, MD USA) was used to measure fluorescence intensity 
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using a line analysis along the segment corresponding to the tissue section. 
Regions from the fluorescence intensity curve were correlated to the various 
grades on the outlined H&E slides; from here, SBRs were calculated in similar 
fashion as described above with the background being set as adjacent normal 
epithelium as underlying muscle was not always visible. All averages were 
provided with standard error of the mean. 
Data was loaded into Prism 6.0 (GraphPad Software, San Diego, CA USA), 
and groups were compared using a Mann-Whitney U test. A p-value of 0.05 or 
less was considered statistically significant. 
EGFR immunohistochemistry and quantification 
To ensure that EGFR expression did indeed vary between the grades of 
dysplasia and was the primary basis for the localization of the anti-body-dye 
complex, conventional immunohistochemistry for EGFR was also applied. 
Antigen retrieval was performed, and slides were stained using a slide 
autostainer in standard fashion (Dako Link 48 and PT Link, Agilent 
Technologies Inc., Santa Clara, CA, USA). Briefly, the slides were blocked with 
EnVision FLEX Peroxidase-Blocking reagent (Dako SM801), incubated for 20 
min in EGFR primary antibody (ThermoScientific, Clone EP38Y), and visualized 
using the Dako FLEX + Rabbit visualization system (Dako SM802, SM803, 
SM805). Counterstain was performed with hematoxylin (Dako SM806). Slides 
were then coverslipped and digitized at 200x magnification using a high-
resolution slide scanner (NanoZoomer 2.0-RS, Hamamatsu Photonics, 
Hamamatsu City, Japan). 
Digitized slides were then loaded into Aperio ImageScope (Leica 
Biosystems Imaging Inc., Vista, CA USA). In ImageScope, 5 representative 
areas were randomly picked for each ROI of normal epithelium, LGD, HGD, and 
SCC. A hue value of 0.1 was chosen in ImageScope to detect the brown 
colored pixels that indicate EGFR expression. For each area, the number of 
pixels with a value below 0.1 was calculated using the Aperio Positive Pixel 
Count Algorithm (Leica Biosystems Imaging Inc., Vista, CA USA). This algorithm 
assigns each pixel as strongly positive, positive, or weakly positive. Weakly 
positive was considered equivalent to the background signal. For each area, 
the total number of strongly positive and positive pixels is divided by the total 
number of pixels in that area. Averages were calculated for each ROI based on 
the 5 representative areas, and a similar comparison between groups was 
performed as described above. 




Eleven patients were enrolled in this study, and the patient characteristics are 
summarized in Table 7.1. After H&E evaluation of all tissue sections, a total of 
44 FFPE blocks were selected based on the presence of normal epithelium, 
LGD, HGD, and SCC, and were further sectioned to characterize EGFR 
expression and subsequent fluorescence histopathology. From these blocks 
219 ROIs were selected; 68 regions of normal epithelium, 53 regions of LGD, 
48 regions of HGD, and 50 regions of SCC. Nine out of eleven patients (81.8%) 
had HGD present on at least one slide. The average mean fluorescence 
intensity (MFI) was 1.5 ± 0.1, 2.0 ± 0.1, 3.2 ± 0.4, and 2.3 ± 0.1 for normal, 
LGD, HGD, and SCC, respectively. When evaluating the signal compared to 
background fluorescence (the fluorescent signal of adjacent muscle), the 
average signal to noise ratio (SBR) was 1.5 ± 0.1, 1.8 ± 0.1, 2.3 ± 0.2, and 2.2 
± 0.1 for the same histologic grades, respectively (Figure 7.1). HGD and SCC 
regions had significantly higher SBRs when compared to LGD and normal 
(p<0.05). By immunohistochemistry, EGFR expression was found to increase 
with advancing grades of dysplasia, with the strongest expression found in 
regions of SCC (Figure 7.2). The grade of dysplasia correlated with the percent 
area of EGFR expression; 23.2 ± 0.2%, 59.3 ± 0.2%, 85.0 ± 0.3%, and 89.8 ± 
0.1% for normal, LGD, HGD, and SCC respectively. HGD and SCC had 
significantly elevated EGFR expression compared to LGD and normal (p<0.05), 
and LGD had significantly stronger EGFR staining than normal (p<0.05). 
Evaluation of tissue blocks 
Five patients were found to have all four grades of epithelium (normal, LGD, 
HGD, and SCC) represented in the same tissue specimen allowing for direct 
comparison of imaging results. From these five patients, 21 tissue blocks were 
analyzed, yielding 86 ROIs; 24 regions of normal epithelium, 20 regions of LGD, 
17 regions of HGD, and 25 regions of SCC. SBR was calculated by comparing 
normal epithelium (background) to LGD (1.4 ± 0.02), HGD (1.8 ± 0.5), and SCC 
(1.9 ± 0.02) (Figure 7.3). A statistically significant difference was found between 
SCC and LGD, as well as between HGD and LGD (p<0.05), but not between 
HGD and SCC. All premalignant and malignant tissues had a statistically 
significantly higher average SBR when compared to normal (p<0.05). 
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Table 7.1 Summary of patient characteristics. Smoking and alcohol use include whether patients 
were currently using, or if there was a history of use. 
Patient Age Gender Tumor location Smoking status Alcohol use 
1 56 M Buccal 27 pack-year hist None 
2 52 M Floor of mouth 10 pack-years 3—4 drinks/week 
3 69 F Buccal None None 
4 85 M Larynx 40 pack-year hist 4—5 drinks/week 
5 54 M Buccal 45 pack-years None 
6 71 M Tongue 30 pack-year hist None 
7 65 F Buccal 45 pack-year hist 1—2 drinks/week 
8 63 F Alveolar ridge None Rare 
9 71 F Tongue None None 
10 71 F Floor of mouth None None 




Figure 7.1 Fluorescence histopathology of 10 μm slides from patient specimen. (a) Average SBR, 
with standard error of the mean, for each grade. (b-i) Representative images of the 
H&E (top) and fluorescence (bottom) for each of the grades. Representative images of 
(b,f) normal epithelium, (c,g) low-grade dysplasia, (d,h) high-grade dysplasia, and (e,i) 
invasive squamous cell carcinoma. LG = low-grade dysplasia, HG = high-grade 
dysplasia, SCC = squamous cell carcinoma. Statistical analysis by Mann-Whitney U 
test. 
Evaluation of whole tissue 
Four primary tumor specimens were included in the analysis. One patient, for 
which multiple contiguous slides were available, was excluded due to an 
inability to accurately reconstruct the primary specimen. For the remaining 
three patients, it was possible to virtually reconstruct the primary specimen from 
the individual brightfield images of macrosections, allowing the registration of 
H&E histology to the original location within the specimen. Due to the small 
sample size and the fact that normal and LGD can be monitored whereas HGD 
and SCC would be acted upon in a similar fashion clinically, normal and LGD 
were grouped, and HGD and SCC were grouped. There was a total of 26 
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normal-to-LGD and 19 HGD-to-SCC regions analyzed by fluorescence imaging 
of the ex vivo whole tissue specimen. The average SBR for normal-to-LGD and 
HGD-to-SCC was 1.14 ± 0.11 and 1.73 ± 0.03, respectively, which was 





Figure 7.2 EGFR immunohistochemistry staining of 10 μm slides from patient’s specimen. (a) 
EGFR expression, with standard error, of the 10 μm slides by grade. (b-i) 
Representative images of the H&E (top) and IHC (bottom) for each of the grades. 
Representative images for (b,f) normal epithelium, (c,g) low-grade dysplasia, (d,h) 
high-grade dysplasia, and (e,i) invasive squamous cell carcinoma. LG = low-grade 
dysplasia, HG = high-grade dysplasia, SCC = squamous cell carcinoma. Statistical 









Figure 7.3 Fluorescence imaging of macroscopic sections from patient specimen. (a) One 
representative H&E with regions of interest outlined (top) and the corresponding 
fluorescence image of the macroscopic tissue section with the corresponding regions 
delineated (bottom). (b) Average SBR (with standard error bars) of the 5 mm, 
macroscopic tissue sections by grade. LG = low-grade dysplasia, HG = high-grade 





Figure 7.4 Fluorescence imaging of whole patient specimen. (a) A representative fluorescence 
image of a specimen. The dotted line corresponds to (b) the H&E with regions of 
interest delineated. (d) The signal value curve over the representative line displayed in 
(a-b). (c) Average SBR, with standard error, of the whole specimen for Normal/LG and 
HG/SCC tissue. LG = low-grade dysplasia, HG = high-grade dysplasia, SCC = 
squamous cell carcinoma, N/L = normal-to-low grade. Statistical analysis by Mann-
Whitney U test. 
 
Discussion 
In this study, we reviewed primary tumor specimens from HNSCC patients 
undergoing intraoperative molecular imaging to evaluate whether an anti-EGFR 
molecular imaging agent can accurately distinguish escalating grades of 
dysplasia from normal epithelium. Interestingly, we found that 81.8% of patients 
in the study had high-grade dysplasia present on at least one tissue section. 
However, dysplasia can be significantly more challenging to detect, both 
preoperatively and intraoperatively for surgeons as well as for surgical 
pathologists, when compared to invasive carcinoma, despite having serious 
patient implications, such as increased locoregional recurrence rates, if left 
untreated.1,2 Fluorescence histopathology demonstrated that fluorescence 
positively correlates with grade of dysplasia on a microscopic level, with HGD 
having greater uptake of the optical contrast agent, and thus greater levels of 
fluorescence signal, compared to LGD and normal epithelium. In fact, the 
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fluorescent signal of HGD in this study was similar to SCC. Evaluation of the 
tissue sections on a macroscopic level and subsequently on the primary 
specimen, showed that these results held true. Furthermore, we demonstrated 
that increasing grades of dysplasia correlated with EGFR expression based on 
digital quantification of EGFR immunohistochemical staining. 
It remains challenging to distinguish dysplasia from normal epithelium 
intraoperatively and numerous techniques have been evaluated to improve its 
detection. For example, topical agents such as acetic acid and toluidine blue 
have been used for decades, and although these have relatively low cost and 
patient burden, they lack sufficient specificity and sensitivity for detecting 
dysplasia.8 Other imaging technologies such as OCT and HRME have been 
tested repeatedly, and some are available for commercial use, but these have 
not been adopted in the management of HNSCC because of the challenges 
with use in the oral cavity and the very limited field of view (often less than 
1-2 mm).5,22 Autofluorescence imaging and in vivo microscopy techniques have 
significant potential but require specific knowledge of histological diagnosis (or 
partnership with pathology) and much like ultrasound, can be difficult to 
acquire the data and document the results.8 Our findings demonstrate that SCC 
and HGD can be selectively identified from adjacent LGD and normal 
epithelium by molecular imaging. Al-though we found no statistical difference 
between SCC and HGD, both lesions were easily differentiated compared to 
adjacent normal epithelium. While only a small subset of cases in the current 
study were available for analysis at the whole specimen level, and grouping the 
lesions into those that require clinical action and those that do not was 
necessary, our data suggest that anti-EGFR based intraoperative molecular 
imaging technology may be able to delineate normal and LGD from HGD and 
malignant lesions. If successfully implemented, the use of widefield real-time 
imaging might improve tumor resection and significantly decrease time and 
financial cost while improving patient outcomes.8 
Our analysis was limited to patients undergoing excision of an invasive 
carcinoma and conducted on dysplasia arising in adjacent mucosa. While it is 
important to intraoperatively detect surgically actionable HGD, analysis of 
patients with HGD and no invasive carcinoma may not provide the same result, 
and such a study is warranted to more accurately determine the efficacy of 
EGFR-based molecular imaging for early detection of HGD. An inherent 
limitation of studying grades of dysplasia is the poor interobserver 
reproducibility for histopathologic diagnosis, particularly with respect to LGD, 
which is challenging to distinguish from reactive or hyperplastic epithelium.23 
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Nevertheless, in this study we have shown that anti-EGFR molecular 
imaging using panitumumab-IRDye800CW has potential for detection of 
premalignant lesions that may go unnoticed or require frozen section for 
confirmation intraoperatively. We have provided data that demonstrates that 
EGFR expression varies between dysplastic epithelium and normal epithelium, 
positively correlating with increasing degrees of dysplasia, and that a 
fluorescence molecular imaging agent positively correlates with worsening 
dysplasia on the microscopic and macroscopic scale. Furthermore, we contend 
this study provides the necessary foundation for testing an anti-EGFR molecular 
imaging as a potential screening tool for early detection of high-grade 
dysplasia in the clinic. 
Conclusion 
Anti-EGFR molecular imaging has the potential to successfully discriminate 
LGD and HGD lesions from SCC and normal epithelium on fluorescence 
histopathology. We posit that our data can encourage future studies assessing 
fluorescence imaging for intraoperative detection of dysplasia, and as a 
potential screening tool for detection of premalignant lesions in clinic. 
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Despite the rapid growth of fluorescence imaging, accurate sampling of tissue 
sections remains challenging. Development of novel technologies to improve 
intraoperative assessment of tissue is needed. 
 
Methods 
A novel contact probe-based fluorescence dosimeter device, optimized for 
IRDye800CW quantification, was developed. After evaluation of the device in a 
phantom setup, its clinical value was defined ex vivo in patients with head and 
neck squamous cell carcinoma who received panitumumab-IRDye800CW. 
 
Results 
Ten patients were enrolled with a total of 216 data points obtained. Final 
histopathology showed tumor in 119 spots and normal tissue in 97 spots. 
Fluorescence-to-excitation ratios in tumor tissue were more than three times 
higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 
0.81-0.91) for tumor detection. 
 
Conclusions 
Fluorescence-guided tissue preselection using a fluorescence dosimeter could 
have substantial impact on tissue sampling for frozen section analysis and 
potentially reduce sampling errors. 
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Introduction 
Surgical resection is the primary treatment for most solid tumors. Failure to 
detect residual cancer leads to poor patient outcome. Due to the complicated 
surgical anatomy in the head and neck region and the presence of the crucial 
structures, such as carotid arteries and cranial nerves, 15%-30% of patients will 
have a positive margin upon final histopathology; a rate that has not changed 
over the last 30 years despite many novel surgical techniques.1-3 Currently, the 
only intraoperative tool broadly used for margin status assessment is frozen 
section analysis.4-7 Accurate sampling of tissue samples to confirm adequate 
resection is crucial for this technique to be effective. However, the decision on 
which tissue to sample for margin status assessment remains highly subjective 
as it mainly depends on the surgeon's experience, visualization of the tumor, 
and tactile feedback, which can lead to significant sampling errors.8 
To improve surgical outcome and margin assessment accuracy, tumor-
specific antibody-based fluorescence imaging has been proposed to achieve 
demarcation and differentiation of cancerous from healthy adjacent tissue.9-15 In 
head and neck squamous cell carcinoma (HNSCC), the epidermal growth 
factor receptor (EGFR) is overexpressed in >90% of tumor cells, making it ideal 
for optical targeted imaging.16 We have previously demonstrated that our near-
infrared fluorescently labeled anti-EGFR antibody, panitumumab-IRDye800CW, 
is highly sensitive and specific for HNSCC.9,17-19 However, despite the rapid 
growth of fluorescence imaging, quantifiable fluorescence measurements using 
an open-field imaging system remain challenging because fluorescence 
imaging is a noncontact imaging technique and consequently is highly 
sensitive to lighting variations, due to irregular and non-flat tissue surfaces, and 
the operating room environment. 
Dosimetry has proven itself valuable for monitoring drug delivery in 
photodynamic therapy (PDT), where it provides a quantitative measurement of 
photoactivatable drug dose within the targeted region.20,21 Building on this 
technique, we have developed a novel contact probe-based fluorescence 
dosimeter device that allows optical measurements of protoporphyrin IX 
concentration in a targeted region on the surface of human tissue.20,22 We 
hypothesize that fluorescence dosimetry using such a contact probe could 
quantify the fluorescence signal of superficial human tissue to discriminate 
between head and neck cancer and healthy adjacent tissue utilizing 
panitumumab-IRDye800CW. This would allow us to perform precise 
fluorescence-guided sampling to preselect regions for frozen section analysis. 
Fluorescence-guided tissue preselection could therefore reduce sampling 
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errors and has great potential implications for improving patient recurrence and 
survival rate or reducing operation time. The objective of this study was to 
validate the parameters and dynamic range of the fluorescence dosimeter in a 
phantom model and subsequently to evaluate its clinical utility for fluorescence-
guided tissue preselection in patients with HNSCC in an ex vivo setting. 
Methods 
Fluorescence dosimetry 
The fluorescence dosimeter used in the study is a modified version of the 
design described extensively elsewhere,20,22 optimized to quantify IRDye800CW 
rather than protoporphyrin IX. A schematic diagram of this optical probe-based 
device is shown in Figure 8.1. This device contains two light sources; white light 
(HL-2000-LL-FHSA; Ocean Optics, Largo, Florida) for reflectance-mode 
measurements, and a 35mW 730 nm laser (COMPACT-35G-730; World Star 
Tech, Markham, Ontario, Canada) for fluorescence measurements. The two 
sources are connected via optical shutters to a bifurcated fiber bundle 
(BFY105LS02; ThorLabs, Newton, New Jersey) to allow a single source port on 
the device enclosure (MSN177-32-35G; TAKACHI, Kawaguchi, Japan). A 
bifurcated fiber probe (RP23; ThorLabs) is attached to the source and detector 
ports of the device, where the source is delivered over the center 200 μm fiber, 
and the detection branch is composed of six surrounding 200μm fibers. 
Reflected and remitted light is collected by the fiber probe (6 mm diameter), 
where the detection branch connects via a filter wheel (USB Filter Wheel; Picard 
Industries, New York, New York) to a spectrometer (USB 4000; Ocean Optics). 
The filter wheel contains a 750 long pass filter (FEL0750; ThorLabs) for use 
during fluorescence measurements to protect the spectrometer from being 
saturated by the laser; a neutral density filter is used during reflectance mode. 
The system components are all controlled over USB using a laptop running 
custom LabView software. The design of the small fibers was specifically 
chosen to reduce scattering and traversed pathlength of the detected signal, 
thereby reducing the nonlinear effects of absorption and scattering to a 
correctable level.23,24 Measured spectra were processed using a linear least 
squares spectral fitting algorithm which separates the IRDye800CW emission 
spectrum from background autofluorescence. The dye-specific spectrum was 
then integrated between 761 and 852 nm and divided by the integrated 
excitation peak (718 and 731 nm) to compute fluorescence-to-excitation ratio 
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(FER). As both excitation and emission are captured in the same spectrum, but 
the excitation is reduced by the 750 nm long pass filter, this process is robust 




Figure 8.1 A, Schematic of the fluorescence dosimeter setup showing system components. Light 
from a 730 nm laser source is delivered over a fiber bundle in contact with the sample 
surface. B, The fiber bundle delivers the light through a 200μm center fiber, while six 
surrounding fibers collect the emitted light. This light passes through a filter and is 
measured by a spectrometer. C, The fluorescence spectra are displayed using a 
LabView program which runs the fluorescence dosimeter. The ratio between 
fluorescence signal and excitation signal is used as a way to control for small variations 
in the amount of excitation light delivered to the sample. 
 
System validation using tissue-mimicking phantoms 
To validate the fluorescence dosimeter for IRDye800CW, a tissue-mimicking 
phantom with homogenous IRDye800CW-carboxylate distribution was created 
in 1% agarose (Life Technologies, Carlsbad, California), 1% whole bovine 
blood (Sigma-Aldrich, Saint Louis, Missouri), and 1% intralipid emulsion 
(Sigma-Aldrich), as previously described by us.18,25 Briefly, the agarose in water 
solution was heated to80 C and allowed to cool down to 45C before adding 
bovine blood, intralipid while continuous stirring to ensure homogeneous 
distribution of the compounds, after which the mixed solution was separated 
with different concentrations of IRDye800CW; [IRDye800CW] = [0, 0.6, 1.2, 2.5, 
5, 10, 20, 40, 80, 160, 320, 640] nM. The mixture was poured into 12 circular 
tubes (diameter 8 mm, length 5 mm) and cooled down to solidify (Figure 8.2A). 
To validate the presence of IRDye800CW-carboxylate in the phantoms, 
phantoms were placed on a black imaging tray and imaged in a closed-field 
fluorescence imaging device (Pearl Triology; LI-COR Biosciences Inc., Lincoln, 
Nebraska) (Figure 8.2B). After imaging, quantitative analysis of the images was 
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performed using the system's integrated software (ImageStudio; LI-COR 
Biosciences Inc.) by drawing regions of interest (ROIs) in the middle of the 
phantom and extracting the mean fluorescence intensity (MFI; Figure 8.2B). 
Subsequently, fluorescence dosimetry was performed with a fiber tip of this 
device on the surface of each phantom (Figure 8.2C). Measurements were 
repeated three times for each surface and the average FER was automatically 




Figure 8.2 Validation of fluorescence dosimetry. A, Phantom setup using tissue-mimicking tube 
with lipid and blood mixture in different concentrations of IRDye-800CW; 
[IRDye800CW] = [0, 0.6, 1.2, 2.5, 5, 10, 20, 40, 80, 160, 320, 640] nM. B, C, An 
IRDye800CW loaded tumor phantom was imaged in close-field imaging and mean 
fluorescence intensity (MFI) was measured. Subsequently, fluorescence dosimetry was 
performed with a fiber tip of this device on the surface of each phantom and 
fluorescence-to-excitation ratios (FERs) were automatically calculated and recorded by 
LabView software. MFIs in closed-field imaging and FERs by fluorescence dosimetry 
are strongly correlated with the IRDye-800CW concentration (r=0.98 and 0.99, 
respectively). 
Clinical study 
A single center, nonrandomized, phase I study was performed in patients with 
biopsy proven HNSCC that were scheduled for surgical resection with curative 
intent. The phase I study evaluating panitumumab-IRDye800CW was approved 
by the Stanford Institutional Review Board (IRB-35064) and the FDA 
(NCT02415881). More details on the phase I study can be found in Gao et al..26 
Briefly, patients were infused 1-5 days prior to surgery with a flat dose of 50 mg 
panitumumab-IRDye800CW. After surgical resection, the tumor specimens 
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were imaged in a closed-field fluorescence imaging device and transported to 
pathology for standard of care histopathological processing. The study was 
performed in accordance with the Helsinki Declaration of 1975 and 
amendments, FDA's ICHGCP guidelines and the law and regulations of the 
United States. Written informed consent was obtained from all patients. 
The workflow of the clinical study is demonstrated in Figure 8.3. To 
evaluate fluorescence dosimetry for its ability to differentiate tumor from normal 
tissue, 5 mm tissue sections were obtained from the primary tumor specimen 
(19). On these tissue sections, three areas were selected that looked grossly 
tumor positive and also three areas were selected that looked grossly tumor 
negative. FERs were then obtained by placing the fiber probe directly onto the 
surfaces of tissue sections. The locations of the measured spots were 
documented on a matching bright field image. Hereafter, tissue was processed 
as per standard of care at pathology and a hematoxylin and eosin (H&E) slide 
was obtained for final diagnosis. On the acquired H&E slide, a board-certified 
pathologist outlined the areas of tumor. The H&E results were then matched 
with the areas from which FERs were obtained. Hereafter, the FER 





Figure 8.3 The workflow of the clinical study to test the ability of the fluorescence dosimetry to 
differentiate tumor from normal tissue is demonstrated. The 5-mm tissue sections that 
grossly contained tumor and normal tissue were assessed by placing the fiber probe to 
the tissue surface. Fluorescence dosimetry was performed at six distinctive spots per 
tissue section. The location of the spots was determined to include tumor and normal 
tissue by gross inspection of the tissue section. The locations of the measured spots 
were documented on bright field captures to allow conformation with final 




For the validation of the fluorescence imaging-based data collected with the 
closed-field imaging device, MFIs, defined as total signal in a ROI divided by 
area of the ROI, was calculated using integrated instrument software (Image 
Studio; LI-COR Biosciences Inc.). Differences of FERs between tumor and 
normal tissues were analyzed using the Mann-Whitney U-test. To determine the 
sensitivity and specificity of dosimeter for tumor detection, a receiver operation 
characteristic (ROC) curve was generated and area under the curve (AUC) 
determined. Values were reported as means with SD and 95% confidence 
intervals (CIs) are given where applicable. Descriptive statistics was performed 
using GraphPad Prism software (Version 6.0c; GraphPad Software, La Jolla, 
California). A two-sided P-value of .05 or less was considered statistically 
significant. 
Results 
Fluorescence dosimetry validation 
We validated the fluorescence dosimetry by comparing it to our previously 
established reliable standard (i.e., closed-field imaging platform; Pearl Triology; 
LI-COR Biosciences Inc.). An IRDye800CW loaded tumor phantom (tumor 
tissue-mimicking lipid and blood mixture) was imaged in close-field imaging 
and measured by fluorescence dosimetry using a concentration of dye 
consistent with what we found in the tumor specimens obtained during the 
clinical trial. Via fluorescence dosimetry, we could detect the light emission and 
calculate the FER within 30 seconds per measurement. In this phantom study, 
MFIs of the closed-field device and FERs of fluorescence dosimeter device 
were found to strongly correlate with the IRDye800CW concentration (Figure 
8.2B, C; r=0.98 and 0.99, respectively). Importantly, a robust correlation was 
found between FERs of fluorescence dosimeter device and MFIs of the closed-
field device (r=0.99) indicating the robustness of the fluorescence dosimeter 
device. 
Fluorescence dosimetry for tumor detection 
To determine if the fluorescence dosimeter could identify the tumor from the 
surrounding normal tissue, we performed primary tumor assessment on 
specimens of 10 consecutive patients with HNSCC (patient characteristics are 
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presented in Table 8.1). Figure 8.4 shows a representative example of 
fluorescence dosimeter measurements in a patient with SCC of the lateral 
tongue. 
 
Table 8.1 Patient characteristics. 
Patient Age Sex Tumor location pTN stage 
1 71 Women Lateral tongue pT2N2b 
2 68 Women Lateral tongue pT3N2b 
3 71 Women Lateral tongue pT1N1 
4 47 Women Retromolar trigone pT4bN3b 
5 69 Men Maxillary sinus pT4aN0 
6 59 Women Lateral tongue pT3N2c 
7 57 Men Lateral tongue pT4aN3b 
8 56 Men Buccal mucosa pT4aN0 
9 70 Men Lateral tongue pT4aN3b 




Figure 8.4 A representative example of fluorescence dosimeter measurements in a patient with 
squamous cell carcinoma of the lateral tongue. FER, fluorescence-to-excitation ratio. 
 
 
Following serial sectioning of the surgical specimen, a total of 36 tissue 
sections were evaluated using the fluorescence dosimeter with a total of 
216 data points obtained. Of the 216 measured spots, final histopathology 
confirmed tumor in 119 spots and normal tissue in 97 spots. FERs in tumor 
tissue were found to be more than three times higher than FERs in normal 
tissue, 1.58 ± 1.35 vs. 0.43 ± 0.50 (p<.0001; Figure 8.5A). 
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Sensitivity and specificity of fluorescence dosimetry for tumor detection 
were determined using a ROC curve. Using 0.5 of FER as cutoff value, 
fluorescence dosimetry showed to be highly sensitive for tumor with decent 
specificity (93% and 63%, respectively). Most importantly, using 0.33 FER as 
cutoff value, a 100.0% sensitivity, although with a decreased specificity to 48%. 
These results indicate that the fluorescence dosimetry has the greatest ability to 
be a “rule out” test. ROC curve evaluation showed an AUC of 0.86 (95% CI: 
0.81-0.91; Figure 8.5B), suggesting the discriminatory power of fluorescence 
dosimetry in identifying potential tumor tissue. 
 
 
Figure 8.5 A, A total of 36 tissue sections were examined, and a total of 216 data points were 
obtained. Fluorescence-to-excitation ratios in tumor tissue area where found to be 
more than three times higher than those in normal tissue area (1.58 ± 1.35 vs 0.43 ± 
0.50, P < .0001; n = 216). B, Sensitivity and specificity of fluorescence dosimetry for 
tumor detection were determined using a receiver operation characteristic (ROC) 
curve. ROC curve evaluation showed that area under the curve (AUC) was 0.86 (95% 
confidence interval: 0.81-0.91). 
 
Discussion 
For decades, surgeons have solely relied on tactile and visual feedback to 
distinguish tumor from normal tissue. The current study assesses the clinical 
application of fluorescence-guided tissue preselection for differentiation of the 
cancerous tissue from normal tissue in an ex vivo setting using a novel contact 
probe-based fluorescence dosimeter device. After evaluation and validation of 
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the device in a phantom setup, its clinical value was defined in patients with 
HNSCC that received panitumumab-IRDye800CW. The fluorescence signal was 
more than three times higher in cancerous tissue compared to healthy tissue 
and the fluorescence dosimeter was capable to pinpoint cancer tissue with 
high sensitivity (93%) and decent specificity (63%). These results suggest that 
fluorescence dosimetry could have potential as a preselection tool for objective 
margin status assessment in the operating room to decrease sampling error. 
Previously, we showed the clinical feasibility to predict close and/or positive 
tumor margins with macroscopic optical specimen mapping of the entire 
surgical specimen in patients with HNSCC using an ex vivo closed-field 
imaging device (18). In the current study, we demonstrate that the fluorescence 
dosimetry can distinguish tumor from normal tissue in formalin-fixation tissue 
sections with high diagnostic accuracy (AUC = 0.86). As the fluorescence 
signal does not significantly differ between formalin-fixated and fresh tissue 
(data not shown here), we believe that this technique can play a crucial role in 
objective specimen-driven sampling for frozen section analysis. Importantly, 
100.0% sensitivity (and 48% specificity) was reached at 0.33 FER as cutoff 
value, which means that false-negative findings, which are generally 
considered far more damaging than false-positive findings, are nonexistent in 
this range. Therefore, despite the limited optical penetration depth of 730 nm 
light (approximately 4-5 mm;27,28) fluorescence dosimetry could be used as a 
sensitive screening tool for detection of superficial tumors from normal adjacent 
tissues. Moreover, the fast measurement time (30 seconds) and small size of 
the device also suggest that it can be easily incorporated within current 
surgical workflow. Although our study represents ex vivo findings, the results 
encourage further validation of our method in a prospective in situ setting. 
Besides the potential for objective and accurate tissue sampling for further 
histopathological analysis, the fluorescence dosimeter could also be a valuable 
tool to monitor treatment response and follow-up in antibody-based photo-
immunotherapy. In a recent study, a fluorescent photosensitizer (IRDye700) 
was conjugated to panitumumab to eliminate microscopic residual disease 
following incomplete surgical resection in a preclinical study, including patient-
derived tumor specimens, and demonstrated favorable results.29 Here, the 
fluorescence dosimeter could easily be modified for detection of IRDye700 in 
order to quantify the concentration of panitumumab to monitor drug delivery in 




Our proposed strategy using the fluorescence dosimeter could have substantial 
impact on tissue sampling for frozen section analysis and therefore potentially 
reduce sampling errors. This technique is optimal for superficial cancers and 
could therefore also be translated to other cancer types, including but not 
limited to melanoma. The data presented here supports further evaluation of the 
fluorescence dosimetry as priority. 
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Identification of lymph node (LN) metastasis is essential for staging of solid 
tumors, and as a result, surgeons focus on harvesting significant numbers of 
LNs during ablative procedures for pathological evaluation. Isolating those LNs 
most likely to harbor metastatic disease can allow for a more rigorous 
evaluation of fewer LNs. Here we evaluate the impact of a systemically injected, 
near-infrared fluorescently-labeled, tumor-targeting contrast agent, 
panitumumab-IRDye800CW, to facilitate the identification of metastatic LNs in 
the ex vivo setting for head and neck cancer patients. Molecular imaging 
demonstrates a significantly higher mean fluorescence signal in metastatic LNs 
compared to benign LNs in head and neck cancer patients undergoing an 
elective neck dissection. Molecular imaging to preselect at-risk LNs may thus 
allow a more rigorous examination of LNs and subsequently lead to improved 
prognostication than regular neck dissection. 
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Introduction 
In patients with solid tumors the presence of lymph node (LN) metastases is 
considered an important negative prognostic factor for survival.1,2 Although 
multiple imaging modalities are available for preoperative staging, including 
positron emission tomography combined with computed tomography (PET/CT) 
and magnetic resonance imaging (MRI), they are suboptimal in detecting 
occult LN (micro-) metastasis. In squamous cell carcinoma of the head and 
neck (HNSCC), there is up to a 30% chance of presence of occult nodal 
metastasis at the time of surgery, despite clinical and radiographic evidence to 
support the absence of tumor in the LNs of the neck (cN0)2. Consequently, 
patients with early-stage disease and no clinical and radiographic evidence of 
regional LN metastasis routinely undergo an elective neck dissection.3-5 
Histopathological evaluation of neck dissection specimens relies on the 
identification and harvesting of LNs from the received neck specimen.6 
Identification of metastatic LNs within the fibro-adipose tissue of the neck 
specimen remains a challenge, despite that gross and histologic examination of 
the neck specimen is critical for accurate staging and guides the extent of 
adjuvant therapy and prognosis.7 The current workflow necessitates that at 
pathology as many LNs as possible are harvested from the neck specimen, 
which are then all macro- and microscopically inspected for the presence of 
metastasis. This workload has been further increased by recent quality 
standards endorsed by the American College of Surgery, which increased the 
standards for number of LNs required for pathological evaluation. 
Advancement in new technologies in near-infrared (NIR) imaging hardware 
and molecular contrast agents have resulted in a significant number of new 
intraoperative imaging contrast agents entering clinic trials. The potential value 
in management of the primary tumor has been emphasized with improved 
sensitivity and specificity of (microscopic) tumor detection in the operative 
setting,8-11 but the benefit of these technologies in detecting regional LN 
metastasis has undergone limited evaluation.12 Although there are currently 13 
open trials listed on ClinicalTrials.gov that evaluate the use of this technology, 
the potential impact on LN assessment at pathology has largely been ignored. 
 
The current study evaluates the impact of a systemically injected, near-
infrared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-
IRDye800CW, to facilitate the identification of metastatic LNs in the ex vivo 
setting for head and neck cancer patients. Molecular imaging demonstrates a 
significantly higher mean fluorescence signal in metastatic LNs compared to 
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benign LNs in head and neck cancer patients undergoing an elective neck 
dissection. Molecular imaging to preselect at-risk LNs may thus allow a more 
rigorous examination of LNs and subsequently lead to improved 
prognostication than regular neck dissection. 
Methods 
Clinical trial design 
We performed a single center, non-randomized, prospective dose ranging 
study in patients with biopsy proven HNSCC that were scheduled for surgical 
resection of curative intent. The primary objective of the study is to determine 
the safety profile of panitumumab-IRDye800CW. The secondary objective is to 
determine the efficiency of panitumumab-IRDye800CW to identify cancer 
compared to surrounding normal tissue. 
The study protocol was approved by the Stanford University Administrative 
Panel on Human Subjects Research and the FDA (NCT02415881). The study 
was performed in accordance with the Helsinki Declaration of 1975 and its 
amendments, FDA’s ICH-GCP guidelines, and the laws and regulations of the 
United States. Written informed consent was obtained from all patients. 
Adult patients with biopsy-proven, primary or recurrent head and neck 
squamous cell carcinoma scheduled to undergo standard-of-care surgery with 
curative intent were eligible. TNM stage was classified using the American Joint 
Committee on Cancer (AJCC) seventh edition criteria38. Exclusion criteria 
included a life expectancy of less than 12 weeks, a Karnofsky performance 
status <70%, prior infusion reactions to monoclonal antibodies, QT prolongation 
on screening electrocardiogram (ECG; >440 ms in males, and >450 ms in 
females), significant cardiopulmonary or liver disease, abnormal electrolyte 
values, and/or utilization of class IA or class III antiarrhythmic agents13. 
Between 9/2016 and 3/2018, 24 patients were enrolled in this study. 
Patients were enrolled into four dose cohorts: 0.5 and 1.0 mg kg−1 in the 
weight-based dosing group and 25 and 50 mg in the fixed dosing group. Two 
patients were excluded from final analysis as they did not undergo a neck 
dissection. 
Panitumumab-IRDye800CW conjugation 
Conjugation of panitumumab-IRDye800CW was performed under cGMP 
conditions, through NCI’s NeXT program13. Briefly, panitumumab (Vectibix; 
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Amgen, Thousand Oaks, California, USA; 147kDa) was conjugated to 
IRDye800CW-NHS via a 2-h incubation at 20 °C in the dark with a dye to protein 
ratio of 2.3:1. Quality control of the conjugate included analysis of drug product 
in sterile vial for particulates, and integrity of the sterilizing filter. Sterile vials 
were transported to Stanford University under temperature-controlled 
conditions and stored at the Stanford University Medical Center Investigational 
Pharmacy. 
Optical imaging of nodal specimens 
Intraoperative imaging was performed pre-, inter-, and post-neck dissection 
using the Spy-Phi camera and IR9000 optical imaging platform modified for 
IRDye800CW fluorescence imaging (Novadaq, Burnaby, Canada). Immediately 
after resection, neck dissection specimens were re-imaged on the back table in 
the operation room using the same open-field imaging platform. Hereafter the 
neck specimens were transferred to a closed-field NIR closed-field optical 
imaging system (Pearl Triology; LI-COR Biosciences Inc., Lincoln, Nebraska, 
USA) and imaged. The closed-field imaging device was used for ex vivo neck 
specimen imaging because it has a wide dynamic range and ensures 
controlled imaging environment, including elimination of ambient light and fixed 
camera-tissue distance39. Subsequently the neck specimens were transported 
to pathology for standard of care processing. The neck specimens were 
formalin-fixed overnight after which they were re-imaged in the closed-field 
imaging device prior to grossing of the LNs. With the fluorescence guide of the 
neck specimen, LN grossing was performed as per standard of care. Grossed 
LNs greater than 5 mm diameter were bisected prior to embedding, per 
standard of care. Remainder fibro-adipose tissue from the neck specimens was 
also collected in additional cassettes. All cassetted LN samples, including the 
fibro-adipose tissues, were then re-imaged on the closed-field imaging device. 
Pathological assessment 
After processing and paraffin embedding, 4 μm thick sections were sliced and 
stained with hematoxylin and eosin (H&E). The H&E slides were studied 
microscopically by a board-certificated pathologist, who was blinded to the 
fluorescence status, to confirm the number of LNs identified and the presence 
or absence of tumor cells in the LNs. The Odyssey imaging platform (LI-COR 
Biosciences Inc.) was used to determine fluorescence in slide-mounted 
sections obtained from formalin-fixed paraffin-embedded blocks. 
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To confirm the presence of EGFR, cytokeratin 5/6, CD68, and CD31 routine 
immunohistochemistry was performed with an autostainer (DAKO Link48 and 
PT link, Agilent Technologies Inc., Santa Clara, California, USA) using an anti-
EGFR antibody (clone EP38Y, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA), anti-cytokeratin 5/6 antibody (clone D5/16B4, Thermo 
Fisher Scientific), anti-CD68 antibody (clone KP1, Thermo Fisher Scientific), and 
anti-CD31 antibody (ab124432, Abcam, Cambridge, MA, USA). Stained slides 
were digitized using a whole slide scanner (Hamamatsu NanoZoomer 2.0-RS, 
Hamamatsu, Japan). 
Fluorescence microscopy 
For fluorescence microscopy, selected tissue slides were deparaffinized, and 
the nuclei were counterstained with 4’,6-diamidino-2-pheny-lindole (DAPI, 
Prolong Diamond, Thermo Fisher Scientific). Stained slides were dried in the 
dark at 4°C overnight. The slides were imaged using a custom set-up inverted 
digital fluorescence microscope (DM6B, Leica Biosystems, Wetzlar, Ger-many) 
equipped with a highly sensitive Leica DFC9000GT camera (4.2 M Pixel 
sCMOS camera), a metal halide LED light source (X-Cite 200DC, Excelitas 
Technologies, Waltham, Massachusetts, USA) for DAPI imaging, and a xenon 
arc lamp LB-LS/30 (Sutter Instrument, Novato, California, USA) for NIR imaging 
of IRDye800CW. Image acquisition and processing was done through LAS X 
software (Leica Biosystems). 
Statistical analysis 
For quantitative analysis of the fluorescence-imaging-based data collected with 
the closed-field imaging device, mean fluorescence intensities (MFIs), defined 
as total counts/region of interest (ROI) pixel area, was calculated using a 
custom ROI generated for each LN using integrated instrument software (Image 
Studio; LI-COR Biosciences). Signal-to-background ratios (SBRs) were 
subsequently calculated by dividing LN MFI by the fibro-adipose tissue MFI. 
Descriptive statistics and figures were obtained using GraphPad Prism (Version 
6.0c, GraphPad Software, La Jolla, California, USA). Data are presented as 
boxplots, where the whiskers indicate the minimum and maximum value, and 
lower and upper hinges correspond to the upper and lower quartiles, center 
line to the median. Sensitivity and specificity values of panitumumab-
IRDye800CW for metastatic LN identification were calculated using ROC 
curves. Threshold values were determined based on Youden’s index using JMP 
(Version 10, SAS, Cary, North Carolina, USA). The likelihood ratio (LR) was 
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defined by the following equation: LR = sensitivity/ (1–specificity). 
Fluorescence intensities between the three different dose groups (<0.5 mg 
kg−1, ≥0.5- <0.75 mg kg−1, and ≥0.75 mg kg−1) were compared using a 
Kruskal-Wallis test with a Dunn’s multiple comparison test as post hoc analyses. 
Fluorescence intensities between pathologically metastatic and benign LNs 
within each dose group was analyzed with a Mann—Whitney U-test. All data are 
presented as mean or mean ± standard deviation (SD), and a two-sided p-
value of 0.05 or less was considered statistically significant. (*p<0.05; **p<0.01; 
***p<0.001; NS not significant). 
Results 
Summary of study design 
A single center, non-randomized, phase I study was performed in 24 patients 
with biopsy proven HNSCC, of which 22 patients received surgical resection of 
the primary tumor and a unilateral or bilateral neck dissection. Patients received 
an infusion with panitumumab-IRDye800CW 1—5 days prior to surgery at a 
range of doses: low (<0.5 mg kg−1), middle (≥0.5—<0.75 mg kg−1) and high 
(≥0.75 mg kg−1). On the day of surgery intraoperative, NIR fluorescence 
imaging was performed to assess cervical LNs in vivo using an open-field 
device. After surgical resection, the neck dissection specimens were imaged in 
a closed-field fluorescence device and subsequently sent for pathology and 
processed as per standard of care. In collaboration with a board-certified 
pathologist (B.A.M), molecular imaging results were correlated to (histo-
)pathological findings.13 
Based on the results of the current study, we propose an enhanced 
workflow using pathological molecular imaging to segregate high-risk 
(metastatic) from low-risk (benign) LNs, as demonstrated in Figure 9.1. 
Patient characteristics 
Table 9.1 shows the characteristics of the 22 patients who received surgical 
resection of the primary tumor and a unilateral or bilateral neck dissection. 
Preoperative MRI imaging was performed in 19 patients (86.4%), and an 18F-
FDG-PET/CT scan was acquired in 16 patients (72.7%). A CT scan was 
performed in seven patients (31.8%). Clinical N stage (cN) was N0 in 14 
patients (63.6%), N1 in five patients (22.7%), and N2 in three patients (13.6%). 
Chapter 9 
144 
The average panitumumab-IRDye800CW dose given was 0.67 mg kg−1 
(range 0.26—1.05 mg kg−1) and the average time of infusion-to-surgery was 2 
days (range 17—120 h). Patients were followed for 30 days post-study drug 
infusion and adverse event data was collected on day 0, day of surgery, day 
15, and day 30. Adverse events were classified according to the National 
Cancer Institute Common Terminology Criteria v4.0. No adverse events were 
reported that were found to be related to the study. Furthermore, no 
abnormalities were found in general physical exam, Karnofsky performance 
status, metabolic panels, complete blood count, serum chemistry, 
prothrombin/partial thromboplastin times, thyroid stimulating hormone levels, 
and ECGs. 
At surgery, a total of 30 neck dissection specimens were obtained; 14 
patients (63.6%) underwent a unilateral neck dissection and a bilateral neck 
dissection was performed in eight patients (36.4%). Following (histo-) 
pathology, a total of 1012 LNs (39 metastatic LNs and 973 benign LNs) were 
identified, averaging 37.5 LNs per neck (range 12-72 LNs), which is consistent 
with our institutional average of 36 LNs per neck (internal quality data, 
unpublished). Of the total number of LNs collected, 946 LNs (93.5%) were 




Figure 9.1 Workflow of Fluorescence Imaging-Based LN Preselection. Following panitumumab-
IRDye800CW infusion 1—5 days prior to the day of surgery, on the day of surgery, the 
neck will be operated on after which the neck specimen is collected and imaged with a 
closed-field imaging device. With the fluorescence guide of the neck specimen, LN 
grossing is performed as per standard of care. Fluorescence-imaging-based 
preselection using the fluorescence signal is performed to select LNs at risk of 
metastasis. Upon showing the feasibility of our approach, we propose that only at-risk 
LNs, which are characterized by a high mean fluorescence intensity (MFI) and signal-
to-background ratio (SBR), have to undergo thorough evaluation at pathology, meaning 
an hematoxylin and eosin staining, and a closed-field fluorescence image is obtained 
to correlate fluorescence-imaging-based findings to (histo-)pathology. Low-risk LNs 
would not require any further evaluation. LN = lymph node. 
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Table 9.1 Patient demographics and pathological characteristics. 
Characteristics N (%) Average (range) 
Number of patients 22 (100)  
Gender, male 16 (72.7)  
Age (y)  60 (32-85) 
Panitumumab-IRDye800CW dose (mg kg-1)  0.67 (0.26-1.05) 
Time of infusion-to-surgery (h)  57 (17-120) 
Diagnostic imaging modality   
   MRI 19 (86.4)  
   18F-FDG-PET/CT 16 (72.7)  
   CT 7 (31.8)  
Primary tumor site   
   Oral cavity 20 (90.9)  
   Hypopharynx 1 (4.5)  
   Larynx 1 (4.5)  
Tumor size (mm)  34 (6-55) 
Clinical N-stage   
   N0 14 (63.6)  
   N1 5 (22.7(  
   N2 3 (13.6)  
Pathological N-stage   
   N0 13 (59.1)  
   N1 1 (4.5)  
   N2 8 (13.6)  
Surgical procedure   
   Tumor resection + unilateral neck dissection 14 (63.6)  
   Tumor resection + bilateral neck dissection 8 (36.4)  
MRI magnetic resonance imaging. 18F fluoride 18, FDG fluorodeoxyglucose, PET/CT positron 
emission tomography combined with computed tomography, CT computed tomography. 
 
Discriminating metastatic from benign LNs 
To evaluate the sensitivity and specificity of pathological molecular imaging 
using an anti-EGFR fluorescent contrast agent for the identification of metastatic 
LNs, we performed closed-field fluorescence imaging of the neck specimens 
and thereafter of the individually dissected LNs prior to processing for (histo-) 
pathological analysis. Fluorescence-imaging data were calculated as mean 
fluorescence intensity (MFI) and signal-to-background ratio (SBR) and then 
compared to histopathology (Figure 9.2a). Fluorescence signal intensity 
analysis showed a significantly higher MFI in metastatic LNs vs. benign LNs, 
0.099 ± 0.014 vs. 0.036 ± 0.001, respectively (mean ± standard deviation (SD); 
Mann—Whitney U-test, p<0.001; Figure 9.2b). Using fibro-adipose tissue for 
reference back-ground signal, the mean SBR was >2-fold higher in metastatic 
LNs compared to the mean SBR in benign LNs, 5.8 ± 0.5 vs. 2.0 ± 0.1 (Mann—
Whitney U-test, p<0.001; Figure 9.2c). 
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The optimal threshold value for MFI was found to be 0.044 at which a 
94.9% sensitivity and a 76.4% specificity was reached [likelihood ratio (LR) 
4.0]. Here, the negative predictive value (NPV) of this technique was 99.7% and 
the positive predictive value (PPV) was 13.9%. 
The optimal threshold value for SBR was 3.0, whereby an 87.2% sensitivity 
and 86.1% specificity (LR 6.2) was reached, with an NPV and PPV of 99.4% 
and 20.1%, respectively. Receiver operating characteristic (ROC) curve 
evaluation showed the area under the curve (AUC) obtained for MFI was 0.89 
(95% confidence interval (CI) 0.86-0.92) and the AUC for SBR was 0.93 (95% 
CI 0.89-0.97), suggesting potential clinical value (Figure 9.2d, e). 
Because the PPV remained relatively low for the single evaluation 
techniques, we evaluated a combined threshold of MFI ≥0.044 and SBR ≥3.0, 
which resulted in a PPV of 36.2% consistent with a sensitivity of 84.6% and 
specificity of 94.0% (Table 9.2). Importantly, this combined MFI and SBR 
threshold method allowed us to preselect 91 LNs (9.0%) from the total of 1012 
collected LNs, compared to 267 LNs (26.4%) in MFI threshold method and 169 
LNs (16.7%) in SBR threshold method. Finally, using the combined MFI and 
SBR threshold method, 915/1012 LNs were scored true negative (fluorescence 
negative, histopathologically confirmed benign LN), 33 LNs as true positive 
(fluorescence positive, histopathologically confirmed metastatic LN), 58 LNs as 
false positive (fluorescence positive, histopathologically confirmed benign LN), 
and 6 LNs as false negative (fluorescence negative, histopathologically 
confirmed metastatic LN). 
To determine the clinical impact of the six false negative LNs (0.6%), we 
evaluated the staging in these four patients. All four patients presented with 
multiple metastatic LNs, none larger than 6 cm and none with extranodal 
extension (staged as pN2); fluorescence imaging detected ≥2 LNs in each 
patient, and therefore the presence of additional small metastatic LNs did not 
impact staging. 
Identification of metastases in small LNs 
In contrast to small (<10 mm) LNs, large LNs are readily identified 
intraoperatively and at pathology while grossing the neck specimen. To assess 
whether our method could identify small metastatic LNs, we evaluated MFI and 
SBR separately for these small LNs (n=946, Figure 9.3a). The fluorescence 
signal intensity of metastatic LNs was >2-fold higher than that of benign LNs 
(Figure 9.3b, c) suggesting that pathologic molecular imaging can detect 
metastatic disease in small LNs. An 81.8% sensitivity and a 94.0% specificity 
was reached with a NPV of 99.5% for small LNs (Table 9.3). 
Optical molecular imaging can differentiate metastatic from benign lymph nodes in HNC 
147 
 
Figure 9.2 Panitumumab-IRDye800CW Distinguishes Metastatic and Benign LNs. a Fluorescence-
imaging data was calculated as mean fluorescence intensity (MFI) and signal-to-
background ratio (SBR) and then compared with histopathology. Dotted line: tumor 
region. Scale bars=5 mm. b Quantitative fluorescence signal analysis showed a 
significant higher MFI in metastatic LNs vs. benign LNs (p<0.001). c Using fibro-
adipose tissue as background signal, the SBR was >2-fold higher in metastatic LNs 
compared to the SBR in benign LNs (p<0.001). d, e Receiver operating characteristic 
curve (ROC) curve evaluation showed that high areas under the curve (AUCs) were 
obtained for MFI (AUC=0.89, 95% confidence interval (CI) 0.86-0.92) and SBR 
(AUC=0.93, 95% CI;0.89-0.97). Data are presented as boxplots, where the whiskers 
indicate the minimum and maximum value, and lower and upper hinges correspond to 
the upper and lower quartiles, center line to the median. Figure 9.2 (b),(c): Benign 
(n=973) and metastatic (n=39). p-values were determined via a two-tailed Mann—
Whitney U test. (*p<0.05; **p<0.01; ***p<0.001; NS not significant) Source data are 
provided as a Source Data file. LN = lymph node. 
 
 
Table 9.2 Diagnostic statistics for determining the threshold for LN preselection. 








number of LNs (%) 
MFI≥0.044 94.9% 76.4% 13.9% 99.7% 77.1% 267/1012 (26.4) 
SBR≥3.0 87.2% 86.1% 20.1% 99.4% 86.2% 169/1012 (16.7) 
MFI≥0.044+SBR≥3.0 84.6% 94.0% 36.2% 99.3% 93.7% 91/1012 (9.0) 




Discriminating metastatic from large reactive LNs 
Large LNs may be reactive (benign) or metastatic, and often complicate 
surgical decision making. We evaluated the fluorescence signal intensity 
between metastatic and benign LNs that were greater than 10 mm. For large 
LNs (n=66), the fluorescence signal intensity from metastatic LNs was almost 
three times that of benign LNs (Figure 9.3b, c), suggesting that our proposed 
approach could distinguish metastatic LNs from the other (reactive) LNs 
greater than 10 mm. A sensitivity of 88.2% and a specificity of 93.9% was 
reached with an NPV of 95.8% (Table 9.3). A much higher PPV was obtained in 
large LNs (83.3%) compared to small LNs (24.7%), likely reflecting the 






Figure 9.3 Fluorescence Signal Intensities of Small and Large Metastatic LNs are Similar. a 
Representative hematoxylin and eosin (H&E) staining and fluorescence image of small 
(<10 mm) and large (≥10 mm) LNs. Dotted line: tumor region. Scale bars =5 mm. b, c 
Mean fluorescence intensity (MFI) and signal-to-background ratio (SBR) of metastatic 
and benign LNs are significantly different when assessing small or large LNs only. 
However, no difference in MFI and SBR are found for metastatic small and large LNs. 
Data are presented as boxplots, where the whiskers indicate the minimum and 
maximum value, and lower and upper hinges correspond to the upper and lower 
quartiles, center line to the median. Figure 9.3(b), (c): In small LNs (n=946), benign 
(n=924), and metastatic (n=22). In large LNs (n=66), benign (n=49), and metastatic 
(n=17). p-values were determined via a two-tailed Mann—Whitney U test. (*p<0.05; 
**p<0.01; ***p<0.001; NS, not significant) Source data are provided as a Source Data 
file. LN = lymph node. 
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Table 9.3 Cumulative statistics for the total number of harvested LNs. 
 Total LNs Small LNs (<10 mm) Large LNs (≥10 mm) p-value 
Number of LNs 1012 946 66  
Metastatic 
   True positive  33 18 15 
   False negative  6 4 2 
NS 
Benign 
   False positive  58 55 3 
   True negative  915 869 46 
NS 
   Sensitivity  84.6% 81.8% 88.2%  
   Specificity  94.0% 94.0% 93.9%  
   Positive predictive value 36.2% 24.7% 83.3%  
   Negative predictive value 99.3% 99.5% 95.8%  
   Accuracy  93.7% 93.8% 92.4%  
NS not significant, LN lymph node. 
 
Higher dose positively correlates with false positive rate 
To study the impact of panitumumab-IRDye800CW dose on the false positive 
and false negative rate, we divided the 22 studied patients over three dose 
groups: <0.5 mg kg−1 (low dose, n=6), ≥0.5-<0.75 mg kg−1 (middle dose, 
n=7), and ≥0.75 mg kg−1 (high dose, n=9). The distribution of true positive, 
false positive and false negative LNs across the 22 patients is shown in Figure 
9.4 by the combined MFI and SBR threshold method described above. Not 
surprisingly the fluorescence signal intensity of metastatic LNs in the low dose 
group was significantly lower compared to the middle or high dose group 
(Kruskal-Wallis test with a Dunn’s multiple comparison test, p<0.01). The SBR 
was not found to vary with dose. Of the total of 58 false positive LNs, 45 LNs 
(77.6%) were found in the high dose group. This resulted in a false positive rate 
of 9.2% in the high dose group vs. 2.1% in the low dose group and 3.0% in the 
middle dose group (Figure 9.5a). Furthermore, PPVs in the low and middle 
dose group were much higher compared to the PPV in the high dose group 
(57.1%, 61.1% vs. 23.7%; Supplementary Table S9.1). Optimal LN preselection 
results were obtained in the middle dose group (≥0.5—<0.75 mg kg−1) where a 
sensitivity of 91.7% and a specificity of 96.9% with an NPV of 99.5% was found. 





Figure 9.4 Patient-based Distribution of True Positive, False Positive and False Negative LNs. A 
total of 1012 LNs was collected from 22 patients of which 915 were true negatives (not 
shown). The number of true positive, false positive and false negative LNs is shown on 
a per patient base. Definitions: True positive = fluorescence positive, 
histopathologically confirmed metastatic LN; True negative = fluorescence negative, 
histopathologically benign LN; False positive = fluorescence positive, 
histopathologically benign LN; False negative = fluorescence negative, 





Figure 9.5 Effect of the Antibody-Dye Dose on the Find Rate of False Positive LNs. a Rates of true 
positive, false positive, false negative and true negative LNs over three groups by 
weight adjusted dose. TP true positive (fluorescence positive, histopathologically 
confirmed metastatic LN); TN true negative (fluorescence negative, histopathologically 
benign LN); FP false positive (fluorescence positive, histopathologically benign LN); FN 
false negative (fluorescence negative, histopathologically confirmed metastatic LN). 
Source data are provided as a Source Data file. b Representative fluorescence images 
of metastatic and benign LNs for the three dose groups. Scale bars = 5 mm. LN = 
lymph node. 
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Fluorescence signal intensity to segregate high-risk LNs 
To identify the minimum number of LNs that would be required for 
histopathological assessment to achieve accurate staging, we ranked the LNs 
by absolute fluorescence signal (as defined by MFI), per neck. We mapped all 
of the LNs harvested from the 14 neck dissections in the nine patients with 
pathologically positive LNs (five patients underwent a bilateral neck dissection, 
Figure 9.6a). Segregation of the LNs by decreasing MFI allowed for accurate 
staging of the neck by histological sectioning of only three LNs with the highest 
fluorescent signal (Figure 9.6b), with high specificity (94.0%). For each patient, 
this method identified sufficient metastatic LNs to establish the presence of 
larger metastases (>3 cm, >6 cm) and determine focality (single vs. multiple 
LNs), laterality, and extranodal extension status, providing all the data 
necessary for accurate American Joint Committee on Cancer (AJCC) staging. 
While on an individual LN basis the sensitivity of 66.7% was relatively low when 
evaluating only three LNs per neck (Figure 9.6c), the data suggests that the 
sensitivity of detecting metastasis could be significantly increased by analysis 
of additional LNs, but with a resulting decrease in specificity (i.e., more false 
positive LNs identified). Although evaluation of only three LNs successfully 
staged 100% of the patients, harvesting and evaluation of up to 10 LNs per 
neck led to a further improved sensitivity of 94.8%, though at the cost of losing 
specificity (decreased to 75.1%). 
Assessment of false positive LNs 
To confirm that false positive LNs were truly benign and not related to sampling 
errors, additional sections were obtained from 28 false positive LNs from six 
neck specimens from five patients that were staged pathological N0 (pN0). 
From each formalin-fixed paraffin-embedded LN, three additional sections were 
collected at 150 μm intervals. Additional sectioning revealed that one out of 28 
(3.6%) of the false positive LNs was positive for tumor (micro-metastasis). As a 
control, additional sections were obtained from patient-matched true negative 
LNs (n=28), of which all were found benign on re-evaluation. Antibody-dye 
distribution in metastatic and benign LNs. To assess the distribution of the 
fluorescent contrast agent on the microscopic level, we compared the 
fluorescence-imaging results to expression of EGFR, cytokeratin 5/6, CD68, 
and CD31 by performing immunohistochemistry of metastatic LNs (true 
positive, false negative) and benign LNs (false positive and true negative). In 
benign LNs, fluorescence was detected throughout the subcapsular and 
trabecular sinuses but not in the follicular regions and fluorescence did not 
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correspond with the very low levels of EGFR expression (Figure 9.7a). The 
number of false positive LNs dramatically increased with dose increases (Figure 
9.5 and Supplementary Table 9.1), suggesting that the fluorescent antibody 
migrated through LNs by vascular flow and/or non-specific lymphatic drainage. In 
metastatic LNs, the fluorescence signal was found in the peripheral aspects of 
macro-metastases and was well distributed within the micro-metastatic foci of 
tumor. Interestingly, in the false negative LNs, it appeared that the tumor was 
large enough to occlude lymphatic flow to the LNs, which was associated with a 
reduced fluorescence signal. Microscopic analysis of metastatic LNs 
demonstrated a clear correlation between EGFR expression and panitumumab-
IRDye800CW uptake on the tumor cell membranes in macro-metastases and 
micro-metastases (Figure 9.7b). Taken together, this data suggests that 
panitumumab-IRDye800CW migrates non-specifically through regional LNs and 
is capable of binding to tumor when present. 
 
 
Figure 9.6 Fluorescence Signal Intensity-based Ranking of Dissected LNs per Neck. a 
Fluorescence signal intensity-based ranking of small and large LNs in the nine patients 
with pathologically positive necks. TP true positive (fluorescence positive, 
histopathologically confirmed metastatic LN); TN true negative (fluorescence negative, 
histopathologically benign LN); FP false positive (fluorescence positive, 
histopathologically benign LN); FN false negative (fluorescence negative, 
histopathologically confirmed metastatic LN). b Using the first three LNs with the 
highest fluorescence signal would provide accurate staging in all patients. c Sensitivity 
and specificity based on the number of LNs per neck that need to be assessed by 
pathology. Source data are provided as a Source Data file. LN = lymph node. 




Figure 9.7 Panitumumab-IRDye800CW Distribution and Correlation to Immunohistochemistry. a 
Hematoxylin and eosin (H&E) staining, near-infrared fluorescence image and EGFR, 
cytokeratin 5/6, CD68 and CD31 immunohistochemistry results of a 4 μm cut section of 
representative true positive, false positive, false negative and true negative LNs. Dotted 
line: tumor region. Scale bars = 5 mm. b Representative microscopic fluorescence 
images of panitumumab-IRDye800CW (IRDye800CW) and EGFR 
immunohistochemistry in macro-metastasis (upper row), micro-metastasis (middle row) 
and uninvolved LN tissue (bottom row). Scale bars = 100 μm. EGFR epidermal growth 





Surgical imaging for the detection of the primary tumor has rapidly evolved in 
the United States with many optical contrast agents being evaluated in clinical 
trials to improve negative margin rates during surgical resection.8,13,14 As 
techniques in pathological molecular imaging improve for primary tumor 
evaluation,15,16 there are distinct advantages that can be translated to 
assessment of regional disease and improvement of the pathology workflow as 
well. 
It is well known that embedding high numbers of LNs results in the 
overload of labor, space, and use of equipment and supplies, all of which 
increase healthcare costs.17 Moreover, methods for processing of specimens in 
surgical pathology have not changed in the past half century. We demonstrate 
that pathological molecular imaging following a systemic injection of an anti-
EGFR imaging agent can guide ex vivo assessment of the resected nodal 
tissue based on fluorescence signal intensity (MFI) and signal-to-background 
ratio (SBR). We found that pathologically metastatic LNs could be successfully 
segregated from benign LNs by means of fluorescence assessment; when LNs 
were preselected based on MFI and SBR, metastatic LNs could be identified 
with high sensitivity (84.6%), specificity (94.0%), and NPV (99.3%) and 
acceptable PPV (36.2%). If prospective studies confirm this approach, our 
proposed LN assessment workflow (Figure 9.1) could result in a 90% reduction 
of the number of LNs that have to undergo pathological processing and 
histological examination. 
Although a combination of direct visualization and palpation is considered 
the gold standard by pathologists for detecting and harvesting LNs from neck 
dissection specimens, this technique is time consuming, can miss smaller LNs, 
and is subject to high interobserver variability, limiting standardization within 
institutions and across medical centers.18 To improve nodal yield and to 
increase detection of small LNs, fat clearance can be performed,19 but this 
technique requires a chemical agent to dissolve the fat tissue around the LNs, 
and thus is time consuming, expensive and potentially hazardous. Local or 
intravenous/intra-arterial injections of methylene blue and indocyanine green 
have been used to improve LN identification at pathology, but due to poor 
tumor specificity this has never become routinely implemented; sensitivities and 
specificities achieved with this approach vary between 52-94% and 76-78%, 
respectively.20-22 Most importantly, none of the current techniques discriminates 
between metastatic LNs and benign LNs. Our proposed method, whereby anti-
EGFR-based fluorescence molecular imaging allows for localization and 
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segregating of LNs that are at the highest risk of harboring metastasis, provides 
an opportunity to ease the process of LN assessment at pathology. In the same 
way that sentinel LN mapping selects LNs most likely to harbor metastatic 
disease, pathological molecular imaging selects high-risk LNs rather than 
requiring complete processing of all the LNs. However, in contrast to sentinel 
LN mapping which requires a re-operation when metastatic LNs are found, 
molecular imaging allowed 95% sensitivity for detection of all metastatic LNs 
with a total of 10 LNs per neck required for histologic processing. To confirm 
that false-positive LNs were not a result of sampling error, 28 false positive (and 
patient-matched true negative) LNs were sectioned an additional 0.5 mm. The 
additional recutting revealed that 3.6% of the false positive LNs were found to 
have micro-metastasis, but none of the true negative LNs. Importantly, this new 
finding would have changed nodal staging in one patient. 
The test performance characteristics of this molecular imaging technique 
are inherently related to the distribution of therapeutic antibodies in LNs after 
systemic administration, which is poorly understood in humans. In our study, 
microscopic imaging of panitumumab-IRDye800CW strongly corresponded 
with metastatic deposits within LNs that showed EGFR expression, and 
accumulation of panitumumab-IRDye800CW was predominantly found at the 
periphery of the metastasis, despite EGFR expression throughout the 
metastatic deposit (Figure 9.7). This suggests that panitumumab-IRDye800CW 
binds to tumor nests and concentrates at the periphery during passive 
lymphatic flow, a process that would be less effective when the afferent 
lymphatic vessels are occluded by an expanding tumor mass (Figure 9.7–
false negative). In benign LNs on the other hand, panitumumab-IRDye800CW 
signal is most likely the result of non-specific accumulation, as demonstrated by 
the dose-dependent increase in fluorescent antibody-complex detection in the 
lymphatic sinuses despite the absence of EGFR expression in those LNs. This 
hypothesis is further supported by studies of anti-human epi-dermal growth 
factor receptor-2 (HER2) receptor monoclonal antibody (trastuzumab) which 
can extravasate and circulate through the lymphatic system after intravenous 
injection.23,24 
Our current results may be significantly improved using the appropriate 
dose. Of the 58 false positive LNs, which were fluorescently positive but 
negative for tumor, 45 (77.6%) were found in the high dose cohort (>0.75 
mg/kg−1). Moreover, the PPV in this high dose group (23.7%) was much lower 
than in the low (57.1%) and middle dose groups (61.1%). This suggests that 
higher doses can increase non-specific drainage from the primary tumor to the 
tumor draining LNs. Because optimal dosing for the primary tumor resection 
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was previously established by us at 50 mg (0.5—0.75 mg kg−1) for head and 
neck cancer,13,25 this will permit molecular imaging of the cervical LNs as well. It 
is important to recognize that optical imaging is highly dependent on the device 
hardware and software26. Although relative SBRs are more likely to be similar 
among the various devices that are being evaluated in clinical trials, results are 
expected to vary based on the intraoperative and pathologic imaging system 
used. 
The process of LN preselection might be further improved by combining a 
radiotracer with fluorescence imaging to allow for a dual-modality in vivo and ex 
vivo molecular imaging strategy whereby preoperative, intraoperative and 
pathological processing can be all combined. A radiolabel would add the 
advantage of preoperative imaging and surgical guidance to deeper lying neck 
LNs, as compared to less than a centimeter of depth for optical agents.27,28 
Alternatively, a paired-agent molecular imaging method, whereby an 
untargeted imaging agent is administered alongside the targeted antibody, 
may be promising for assessing tumor burden in LNs based on preclinical 
data.29-31 In a mouse model, this method demonstrated that the uptake of the 
untargeted agent could estimate non-specific uptake in LNs and combined with 
targeted agent the ratio of targeted vs. untargeted agent provided 
unprecedented sensitivity to cancer cell presence.30,32 This paired-agent 
molecular imaging strategy is highly promising for metastatic LN identification; 
however, there are significant regulatory and financial barriers with 
implementation of a clinical trial with this strategy. 
We describe the use of anti-EGFR molecular imaging for ex vivo nodal 
evaluation, which could improve standardization, efficiency and accuracy of 
histopathologic processing. Although not sufficient to justify the added cost of 
the imaging contrast agent and infusion, it would complement intraoperative 
imaging of the primary tumor, which we and others have shown to have 
enormous potential to improve quality of oncologic resections. Improvements of 
NIR open camera systems will likely also lead to the ability to accurately identify 
metastatic LNs in vivo.26 In addition, optoacoustic imaging could improve depth 
of imaging by several centimeters.33-37 The principles of optoacoustic imaging 
are similar to fluorescence imaging, but optoacoustics detects acoustic waves 
generated by the optical excitation of the fluorophore. Combining fluorescence 
imaging with optoacoustic imaging may thus allow for non-invasive detection of 
metastatic LNs in the in vivo setting to provide additional guidance for 
intraoperative identification of metastatic LNs. 
Fluorescence molecular imaging using an anti-EGFR contrast agent can 
identify LNs at risk of harboring metastatic disease. Using fluorescence signal 
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intensity to rank LNs in order of descending value, only 10% of harvested LNs 
required histopathological assessment to provide accurate regional staging. 
This strategy would decrease resource utilization, standardize pathological 
processing of LNs and improve diagnostic accuracy. Molecular imaging for 
pathological purposes should be carefully evaluated as the development of 
intraoperative molecular imaging for primary tumor resections becomes 
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For successful surgical excision of many solid malignancies, distinguishing 
diseased from healthy adjacent tissue is pivotal. Currently, surgeons use visual 
and tactile feedback to make this important intraoperative distinction. Although 
surgical and thus patient outcomes largely depend on obtaining adequate 
surgical margins, positive surgical margin rates in most branches of surgical 
oncology remain high and have been mostly stagnant over the past 15 years.1 
This is a burden in the management of head and neck cancers, which have the 
highest number of positive margins, ranging from 15-30%.2-4 Another challenge 
in head and neck squamous cell carcinoma (HNSCC) management lies in the 
presence of occult nodal metastasis. During surgery, 30% of lymph node (LN) 
metastasis has a chance of being missed despite clinical and radiographical 
clearance.5 It is suggested that these high rates are impartial caused by the 
excessive pathological workload inherent to LN evaluation.6 To effectively deal 
with these challenges, this thesis evaluated the clinical value of fluorescence 
imaging for both intraoperative and pathological assessment and potentially 
improve patient outcomes.  
The work described in Chapter 2 and Chapter 3 assessed the clinical 
value of in situ fluorescence imaging for primary tumor and margin assessment. 
Both prospective studies illustrated that after systemic infusion of 
panitumumab-IRDye800CW extent of disease could successfully be visualized 
in situ using a dedicated hand-held imaging device. In this setting, qualitive 
information concerning surgical margins, adjacent tissue conditions and 
resection completeness becomes available to the surgeon in real-time. 
Throughout a surgical case, this information acts as a third layer of information 
on top of traditionally required visual and tactile tissue aspects. In addition, we 
found that different tissue types (i.e. mucosa, tongue, gingival and tumor) 
display a unique fluorescent pattern that enables easy tissue recognition and 
possibly provides an important bridge to future use of computer-based pattern 
recognition programs. Nevertheless, for current surgical use, it is important to 
bear in mind that like most novel surgical techniques, routine use is warranted 
to develop camera handling and pattern‐recognition skills to benefit from the 
fluorescence imaging information.7 The major challenge encountered during in 
situ fluorescence imaging, was the lack of quantitative data due to the absence 
of a controlled environment, where light (intensity) and camera-to-tissue 
distance could be standardized. In Chapter 2 different clinical light settings 
were tested in the operating room to establish optimal light conditions for open-
field imaging acquisition, while minimizing surgical workflow disturbance. We 
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found optimal light settings — those with the least interruption of surgical 
workflow — were having ambient lights turned on, while over-head lights turned 
off. Although a slight interruption of surgical workflow is initiated by open-field 
imaging, the lack of quantitative data that causes difficulties concerning 
interpatient comparison, demanded the exploration of alternative strategies 
(Chapter 4 and Chapter 5). 
To account for ambient light contamination, lack of quantitative imaging 
data, and to further minimize workflow disturbances, we evaluated 
intraoperative closed-field imaging of ex vivo tumor specimens on the back-
table of the operating room. Opposed to open-field systems, closed-field 
systems allow for fluorescence signal intensity quantification creating 
opportunity for interpatient and intertumoral comparison. In Chapter 4-6, margin 
assessment was performed by fluorescently mapping the entire tumor 
specimen’s surface, to look at the deep as well as the peripheral surface(s). We 
discovered if an area had a potentially close margin (<5 mm), this area was 
likely to be fluorescent (95% sensitivity and 89% specificity). If an area had no 
fluorescence, the likelihood of this region harboring tumor within 5 mm were 
less than 2%. This strategy proved to be very helpful in determining specific 
regions where tumor is to be expected closest to the surface and therefore 
warrant further clinical investigation. A specific challenge is the deep margin. 
As the deep margin is covered by overlaying healthy tissue, intraoperative 
detection of tumor that is close (1-5 mm) but not breaching the margin has a far 
higher risk to be missed, compared to cancer at the peripheral margin. To 
overcome this challenge, we developed a method that isolates the highest 
intensity region to pinpoint the closest margin on the specimen’s deep surface 
(Chapter 6). This method, analogue to the sentinel lymph node technique,8 
proved highly accurate in pinpointing specific regions where tumor is closest to 
the specimen’s deep surface. Meaning that if a surgeon would assess the 
entire deep and peripheral surface on the surgical specimen, one would only 
need to sample the sentinel margin — which is the closest margin — to see if an 
adequate margin distance has been reached. This approach has two major 
advantages over previously established imaging strategies.9,10 Firstly, 
interpatient variabilities which alter signal intensity and have previously been 
identified as problematic for open and closed-field surgical imaging (REF), 
have become redundant by using patients as their own internal control. 
Secondly, besides surgical implications, we found that fluorescence-imaging 
could have important potential for pathological workflow. Methods for specimen 
processing and handling in surgical pathology have not changed over half a 
century, resulting in work overload and excessive use of space and equipment, 
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all of which increase healthcare costs.11 Segregation of presumed cancer 
positive and negative LNs with ex vivo fluorescence imaging led to 
identification of metastatic LNs with high sensitivity, specificity and negative 
predictive values (85%, 94% and 99%, resp.). Indicating that if prospective 
studies have similar results, this approach could lead to a 90% reduction of LNs 
in need of (histo)pathological evaluation. 
Limitations  
It is likely that Intraoperative fluorescence imaging will have a major impact on 
the field of surgical oncology.12-14 Nevertheless, difficulties in data interpretation 
are caused by factors inherent to surgical tissue imaging. It is therefore of great 
importance that factors such as optical tissue properties, interpatient variations 
and tumor heterogeneity, are recognized by surgeons using these techniques 
in clinical practice. 
Optical imaging depends on the detection of photons deriving from the 
exited fluorophore (i.e. signaling fragment of agent) within the tissue. Optical 
tissue properties, such as scattering and absorption, define the route in which 
photons travel through tissue and how many eventually reach the camera. 
Notably, as the travel distance (i.e. penetration depth) through tissue rises 
these effects tend to increase substantially.15 In addition, the effect of 
autofluorescence, which is caused by interfering photons from healthy 
untargeted tissue (i.e. muscle, adipose tissue etc.), acts as potential 
confounding factor. Another important difficulty which makes imaging analysis 
and data interpretation challenging is caused by interpatient variability. In other 
words, no patient presents with the same fluorescence signal intensity. Factors 
such as agent infusion-to-surgery time, pharmacokinetic clearance and agent 
tumor uptake, vary substantially per patient and make interpatient comparison 
challenging. To overcome this problem, we propose the use of patients as their 
own internal control. As this circumvents the need for interpatient comparison, 
this imaging strategy is expected to be compatible with any homogenous 
distributed agent and quantitative imaging platforms. 
Human tumors contain cells that differ in clinically significant phenotypic 
types, creating intra-tumoral heterogeneity.16 This variability in expression 
potentially impacts the quantity of tracer-target binding and as a result cause 
inconsistent imaging data.12 However, for HNSCC, known to overexpress EGFR 
in more than 90% of squamous cells,17,18 one single probe was found to be 
sufficient. Our clinical trial indicated that of out all 61 surgical HNSCC cases, 
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100% of tumors expressed significant EGFR levels for consistent optical 
imaging, marking panitumumab as a more than suitable candidate for HNSCC 
imaging (Unpublished data, Rosenthal lab). Due to spider-like infiltration pattern 
of HNSCC, surgeons excise tumor tissue with a gross 10mm margin of healthy 
surrounding tissue to ensure all infiltrating tumor strands are caught within this 
surgical margin. Although the importance of radical resection is described 
extensively in literature, the actual tumor to surgical margin distance is still 
subject of ongoing debate.19-21 Nevertheless, the majority of surgeons accept a 
histological margin of 5mm or more as adequate and less than 5mm as close or 
inadequate. Today, surgeons define the surgical margin based on subjective 
tissue information leading to significant inter-surgeon differences.22 Optical 
fluorescence imaging could play an important role in objectively defining the 
distance required for each margin individually, provided that this technique 
could detect infiltrating tumor strands.23 
Difficulties in defining clinical trial efficacy endpoints 
Large clinical trials are mandatory to investigate if surgical procedures guided 
by optical imaging achieve better surgical outcomes and benefit for the patient. 
However, as direct impact on patient survival is difficult to measure, surrogates 
of clinical benefit need to be reviewed to set optimal and relevant endpoints for 
these trials.  
The work described in this thesis broadly states the potential of real-time 
fluorescence imaging in guiding surgical tumor resection, however, the true 
value of this technique will only be fully understood when patient outcome data 
becomes available. Nevertheless, the effect of imaging on patient outcome 
data, commonly described in terms of survival (e.g. disease-free and 5-year 
survival), remains problematic to measure in HNSCC and many other tumor 
types. To explain this, let us first discuss an example where survival is a valid 
and effective measurement of fluorescence imaging. In the late 90s, Walter 
Stummer and his colleagues started using the 5-ALA tracer for detection of 
glioblastoma multiforme (GBM) cells.23,24 Interestingly, these cells accumulate 
significant amounts of PpIX, which is converted to fluorescent 5-ALA, making 
distinction between healthy and diseased brain tissue possible. In the first 
large, randomized phase III study, Stummer and colleagues not only showed 
that using 5-ALA led to far better complete resection rates compared to 
standard surgery (65% vs 36%, p<0.0001, respectively), but also prolonged 6-
month progression-free survival (41% vs 21%, p<0.0003) in patients with 
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malignant glioma. Not surprisingly, it was the direct impact of 5-ALA imaging on 
the progression-free survival that led to the first (and only!) FDA approved 
cancer specific imaging agent.25,26 This, however, inevitably leads to the 
question: “Do all intraoperative imaging trials need to show patient benefit in 
terms of survival to gain approval?” and if this is not the case, what other 
efficacy endpoints can be acquired during clinical testing to obtain approval. 
Currently, clinical trials need to show clear patient benefit for approval of their 
method, simply showing that agents reach the targeted tumor with high 
sensitivity and specificity is not considered sufficient by regulatory agencies. 
However, evidence that leads to findings that are known to improve patient 
outcomes in a controlled clinical setting, are considered beneficial. This 
indicates that the medical agencies (FDA and European Medicine Agency) not 
necessarily require direct measurements of patient outcome (e.g. prolonged 
survival), but also settle with alterations caused by imaging of established 
correlations.26 For HNSCC, we suggest that clinical trial endpoints to assess the 
efficacy of optical imaging should be focused more on intraoperative margin 
assessment, regional lymph node metastasis and local recurrence, rather than 
overall survival rates. For example, when intraoperative imaging leads to 
improved detection of positive margins, it is considered to be beneficial for 
patients, as the correlation between positive margins and poor overall survival 
has been well-established. In HNSCC, we can measure what the current 
standard of care could benefit from intraoperative fluorescence imaging by 
recording clinically significant events (i.e. changes caused by intraoperative 
imaging that are known to improve surgical outcomes) or comparison to 
traditional visual and tactile assessment by a surgeon. Thus, within an in situ 
research-setting, similar to the set-up used in Chapter 3, we can objectively 
record clinically significant events caused by intermitted (before first incision, 
during surgery and post-excision) imaging. Note that the definition of clinically 
significant events which should be concise and objective rather than 
subjective. Within an ex vivo research-setting, the surgeon excises the tumor 
specimen and marks areas where he/she thinks tumor is harbored closest to 
the surgical margin. Subsequently, that same specimen is assessed using 
fluorescence imaging to also pinpoint and mark areas where the margin might 
be close. These marked areas are then sectioned perpendicular to the tumor 
for histopathological assessment, to evaluate if one method is superior, similar 
or inferior in detecting close margins.  
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Future perspectives   
Years of preclinical testing have laid a solid foundation for successful surgical 
fluorescent tracer development, making imaging instruments and platforms the 
current lingering factors for surgical imaging. However, as instrumentational 
hardware and software advances rapidly and multimodality approaches are 
being developed, we assume within the next five years, intraoperative cancer 
detection with high sensitivity and specificity will be common clinical practice.27 
Over the past 100 years, a wide variety of different imaging modalities 
have made tremendous impact on modern medicine. With each specific 
modality having its own set of benefits and shortcomings, combining imaging 
modalities has shown to be beneficial in numerous cases and consequently 
novel dual- and multimodality platforms are emerging rapidly. One famous 
example is that of 18F-FDG PET/CT, which success was made visible by the 
rapid, widespread use of this technique. Subsequently, promising results have 
been shown in studies combining radio-guidance with optical imaging. These 
hybrid tumor-targeting tracers conjugated to a fluorophore as well as a 
radiotracer, showed to be effective in both preoperative and intraoperative 
settings.28 In this era of surgery, a favorable window of opportunity to combine 
different modalities into multimodality image-guided approaches is emerging. 
However, it is important to bear in mind that most of these multimodality 
strategies require an essential interdisciplinary collaboration of surgeon, 
pathologist and often other disciplines.  
We believe that with combining different modalities, frozen section analysis 
(FSA), will in time, become obsolete. Today’s gold standard for intraoperative 
assessment of surgical margins and lymph node involvement is FSA. Besides 
being time- and work intensive, an objective sampling method for FSA is still 
lacking. On top of that, FSA can only sample a small fraction of the entire 
specimen’s surface, and as surgeons solely rely on visible and tactile 
information, they struggle to identify areas to sample for margin status.2,19,29 
Currently, we are pursuing a multi-modality approach to overcome the 
problems hampering our current golden standard (i.e. sampling selection, time, 
sampling errors). By combining the sentinel margin strategy (Chapter 5) with a 
technique that assesses histopathology in the operating room. Sentinel margin 
analysis would allow assessment of the entire specimen’s surface to pinpoint 
suspicious regions for objective sampling, followed by a technique enabling 
histopathological evaluation within the operating room. Although, multiple 
modalities, such as Raman spectroscopy and optical coherence 
tomography/microscopy (OCT/OCM), seem suitable to fit the purpose of 
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intraoperative histopathological evaluation, they interfere with the fluorescent 
agents distributed throughout the tissue.30,31 An appropriate candidate is light-
sheet microscopy. Liu and co-workers developed a dedicated light-sheet 
microscope with open-top to handle small tissue sections, similar to FSA-
samples, for rapid and non-destructive pathology.32,33 The goal of such multi-
modal imaging strategy is to first use fluorescence imaging to identify the high-
risk “sentinel margin” on the excised specimen, followed by high-resolution 
microscopy of cross-sections cut from the sentinel margin’s location. Compared 
to intraoperative pathological consultation using FSA, which usually takes 20-30 
minutes per sample, light-sheet microscopy has an exceptionally high imaging 
speed. After brief staining (20s) of breast tissue with acridine, light-sheet 
microscopy takes less than one minute to image 4 cm2 (normal size of sampled 
margin for FSA is approximately 1cm2) with the same subcellular resolution as 
traditional H&E histopathology.32 In addition, as the data is directly digitalized, 
histopathological evaluation by a pathologist could be performed from a 
location outside the operating room.  
The strategy for pathological lymph node (LN) imaging described in 
Chapter 8 shows a potential decrease in resource utilization, a standardization 
of pathological LN processing and improved diagnostic accuracy. Prospective 
studies are warranted to confirm our approach for LN assessment which can 
result in a 90% reduction of LNs needing evaluation. However, future focus 
should not only be on pathological imaging, but rather on in situ detection of 
metastatic LNs using open-field systems, as intraoperative detection of 
metastatic LNs would have a major impact on surgical and thus patient 
outcome.  
Conclusion  
Within the era of minimal invasive surgery — a revolution in surgery that started 
nearly three decades ago — the concept of precision medicine is rapidly 
gaining ground, enabling exciting human-machine collaboration. Fluorescence 
guided surgery is one of its apprentices, a promising surgical imaging 
technique, which can easily be integrated into surgical oncology as it enables 
real-time imaging, does not require bulky or expensive equipment and provides 
both qualitative and quantitative imaging data. The imaging data can easily be 
incorporated with the surgeon’s armamentarium, strengthening our assumption 
that the next phase for surgical oncology will orient towards harmonious 
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The main objective for curative oncologic surgery is to remove tumor tissue in 
conjunction with tumor-free margins. The essence for surgeons hereby lies in 
distinguishing healthy from diseased tissue to ensure satisfying prognosis. 
Today, surgeons make this important distinction based on tissue palpation and 
visual appearance, occasionally followed by frozen section analysis (FSA) — a 
technique that has substantial flaws, especially in complex surgery such as the 
head and neck. This might in part explain the high rates of tumor-positive 
margins and subsequent suboptimal overall survival rates afflicted with surgical 
head and neck oncology.  
The past decades, intraoperative imaging techniques utilizing near-infrared 
(NIR) fluorescence have been developed to aid surgeons in distinguishing 
tumor from healthy adjacent tissue. These real-time imaging techniques provide 
an essential step towards improving surgical outcome through enhanced tumor 
visualization and thereby increase patient survival. The first targeted fluorescent 
agents have been evaluated in multiple early phase trials and are now entering 
large scale clinical testing. It is now that we can start to monitor where the true 
clinical capacity of this technique lies.  
This thesis aims to lay a clinical foundation and explore the future 
possibilities of intraoperative fluorescence-guidance for surgical head and neck 
oncology. By providing an overview of various in situ and ex vivo imaging 
strategies, the work aims to illustrate the clinical possibilities and subsequently 
smoothen the transition of fluorescence imaging into today’s clinic.  
Part I, comprises Chapter 2 and Chapter 3, which describes the use of 
open-field in situ imaging for intraoperative tumor assessment. Both 
prospective studies explored systemic infusion of panitumumab-IRDye800 
primary tumor and margins could be visualized in situ using a dedicated hand-
held imaging device. In this manner, real-time qualitive information such as 
extension of disease and resection completeness could easily become 
available to the surgeon. We found that this qualitative information caused 
clinically significant changes in 21.4% of patients (n=14). In addition, we 
showed that different tissue types (mucosa, tongue, gingival and tumor) have 
unique fluorescent patterns — visually, signal intensity and signal distribution — 
which can be unified with the surgeon’s armamentarium to distinguish normal 
from cancerous tissue. Taking the above into account, we believe that the true 
advantage of in situ imaging can be established when the surgeon constantly 
incorporates imaging information with tissue specifics acquired from tactile and 
visual feedback. It is hereby important to bear in mind that, as with most 
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surgical techniques, routine use is warranted to permit development of pattern-
recognition skills to identify suspicious areas using fluorescence imaging. 
One significant challenge encountered using in situ fluorescence imaging is 
the lack of quantitative data due to the absents of a controlled environment 
where light, camera distance and signal can be standardized. In Chapter 2, 
different surgical light settings were tested in the operating room to establish 
optimal light conditions for open-field imaging acquisition while minimizing 
surgical workflow disturbance. We found that the optimal light settings — those 
with the least interruption of surgical workflow — were when ambient lights were 
turned on, while over-head lights turned off. Although only a slight interruption 
of surgical workflow was caused by surgical imaging, adding the lack of 
quantitative assessment made us explore alternative strategies to achieve 
quantitative assessment with negligible disturbance of clinical workflow. 
Part II describes several innovative strategies utilizing closed-field ex vivo 
imaging. Closed-field imaging provides a quantitative method that account for 
ambient light contamination and camera distance. On the back-table in the OR, 
parallel to the procedure, surgical (tumor) specimen are imaged within a black-
box that is capable of fluorescently mapping the entire surface of the specimen 
in a quantitative fashion. In Chapter 4, rapid non-invasive margin assessment 
was performed by fluorescently mapping the entire tumor specimen’s surface in 
3D. In this manner, fluorescent signal from panitumumab-IRDy800CW showed 
capable to detect margins less than 5mm with high sensitivity and specificity 
(95% and 89%, respectively). Furthermore, for a <2mm cut-off, fluorescence 
was able to detect 100% of cancer within that range. The area under the curve 
(AUC), measuring the discriminatory power of fluorescence for the clinically 
relevant 5mm cut-off was 0.97 (p<0.0001, n=160). This suggests that the 
operating surgeon can either directly resect additional tissue after clinical 
evaluation of the fluorescence intensive spot(s) or sent tissue samples from 
these highlighted areas for FSA.  
Chapter 5 and Chapter 6 describe a method that utilizes fluorescence 
intensity-peaks to create a strategy similar to that of sentinel lymph node 
assessment. Assessment of areas with the highest fluorescence intensity where 
found to correlate with the closest surgical margin. Meaning these intensity 
peaks (i.e. sentinel margins) on the superficial and deep surface reassembled 
the areas where tumor is harbored closest to the specimen’s surgical edge. 
Therefore, if a surgeon would want to assess the entire deep surface on the 
surgical specimen, one would only need to sample the sentinel margin — the 
presumed closest margin — to see if adequate margin status is reached. 
Utilizing the relative intensity approach has two major advantages over previous 
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established strategies: first, interpatient variabilities such as dose differences, 
drug uptake, signal intensity and tumor location, which have previously been 
identified as problematic for open and closed-field surgical imaging have been 
minimized significantly as patients serve their own internal control; second, this 
sentinel margin technique is believed to be compatible with any fluorescent 
probe with relative homologues tumor distribution as well as various 
fluorescence imaging systems.  
During the study described in Chapter 5, we experienced that intraoperative 
assessment of the deep surgical margin remained more challenging compared 
to peripheral margins (Figure 1). As the deeper margin has most to gain from a 
successful first surgery because this margin presents higher risk of leaving 
residual cancer cells within a concealed area. Due to obscuring tissue layers, 
local recurrence will likely be found in a more advanced stage compared to the 
superficial margin. In addition, tumor tissue that is close (1-5 mm) but not 
breaching the deep surface has a far higher risk to be missed since the cancer 













Figure 1  
 
 
Chapter 7 explores the ability of fluorescence imaging to detect high- and 
low-grade dysplasia. Dysplasia can be considerably more challenging to 
detect preoperatively, intraoperatively and during pathological assessment then 







This study provides data that demonstrates that increasing grades of 
premalignant dysplasia correlates with EGFR expression on both a microscopic 
and macroscopic scale. Interestingly, high-grade dysplasia was seen in 82% of 
patients (n=11), indicating the seriousness of premalignancies. Furthermore, 
this proof-of-principle could provide the foundation for future testing of 
fluorescence imaging as potential screening tool for high-grade detection. 
Part III investigates the possibilities of fluorescence imaging for surgical 
pathology in preselection of high-risk tissues. Chapter 8 studies the use of 
probe-based fluorescence dosimetry to preselect areas for FSA and which 
could reduce sampling errors. The fluorescence signal in pathological 
macroscopic tissue sections was measured and correlated to presents or 
absents of tumor tissue. The study illustrated the ability of dosimetry to 
accurately distinguish healthy from tumor tissue (AUC = 0.86). The diagnostic 
value of this technique is illustrated when a 100.0% sensitivity (and 48% 
specificity) is reached at 0.33 FER (fluorescence-to-excitation value) as cutoff 
value, which indicates that false-negative findings — which are generally 
considered far more damaging than false-positive findings — are nonexistent in 
this range. Chapter 9 studies the potential of fluorescence imaging in facilitating 
the identification of metastatic lymph nodes in an ex vivo setting. As 
identification of lymph node metastasis is essential for disease staging and 
prognosis, surgeons dissect large numbers of lymph nodes, putting a 
significant workload on surgical pathologists leading to increased risk of 
missed metastasis. This study hypothesizes that fluorescence could aid in 
isolating high-risk lymph nodes, and subsequently are subject to a more 
rigorous evaluation of fewer lymph nodes. From 22 patients, a total of 1012 
lymph nodes — 39 metastatic, 973 benign — were histologically identified. These 
histopathological findings were correlated to fluorescence imaging data of the 
same nodes as mean fluorescence intensity (MFI) and signal-to-background 
ratio (SBR). After establishing thresholds for both MFI and SBR (≥ 0.044 and 
≥3.0 respectively) as single unit using receiver operation characteristic (ROC) 
curve analysis, we found suboptimal positive predictive values (PPVs). 
However, by combing both thresholds adequate sensitivity (85%), specificity 
(94%) and PPV (36%) could be reached. Meaning that only 91 lymph nodes 
(9%) of a total of 1012 nodes had to be evaluated to find all metastatic lymph 
nodes. If confirmed in prospective studies, this strategy could lead to a 90% 
reduction of lymph nodes in need of pathological processing saving extensive 
labor and healthcare costs.  
This thesis explores the clinical possibilities of various fluorescence imaging 




Het doel van oncologische curatieve hoofd-halschirurgie, is het verwijderen van 
de tumor met tumor-negatieve snijranden. Voor een bevredigende prognose is 
het essentieel voor de chirurg om tijdens de operatie onderscheid te maken 
tussen gezond en ziek weefsel. Vandaag de dag wordt dit onderscheid 
gemaakt op basis van palpatie (tast) en visuele inspectie van het weefsel, soms 
gevolgd door vriescoupe-onderzoek, een intraoperatieve techniek waarbij 
kleine stukjes weefsel worden genomen voor een directe, histologische 
weefselidentificatie door een patholoog. Gezien het hoge aantal tumor-positieve 
snijranden (tot wel 30%) gecorreleerd met oncologische hoofd-halschirurgie, 
heeft deze groep patiënten, in aanvulling op de huidige vorm van 
tumoridentificatie, mogelijk baat bij intraoperatieve beeldvorming.  
De afgelopen decennia is uitgebreid preklinisch onderzoek gedaan naar 
beeldvormingstechnieken, waarbij onder andere gebruik wordt gemaakt van 
near-infrared (NIR) fluorescentie om tumorweefsel via aankleuring te 
detecteren. Momenteel is een aantal grootschalige klinische trials gestart, 
aansluitend op de evaluatie van een veelvoud fluorescente tracers in early-
phase trials.  
Na het intraveneus toedienen van fluorescent-gelabelde tumorspecifieke 
antistoffen kan tumorweefsel, met gespecialiseerde camerasystemen, in de 
operatiekamer gemarkeerd worden. Hierdoor wordt differentiatie tussen tumor 
en aangrenzend gezond weefsel gefaciliteerd. Doordat deze fluorescente data 
direct beschikbaar is voor de chirurg, kan deze informatie constant 
geïncorporeerd worden met traditionele informatie verkregen door palpatie en 
visualisatie. Met deze verrijkte informatiestroom kunnen vervolgens belangrijke 
intraoperatieve beslissingen worden genomen, zoals waar resectievlakken 
moeten komen, of de resectie succesvol lijkt maar ook welk weefsel ingestuurd 
moet worden voor vriescoupe-onderzoek. Hierdoor biedt intraoperatieve 
beeldvorming een essentiële stap, waardoor mogelijk de chirurgische uitkomst 
en daarmee ook de prognose voor oncologische hoofd-halspatiënten verbeterd 
kan worden. 
Het doel van dit proefschrift is het leggen van een klinische fundering, door 
het verkennen van de brede toepasbaarheid van intraoperatieve fluorescentie-
geleide chirurgie in het hoofd-halsgebied. Verschillende soorten fluorescente 
beeldvorming strategieën zijn onderzocht en uitgewerkt voor gebruik in de 
huidige klinische werkomgeving. Door het illustreren van de klinische 
mogelijkheden beoogt dit werk ook, de transitie van intraoperatieve 
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fluorescente beeldvorming, van de onderzoeksbank naar de kliniek te 
vergemakkelijken.  
Deel I, bestaande uit hoofdstukken 2 en 3, beschrijft het gebruik van in 
situ beeldvorming (d.w.z. beeldvorming van weefsels in de patiënt) voor het 
intraoperatief beoordelen van primaire hoofd-halstumoren. Tijdens de operatie 
werd, met behulp van een in de hand gehouden fluorescentie-camera, gekeken 
naar de infiltratie van de primaire tumor, de afstand van de tumor tot de 
snijvlakken voor, tijdens en na de excisie, en naar het wondbed. Hierbij werd 
gekeken hoe vaak de verkregen fluorescente informatie, die in real-time, 
beschikbaar kwam, leidde tot klinisch significante veranderingen. Hierbij 
werden klinisch significante veranderingen gevonden bij 21,4% van de 
patiënten (n=14). Ook werd aangetoond dat de verschillende intraorale 
weefseltypen (slijmvliezen, tong, tandvlees en tumor), unieke fluorescerende 
patronen bevatten - visueel, signaalintensiteit en signaalverdeling - die met het 
chirurgisch arsenaal verenigd kunnen worden om zo gezond- van 
kankerweefsel te onderscheiden. Daarbij is het een vereiste, dat net zoals bij 
de meeste chirurgische technieken, routinematig gebruik nodig is voor het 
ontwikkelen van de patroonherkennings-vaardigheden om verdachte gebieden 
te identificeren met behulp van fluorescente beeldvorming. Verder is het 
belangrijk te beseffen dat deze data interpretatie nog altijd een zekere mate 
van subjectiviteit bevat, omdat het vooralsnog kwalitatieve in situ data betreft. 
De belangrijkste uitdaging bij het gebruik van in situ beeldvorming is dan ook 
het ontbreken van kwantitatieve data door de afwezigheid van een 
gecontroleerde omgeving, waar licht, camera-afstand en signaal kunnen 
worden gestandaardiseerd.  
In hoofdstuk 2, is naast primaire tumor beeldvorming, ook gekeken naar 
ideale lichtomstandigheden in de operatiekamer voor in situ beeldvorming. Het 
beste resultaat, daar waar de minste verstoring van chirurgische workflow werd 
bereikt, was wanneer de overhead verlichting tijdelijk werd uitgezet. Deze 
verlichting interfereert met de fluorescentiecamera’s tijdens het in beeld 
brengen van de tumoren. Ook al is deze tijdelijke onderbreking van de 
chirurgische workflow minimaal (30-40 seconden), tezamen met de afwezigheid 
van kwantitatieve data, kan het gezien worden als een tekortkoming van in 
situ beeldvorming. Om deze reden is verder onderzoek verricht naar ex 
vivo beeldvorming (d.w.z. beeldvorming van weefsels buiten de patiënt), 
waarbij deze tekortkomingen niet voorkomen of minder op de voorgrond staan. 
Deel II beschrijft verschillende innovatieve strategieën waarbij ex 
vivo beeldvorming is gebruikt in een zogeheten closed-field setup. In deze 
opstelling, wordt weefsel uit de patiënt geëxcideerd en vindt beeldvorming 
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vervolgens plaats in een kleine gesloten ruimte, waar gecontroleerd kan 
worden voor licht en camera-afstand. Het voordeel van deze 
beeldvormingsstrategie is dat het parallel aan de chirurgische procedure 
plaatsvindt en gekwantificeerde data oplevert, wat vergelijking tussen patiënten 
mogelijk maakt. Hierdoor is het mogelijk het gehele oppervlak van een 
geëxcideerde tumor met snijranden (of ander specimen) op kwantitatieve wijze 
in kaart te brengen, een proces genaamd fluorescent mapping.  
In hoofdstuk 4 is gekeken naar een snelle niet-invasieve snijrandbepaling 
door het gehele oppervlak van het tumor-specimen driedimensionaal in kaart te 
brengen. Bij deze strategie bleek de gebruikte tracer (panitumumab-
IRDy800CW) in staat om klinisch relevante snijranden van minder dan 5 mm te 
detecteren, met een hoge gevoeligheid en specificiteit (respectievelijk 95% en 
89%). Wanneer gekeken werd naar snijranden van <2 mm, was 100% van de 
snijranden met kanker binnen deze 2 mm fluorescent. Het discriminerend 
vermogen van fluorescentie, de area under the curve (AUC), voor de klinisch 
relevante 5 mm-grenswaarde was 0,97 (p<0,0001, n=160). Met deze informatie 
kan de operateur ofwel terug kan gaan naar de locatie van een fluorescente 
“hotspot”, om na klinische evaluatie (door middel van palpatie en visualisatie) 
meer weefsel te reserceren en alsnog een adequate marge te waarborgen, of 
een weefselmonster van dit verdachte gebied te nemen voor vriescoupe-
onderzoek. 
De uitdaging bleef echter bestaan rond interpatiënt verschillen in termen van 
variatie in gemeten fluorescentie-intensiteit, waardoor in hoofdstuk 5 en 
hoofdstuk 6 is gekeken naar een alternatieve analysestrategie. Door gebruik te 
maken van relatieve fluorescente intensiteitsverschillen kan de patiënt als 
zijn/haar eigen interne controle gebruikt worden. Hiermee kon een strategie 
ontwikkeld worden die vergelijkbaar is met de schildwachtklierprocedure 
(sentinel node procedure). Zo werd gevonden dat de relatieve, hoogste 
fluorescente intensiteit op een gerecerdeerd tumorspecimen correleert met de 
kleinste chirurgische marge (de afstand van de tumor tot het snijvlak). De 
zogenoemde “sentinel margins”, geven daarmee de gebieden aan, op zowel 
de oppervlakkige als de diepe snijvlakken (Figuur 1), waar tumor het dichtst 
van de snijrand zit. Dus wanneer de chirurg twijfelt over de adequaatheid van 
de resectie, kan het identificeren van de dichtstbijzijnde marge door middel van 



















Figuur 1  
 
 
Het gebruik van de relatieve intensiteit-benadering heeft twee grote 
voordelen ten opzichte van eerder vastgestelde strategieën: ten eerste, zijn 
variaties tussen patiënten zoals dosisverschillen, medicijnopname, 
signaalintensiteit en tumorlocatie, aanzienlijk geminimaliseerd omdat patiënten 
als eigen controle dienen. Deze variaties werden eerder als problematisch 
geïdentificeerd voor zowel in situ en ex vivo beeldvorming; ten tweede, wordt 
aangenomen dat deze sentinel margin techniek compatibel is met elke 
homogeen gedistribueerde fluorescente tracer, evenals met verschillende 
intraoperatieve camerasystemen (mits sensitief genoeg). 
In hoofdstuk 7 komt de detectie van hoog- en laaggradige dysplasie door 
middel fluorescente beeldvorming aan bod. De preoperatieve, intraoperatieve 
en pathologische identificatie (en beoordeling) van dysplasie door middel van 
palpatie en visualisatie is, in vergelijking met carcinomen, aanzienlijk moeilijker. 
Derhalve is gekeken naar de mogelijkheden van fluorescente beeldvorming 
voor het detecteren van dysplasie in een ex vivo setting. Een correlatie werd 
gevonden tussen de toenemende graden van dysplasie en de mate 
van epidermal growth factor receptor-expressie (EGFR). Dit betekent een 
verhoging van fluorescent signaal, op zowel microscopisch als macroscopisch 
niveau, bij een toename in ernst van dysplasie. Dit proof-of-principle onderzoek 
kan in de toekomst mogelijk als basis dienen voor het ontwikkelen van een pre- 







Deel III onderzoekt de mogelijkheden van fluorescente beeldvorming voor 
chirurgische pathologie bij preselectie van risicovolle weefsels. Hoofdstuk 8 
richt zich op het gebruik van probe-based fluorescentiedosimetrie om 
verdachte gebieden voor vriescoupe-onderzoek vooraf te selecteren, om zo 
sample fouten te verminderen. Het fluorescentiesignaal in pathologische, 
macroscopische weefselsecties, werd gemeten en gecorreleerd met de aan- of 
afwezigheid van tumorweefsel. De studie illustreerde het vermogen van 
dosimetrie om gezond weefsel van tumorweefsel nauwkeurig te onderscheiden 
(AUC = 0,86).  
Hoofdstuk 9 onderzoekt de potentie van fluorescente beeldvorming bij het 
vergemakkelijken van de identificatie van metastatische lymfeklieren in een ex 
vivo setting. De identificatie van lymfekliermetastase is van essentieel belang 
voor stadiëring en prognose van ziekten. Voor het komen tot de juiste 
stadiëring, reserceren chirurgen grote aantallen lymfeklieren met een 
aanzienlijke belasting voor pathologen tot gevolg. Deze hoge werkdruk kan op 
zijn beurt weer aanleiding zijn tot een verhoogd risico op gemiste 
lymfekliermetastasen. Deze studie suggereert dat fluorescente beeldvorming 
ondersteuning kan bieden bij het isoleren van lymfeklieren met een verhoogd 
risico op metastasen. Deze hoog-risico klieren kunnen vervolgens gescheiden 
worden van laag-risico klieren, wat uiteindelijk leidt tot de mogelijkheid van een 
strengere evaluatie van minder lymfeklieren. Van 22 patiënten werden in totaal 
1012 lymfeklieren - 39 gemetastaseerd, 973 goedaardig - histologisch 
geëvalueerd. Deze histopathologische bevindingen werden vervolgens 
gecorreleerd met fluorescentiebeeldvorming van dezelfde klieren, als mean 
fluorescence intensity (MFI) en signal-to-background ratio (SBR). Na het 
vaststellen van drempelwaarden voor zowel MFI als SBR (respectievelijk ≥0,044 
en ≥3,0) als afzonderlijke eenheid met behulp van analyse van de receiver 
operating characteristics curve (ROC-curve), vonden we suboptimale, positieve 
voorspellende waarden (PPV's). Echter, door beide drempels samen te 
gebruiken, kon een adequate sensibiliteit (85%), specificiteit (94%) en PPV 
(36%) worden bereikt. Dit betekent dat slechts 91 (9%) van in totaal 1012 
lymfeklieren moesten worden geëvalueerd, om alle metastatische lymfeklieren 
te identificeren. Als deze resultaten worden bevestigd in prospectieve studies, 
zou deze strategie leiden tot een vermindering van 90% van het totaalaantal te 
onderzoeken lymfeklieren, wat aanzienlijk arbeids- en gezondheidszorgkosten 
bespaart. 
 
Dit proefschrift onderzocht de klinische mogelijkheden van verschillende 
fluorescente beeldvormingsstrategieën, voor toepassingen rond oncologische 
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hoofd-halschirurgie. Binnen de begrenzingen van deze techniek, blijkt uit dit 
werk dat fluorescente beeldvorming uitermate geschikt lijkt voor het begeleiden 
van een succesvolle, radicalere resectie. Daarbij biedt dit werk handvatten voor 
toekomstige prospectieve studies. Deze studies zijn een volgende stap om te 
verifiëren of deze techniek daadwerkelijk leidt tot een meer accurate resectie 




Vanzelfsprekend is dit proefschrift niet tot stand gekomen zonder de 
assistentie, ondersteuning, dan wel afleiding van velen. Promoveren is per 
definitie een teamprestatie. Vandaar dat ik op deze plaats graag een aantal 
mensen wil bedanken. 
 
Eben L. Rosenthal 
Dear Eben, it was an absolute pleasure to work with you. What began as a 24-
week internship has grown into a prosperous teamwork effort, spanning over 
more than two years.  And quite remarkable, we did not only work together but 
also lived under the same roof. The Rosenthal Ranch and its family had been 
my home for 1.5-years, in which you thought me from your vast experience 
about research, trials and grant proposals, but also something far more 
important: what kind of doctor I want to be. Eben, Mary, Sarah, Walker, Dutchy 
and Pippa thank you for everything, and I look forward meeting you all again! 
 
Tim Forouzanfar,  
Beste Tim, hoewel de samenwerking over een grote afstand en tijdsverschil 
vaak moeilijk gaat, ging het bij ons, heel gemakkelijk. Het is een grote eer om 
bij de afdeling Mondziekte-, Kaak- en Aangezichtchirurgie van het VUmc te 
mogen promoveren. Tevens wil ik jou en de rest van de staf bedanken voor de 
mogelijkheid hier mijn opleiding tot MKA-chirurg te mogen vervolgen.  
 
Nynke S. van den Berg 
Lieve Nynke, dank voor alles wat jij mij hebt geleerd. Vanaf dag één stond je 
voor mij klaar, met tips, tricks en met name omwegen om zo snel mogelijk de 
papieren rompslomp, zoals deze alleen in Amerika bestaat, rond te krijgen. We 
hebben gelachen, hard gewerkt, niet gewerkt, geschreewd en voetbal 
gekeken, en dat alles op onze 6 vierkante meter in het CCSR-gebouw. Zij aan 
zij hebben we vele dagen data verzameld, onvermoeid ge-imaged, en vele 
mooie publicaties geschreven. Ik wens je veel success bij Intuitive en met je 
verdere loopbaan. Tankewol foar alles en ik winskje jo it bêste fan lok by 
Intuitive en yn jo fierdere karriêre! 
 
Graag wil ik de leden van de leescommissie, Janneke Klein-Nulend, Jan de 
Visscher, Jan Roodenburg, Stijn Keereweer en Jan van Gemert bedanken voor 
hun tijd en inzet. Ook wil ik hen bedanken die plaats hebben genomen in de 




The Rosenthal lab  
Naoki, my friend and number one lab companion. I still cannot believe the 
courage you possess. With your family, a few English words, a lot of sign 
language and an ocean of goodwill you arrived in the USA. I enjoyed all the fun 
we had cooking the data, drinking coffee and many, many beers. I was very 
fortunate to work with you and wish you all the best on your future endeavors. 
I’m confident you will one day be professor at the Nagoya University. I hope to 
visit you in the near future! Say hi to Tomoko and Kanako! 
 
Guolan Lu, Shayan-my-man Fakurnejad and Quan Zhou, thanks for your input, 
the laughs, cries, lab-meetings and especially all cell staining adventures we 
had. Although we come from various backgrounds and different cultures, I 
couldn’t have hoped for a better team than what we were. Guolan, I hope you 
and your family are well and continue to do so. Thank you for all the advice you 
gave me. Even when you were so immensely busy yourself, you never passed 
an opportunity to help me. I’m sure that one day you’ll be PI, and I bet one of 
the best. Good luck! 
Shayan, I still think back of the great time we had in Austin Texas during the 
COSM 2019. Too bad we got to know each other much better when I almost left 
again for the Netherlands. Remember, when you ever visit the land of the 
Dutch, let me know. You always got a place to stay. I wish you the best of luck 
on your ENT-training. Thanks for everything!  
Quan, I still have you and your fathers gift hanging on my wall. I admire the 
knowledge you possess, not only about research or ancient China but even 
more so: your understanding of people in general. I loved all the talks we had 
and wish you all the best with your future plans. I, for one, hope that one day 
you’ll dominate the world of table tennis.  
 
Berend van der Wildt 
Beer, ouwe pikkebaas. Koffie en geouwehoer, vaste prik op elke dag van de 
week. Zoals jij in het leven staat is bewonderingswaardig. Je hebt mijn tijd aan 
Stanford zo onmogelijk veel leuker gemaakt en ik ben ontzettend dankbaar dat 
ik je een vriend voor het leven mag noemen. Dank voor al je hulp. 
 
TOVA X 
Tovisten en tovistinnen, bij elkaar geraapt zooitje dat we zijn, uit alle uithoeken 
van het land en sommige zelfs daarbuiten (Rick), wil ik jullie graag bedanken 
voor alle lol die we hebben gehad, nog steeds hebben en nog zullen beleven. 
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Terwijl de coronacrisis de gehele maatschappij piepend en krakend tot 
stillstand heeft gebracht, buffelen wij gestaag door naar de eindstreep van een 
eindeloos lijkend studietraject. Mij hoor je niet klagen! Fons Slieker; Fons, graag 
wil ik je persoonlijk bedanken voor het doorlezen en aanpassen van de laaste 
versie van mijn proefschrift. En inderdaad, een proefschrift is geen trailer van 
een Amerikaanse blockbuster, maar soms ook wel. Je bent een goede maat, 
dank!  
Robin Tan; Tannie, (S)Tan’s clinics, ik zie het helemaal voor me: fietsen, 
vrijmibo en sporadisch wat werk. Ik kan niet wachten om met je in opleiding te 
gaan! Florine Weinberg; Floletarier, lieve Flo, ik ben blij dat ik je heb leren 
kennen. Je betekent veel voor me. Ik wens je ontzettend veel succes met je 
opleiding en, hoe kan het ook anders, je promotie, waar je mij altijd over mag 
lastigvallen. Als ik ooit een ingreep op MKA-gebied moet hebben, ben jij 
degene bij wie ik aanklop. Het ga je goed! 
 
Stijn Bekkers; Stijnie, mijn trouwe vriend. Vanaf ons 15de levensjaar, precies de 
helft van mijn leven nu, kennen wij elkaar al. En wat hebben we veel 
meegemaakt in die tijd, als ware buffalo soldiers hebben we stad en land 
bereisd, we hebben geëxperimenteerd, gefilosofeerd, maar vooral gelachen. 
Met een gezonde broederlijke concurrentie en met name broederlijke hulp zijn 
wij gekomen tot waar we nu zijn. Het besluit om het leven zo in te vullen als je 
zelf wilt is jou op het lijf geschreven en je zult er nog ver mee komen. Let hierbij 
wel, het leven is te belangrijk om al te serieus te nemen. Ik wens je ontzettend 
veel succes met je toekomstplannen en hoop dat we ooit tegenover elkaar op 
OK staan. Dank dat ik altijd alles met je kan delen, en ik vind het een eer dat je 
mijn paranimf wil zijn.  
 
Casper Kuijpers; Cappie grappol Kuijpers, een aaneengesloten tocht van 617 
km, door alle gewesten van ons land, over een tijdsbestek van 29 uur is ons 
niet in de koude kleren gaan zitten. Ik kan gerust zeggen dat het de grootste 
uitdaging is geweest die ik tot nu toe heb getrotseerd. Mede door jouw 
doorzettingsvermogen en positieve kijk hebben we de eindstreep voor de 
Waalbrug gehaald. En het is dat doorzettingsvermogen dat je heeft gebracht 
tot een nieuw hoofdstuk in jouw leven: piloot bij KLM! Ik heb het vaak tegen je 
gezegd, maar zeg het hier graag nogmaals: ik ben ongelofelijk trots op alles 
wat je hebt bereikt en waarschijnlijk nog zult bereiken. “Grijp het leven bij de 
ballen en sneeuw niet onder.” Ik weet zeker dat wij vrienden voor het leven zijn 




Nelis Claassen; Neltin, SSgN-boys, kleine jongens, kattenkwaad en stiekeme 
sigaretten, maar altijd met een goed kompas en de juiste normen en waarden. 
De belangrijkste pijlers waarop je geluk uit het leven kan halen. Dank voor de 
hulp met de lay-out van het proefschrift, en nog veel meer dank voor alle 
belangrijke levenslessen uit het verleden. Ik was een ander persoon geweest 
als ik jou niet had gekend.  
 
Verder wil ik hier de vele vrienden bedanken die misschien niet direct hebben 
bijgedragen aan dit werk, maar desalniettemin mij hebben gevormd tot wie ik 
ben. Nijmeegse vrienden; van mr. Jacks tot het Eurocafé, allen zijn uitgevlogen 
naar Amsterdam om vervolgens allemaal weer terug te komen naar ons Nimma. 
De vrijheid, mentaliteit en wijdse natuur zal ik de komende jaren moeten 
missen. Gelukkig laat echte vriendschap zich rekken over zowel afstand als tijd, 
en maak ik mij geen zorgen over het voortbestaan van onze vrienden-
weekendjes tot na ons 60ste. Eva, Bert, Robin, Sofie, Floris, Hugo, Wald, Koke 
en Ate, het ga jullie goed! 
De heren, dames en reguliere bezoekers van de Amsteldijk, Pierre, Naomi, 
Marijn, Esther, Berber, Jesse, Willem, Milan en Romy. Zonder enige twijfel 
namen jullie Ras-Amsterdammers mij op in de vriendengroep. Acht jaar lang 
hebben ik mij thuis gevoeld in Amsterdam, niet door de stad of het huis, maar 
enkel en alleen door jullie. Ik ben dankbaar jullie te kennen! 
 
Rob Baatenburg de Jong; Baat, graag wil ik je persoonlijk bedanken voor alles 
wat je voor mij hebt betekend en nog steeds doet. Jij kent me al vanaf mijn 
geboorte en over de jaren heen heb je mij groot zien worden en altijd voor mij 
klaar gestaan wanneer ik advies of hulp nodig had, iets dat ik nooit zal 
vergeten. Ik bewonder de manier hoe jij in het leven staat; met een zeer goed 
ontwikkeld moreel compas heb je al vele ‘professionele zaken’ van jouw visie 
voorzien en een tegenslag is voor jou niets meer dan een kans om iets beter te 
maken. Ik hoop dat je inmiddels over de schok van mijn vakgebied keuze bent 
heen gekomen.  
 
Mijn ouders 
Lieve Aad en Merit, ik ben geworden tot wie ik ben, door alle liefde die ik heb 
gekregen en de levenslessen die jullie mij hebben meegeven. Nu ik zelf wat 
ouder ben, ben ik deze normen en waarden meer en meer gaan waarderen. 
Jullie mogen ongelofelijk trots zijn op de manier waarop jullie onze opvoeding 
met onvoorwaardelijke liefde hebben verzorgd. Door de kunst van het minimale 
ingrijpen wisten jullie mij op de juiste momenten de goede kant op te sturen. Ik 
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kan me geen betere ouders wensen, en ik ben dan ook ongelofelijk trots dat 
jullie mijn ouders zijn! 
 
Sacha en Isabelle van Keulen 
Lieve Sas, we kennen elkaar al 27 jaar, naast onze ouders, ken ik jou dus 
eigenlijk het langst van iedereen. En wat hebben veel samengedaan: 
gelachten, gehuild, gevaren, geleerd, we hebben zelfs samengewoond op de 
Amstel dyka 120 twee-hoog. Dit maakt de band die wij hebben gelukkig sterk 
genoeg om door alles heen te komen. Je hebt mij vaak uitgelachen wanneer je 
mijn werk na moest kijken. Ik hoop dat je de groei van “de maatschappij 
zoekt...” naar de totstandkoming van dit proefschrift kan waarderen.  
Bellebop, met jou kan je de oorlog winnen. Altijd sta je klaar voor een broer in 
nood; van verjaardagsfeestjes, relatieadvies tot het voederen na ooglaser-
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voor hoe jij het leven tackelt. Hoe gemakkelijk, en zonder enige pretentie, jij je 
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